COMPOSTOS E FORMULAÇÕES ÚTEIS COMO ADJUVANTES DE VACINAS

Stable nanoemulsion adjuvants containing specific compounds enhance vaccine immunogenicity by boosting immune responses, addressing the need for effective and safe adjuvants to improve vaccine efficacy.

BR112025025073A2Pending Publication Date: 2026-11-10MERCK SHARP & DOHME LLC
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
BR112025025073
Authority / Receiving Office
BR · BR
Patent Type
Applications
Current Assignee / Owner
Priority Date
2023-05-18
Filing Date
2024-05-16
Publication Date
2026-11-10

AI Technical Summary

Technical Problem

Many vaccines are poorly immunogenic or elicit an insufficient immune response, necessitating the use of adjuvants to enhance the immune response against targeted antigens, but there is a need for safe and effective adjuvants for vaccine use.

Method used

Formulations comprising compounds of Formulas I, Ia, II, IIa, III, IIIa, IV, and IVa, or their pharmaceutically acceptable salts, combined with emulsifiers and terpenes, are used to create stable nanoemulsions (SNEs) that enhance immune responses when administered with antigens.

Benefits of technology

The SNE adjuvant formulations effectively boost the immune response, potentially reducing the amount of antigen needed and the number of injections required for durable protection against diseases.

✦ Generated by Eureka AI based on patent content.
Patent Text Reader

Abstract

The invention relates to novel compounds having a structure as set forth in any one of Formulas I, Ia, II, IIa, III, IIIa, IV or IVa, as described herein, and formulations comprising such novel compounds. The novel compounds and formulations of the invention may be useful in vaccine compositions. In some embodiments, the invention relates to compositions comprising at least one antigen and compounds having a structure as set forth in any one of Formulas I, Ia, II, IIa, III, IIIa, IV or IVa, as described herein, or pharmaceutically acceptable salt(s) thereof, wherein the compositions are prepared as stable nanoemulsions (herein referred to as "SNE adjuvant compositions" or "SNEs").
Need to check novelty before this filing date? Find Prior Art

Description

[001] This patent application claims the benefit of U.S. Provisional Patent Application Serial No. 63 / 503,015, filed May 18, 2023, the contents of which are incorporated by reference into the present invention. BACKGROUND OF THE INVENTION

[002] Many vaccines are poorly immunogenic or elicit an insufficient immune response that may not provide adequate protection against a targeted infectious agent. Therefore, an adjuvant may be necessary to help generate an immune response with sufficient magnitude, quality, and persistence required for vaccine use. An adjuvant may be used in an immunogenic composition comprising an antigen of interest to enhance the immune response against the antigen, decrease the amount of antigen needed to elicit the desired immune response, or decrease the number of injections required in a clinical regimen to induce a durable immune response and provide protection against disease. Despite the success of adjuvants for certain compositions, there is a need for additional adjuvants that are safe for use in vaccines and immunogenic compositions and effective in enhancing the immune response against an antigen of interest. SUMMARY OF THE INVENTION

[003] The present invention relates to compounds of Formulas I, Ia, II, IIa, III, IIIa, IV and IVa and pharmaceutically acceptable salts thereof. Furthermore, the invention relates to formulations and compositions comprising one or more of the compounds of Formulas I, Ia, II, IIa, III, IIIa, IV and IVa or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier. Still further, the invention relates to formulations and compositions comprising one or more of the compounds of Formulas I, Ia, II, IIa, III, IIIa, IV Petition 870260002828, dated 12 / 01 / 2026, p. 11 / 237 2 / 211 and IVa or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier, wherein formulations and compositions are useful as vaccines.

[004] The invention also relates to formulations comprising i) one or more compounds of the invention or pharmaceutically acceptable salt(s) thereof; ii) one or more emulsifiers; and iii) one or more terpenes.

[005] The invention also relates to formulations comprising i) one or more compounds of the invention or pharmaceutically acceptable salt(s) thereof; ii) one or more sorbitan-based surfactants, and iii) one or more terpenes.

[006] The invention also relates to formulations comprising one or more of the compounds of Formulas I, Ia, II, IIa, III, IIIa, IV or IVa or pharmaceutically acceptable salt(s) thereof and further comprising sorbitan trioleate (SPAN-85); polysorbate-20 (PS-20) or polysorbate-80 (PS-80) and squalene. In some embodiments, the formulations are prepared as stable nanoemulsions (herein referred to as “SNE adjuvant formulations” or SNEs).

[007] The invention also relates to compositions comprising antigens and an SNE disclosed in the present invention. As an example, a specific SNE comprises the compound N-(5-(4-(4-((5-amino-7-(butylamino)-2H-pyrazolo[4,3d]pyrimidin-2-yl)methyl)-3,5-dimethoxyphenyl)piperazin-1-yl)-5-oxopentil)stearamide, also referred to as Compound A-1”. This specific SNE is referred to as Compound A-1-SNE and comprises Compound A-1, SPAN-85, PS-20 or PS-80 and squalene. As another example, a specific SNE comprises the compound N-(5-(4-(4-((5-amino-7-(butylamino)-2H-pyrazolo[4,3d]pyrimidin-2-yl)methyl)-3-methoxyphenyl)piperazin-1-yl)-5-oxopentil)stearamide, also referred to as Compound B-1”. This specific SNE is referred to as Petition 870260002828, dated 12 / 01 / 2026, p. 12 / 237 3 / 211 Compound B-1-SNE comprises Compound B-1, SPAN-85, PS-20 or PS-80 and squalene. As another example, a specific SNE comprises the compound N-(4-((4-((5-amino-7-(butylamino)-2H-pyrazolo[4,3-d]pyrimidin-2-yl)methyl)-3,5-dimethoxybenzyl)(methyl)amino)butyl)stearamide, also referred to as “Compound C-4”. This specific SNE is referred to as Compound C-4-SNE and comprises Compound C-4, SPAN-85, PS-20 or PS-80 and squalene.

[008] The invention also relates to immunogenic compositions comprising antigens and an SNE disclosed herein.

[009] The invention also relates to methods of treating or preventing a disease in a patient in need thereof by administering to the patient an immunogenic composition of the invention. BRIEF DESCRIPTION OF THE DRAWINGS

[010] Figure 1 (Example 10) shows the OD640 reading after incubation with different concentrations of Compound B-1-SNE with HEK-Blue™ 293 cells (InvivoGen) expressing human TLR7 (top panel) or TLR8 (bottom panel). The Y-axis represents the total concentration of Compound B-1-SNE.

[011] Figure 2 (Example 11) shows the pre-immune (day 0, pooled sera), post-dose 1 (day 21), post-dose 2 (day 42), and post-dose 3 (day 70) anti-6B IgG titers after immunization of mice with the formulations described in Table 18. Error bars represent geometric means with 95% confidence intervals. Transformed data analyzed by one-way ANOVA with Dunnett's post-hoc test, *p < 0.05.

[012] Figure 3 (Example 11) shows the pre-immune (day 0), post-dose 1 (day 21), post-dose 2 (day 42), and post-dose 3 (day 70) OPA anti-6B titers of pooled sera after immunization of mice with the formulations described in Table 18.

[013] Figure 4 (Example 12) shows the ratio of IgG serotype titers Petition 870260002828, dated 12 / 01 / 2026, p. 13 / 237 4 / 211 specific serotypes in rhesus monkeys after immunization with PCV24 with Compound B-1-SNE (150 μg Compound B-1 dose), PCV24 with Compound B-1-SNE (50 μg Compound B-1), and PCV24 with Compound B-1-SNE (15 μg Compound B-1), compared to a post-dose adjuvant-formulated PCV24 immunization 3. Data from serotypes 6C and 15B are included to assess cross-reactivity.

[014] Figure 5 (Example 12) shows the ratio of serotype-specific IgG titers in rhesus macaque infants after PCV24 immunization with Compound B-1-SNE (150 μg Compound B-1 dose), PCV24 with Compound B-1-SNE (50 μg Compound B-1), and PCV24 with Compound B-1-SNE (15 μg Compound B-1), compared to a post-dose APA-formulated PCV24 immunization. Data for serotypes 6C and 15B are included to assess cross-reactivity.

[015] Figure 6 (Example 12) shows the ratio of serotype-specific IgG titers in rhesus macaque infants after PCV24 immunization with Compound B-1-SNE (150 μg Compound B-1 dose), PCV24 with Compound B-1-SNE (50 μg Compound B-1) and PCV24 with Compound B-1-SNE (15 μg Compound B-1), compared to a PCV24 immunization at post-dose 3.

[016] Figure 7 (Example 13) shows the ratio of serotype-specific IgG titers in rhesus macaque infants after PCV24 immunization with Compound B-1-SNE (100 μg Compound B-1 dose), PCV24 with Compound B-1-SNE (10 μg Compound B-1) and PCV24 with Compound B-1-SNE (1 μg Compound B-1) with Compound B-1-SNE (0.1 μg Compound B-1) compared to a PCV20 immunization at post-dose 3.

[017] Figure 8 (Example 14) shows the ratio of serotype-specific IgG titers in mice after PCV26 immunization with Compound B1-SNE (10 μg dose of compound B-1) compared to immunization with Petition 870260002828, dated 12 / 01 / 2026, page 14 / 237 5 / 211 PCV26 formulated with APA in post-dose 2. Data from serotypes 6C and 15B are included to assess cross-reactivity.

[018] Figure 9 (Example 14) shows the IgG2a / IgG1 titer ratio of serotype-specific antibodies in mice after PCV26 immunization with Compound B-1-SNE (10 µg dose of Compound B-1) or PCV26 formulated with APA at post-dose 3. Responses from three representative serotypes, 18C, 19F, and 24F, are shown (from left to right).

[019] Figure 10A (Example 14) shows that mice immunized with PCV26 with Compound B-1-SNE (10 µg dose of Compound B-1) or PCV26 formulated with APA are protected against intratracheal challenge with S. pneumoniae 24F. Bacteremia was quantified 24 hours after infection with serotype 24F bacteria and presented as log CFU / mL.

[020] Figure 10B (Example 14) shows that mice immunized with PCV26 with Compound B-1-SNE (10 sqg dose of Compound B-1) or PCV26 formulated with APA are protected against intratracheal challenge with S. pneumoniae 24F. Survival was assessed for approximately 240 hours after infection with bacteria of serotype 24F. DETAILED DESCRIPTION OF THE INVENTION

[021] The invention provides a compound having the structure shown in Formula I: in which: Rae selected from H, -OH, (C1-C6)alkyl, (C1-C6)alkenyl, (C1 Petition 870260002828, dated 12 / 01 / 2026, p. 15 / 237 6 / 211 Celalquinyl -O(C1-C6)alkyl, -O(C1-C6)alkenyl, -O(C1-C6)alkynyl, chlorine, fluorine and -NR'R'', wherein said (C1-C6)alkyl, (C1-C6)alkenyl, (C1-C6)alkynyl, -O(C1-C6)alkyl, -O(C1-C6)alkenyl and -O(C1-C6)alkynyl are optionally substituted with one to four substituents, selected independently from the group consisting of -OH, -O(C1-C4)alkyl, -O(C1-C4)alkenyl, -O(C1-C4)alkynyl, chlorine and fluorine; Ra' is selected from H, -OH, (Ci-C6)alkyl, (Ci-C6)alkenyl, (CiC6)alkynyl, -O(Ci-C6)alkyl, -O(Ci-C6)alkenyl, -O(Ci-C6)alkynyl, chlorine, fluorine and -NR'R, wherein said (Ci-C6)alkyl, (Ci-C6)alkenyl, (CiC6)alkynyl, -O(Ci-C6)alkyl, -O(Ci-C6)alkenyl and -O(Ci-C6)alkynyl are optionally substituted with one to four substituents, selected independently from the group consisting of -OH, -O(CiC4)alkyl, -O(Ci-C4)alkenyl, -O(Ci-C4)alkynyl, chlorine and fluorine; Ra'' is selected from H, -OH, (Ci-C6)alkyl, (Ci-C6)alkenyl, (Ci-C6)alkynyl, -O(Ci-C6)alkyl, -O(Ci-C6)alkenyl, -O(Ci-C6)alkynyl, chlorine, fluorine and -NR'R'', wherein said (Ci-C6)alkyl, (Ci-C6)alkenyl, (Ci-C6)alkynyl, -O(Ci-C6)alkyl, -O(Ci-C6)alkenyl and -O(Ci-C6)alkynyl are optionally substituted with one to four substituents, selected independently from the group consisting of -OH, -O(Ci-C4)alkyl, -O(Ci-C4)alkenyl, -O(Ci-C4)alkynyl, chlorine and fluorine; R' and R'' are independently selected from H, (Ci-C6)alkyl, (Ci-C6)alkenyl and (Ci-C6)alkynyl, wherein said (Ci-C6)alkyl, (Ci-C6)alkenyl and (Ci-C6)alkynyl are optionally substituted with one to four substituents, independently selected from the group consisting of -OH, -O(Ci-C4)alkyl, -O(Ci-C4)alkenyl, -O(Ci-C4)alkynyl, chlorine and fluorine, or R' and R'', together with the nitrogen to which they are attached, combine to form Petition 870260002828, dated 12 / 01 / 2026, p. 16 / 237 7 / 211 a (Ca-Ce)heterocycloalkyl, wherein said (Ca-Ce)heterocycloalkyl is optionally substituted with one to four substituents, independently selected from the group consisting of -OH, -O(Ci-C4)alkyl, -O(Ci-C4)alkenyl, -O(Ci-C4)alkynyl, chlorine and fluorine; each occurrence of Rbé selected independently from H, -OH, (Ci-Ce)alkyl, (Ci-Ce)alkenyl, (Ci-Ce)alkynyl, -O(Ci-Ce)alkyl, -O(Ci-Ce)alkenyl, -O(Ci-Ce)alkynyl, chlorine, fluorine or NR'R'', wherein said (Ci-Ce)alkyl, (Ci-Ce)alkenyl, (Ci-Ce)alkynyl, -O(Ci-Ce)alkyl, -O(Ci-Ce)alkenyl and -O(Ci-Ce)alkynyl are optionally substituted with one to four substituents, selected independently from the group consisting of -OH, -O(Ci-C4)alkyl, -O(Ci-C4)alkenyl, -O(CiC4)alkynyl, chlorine and fluorine; A is a carbon- or nitrogen-bonded spacer selected from (Ci-Ce)alkyl, (Ca-Ce)heterocycloalkyl, heterocycloalkyl-C(O)-Rz-, (CiC4)alkyl-N(Rz)-Rz-, aryl and heteroaryl, wherein said (Ci-Ce)alkyl, (CaC6)heterocycloalkyl, aryl and heteroaryl are optionally substituted with one to six substituents, independently selected from the group consisting of -OH, (Ci-Ce)alkyl, (Ci-Ce)alkenyl, (Ci-Ce)alkynyl, -O(Ci-Ce)alkyl, -O(Ci-Ce)alkenyl, -O(Ci-Ce)alkynyl, chlorine, fluorine and NR'R, wherein said (Ci-Ce)alkyl, (Ci-Ce)alkenyl, (C1-C6)alkynyl, -O(C1-C6)alkyl, -O(C1-C6)alkenyl and -O(C1-C6)alkynyl are optionally substituted with one to six substituents, selected independently from the group consisting of -OH, -O(C1-C4)alkyl, -O(C1-C4)alkenyl, -O(C1-C4)alkynyl, chlorine and fluorine; each occurrence of Rz is independently H or (C1-C6)alkyl; B is a functional group selected from Petition 870260002828, dated 12 / 01 / 2026, p. 17 / 237 8 / 211 , 4-NC-n1 JHc-θψ ,^C-of , 4-C-Nf oooooe -CiII O · ; D is a lipid selected from (Cs-C2o)alkyl, (C6-C2o)alkenyl and (C6-C2o)alkynyl, wherein said (C6-C2o)alkyl, (C6-C2o)alkenyl and (C6-C2o)alkynyl are optionally substituted with one to six substituents, selected independently from the group consisting of -OH, -O(C1-C4)alkyl, -O(C1-C4)alkenyl, -O(C1-C4)alkynyl, Hζchlorine and fluorine; or D is Z; each occurrence of Z is independently selected from (C6C20)alkyl, (C6-C20)alkenyl and (C6-C20)alkynyl, wherein said (C6C20)alkyl, (C6-C20)alkenyl and (C6-C20)alkynyl are optionally substituted with one to six substituents, independently selected from the group consisting of -OH, -O(C1-C4)alkyl, -O(C1-C4)alkenyl, -O(C1-C4)alkynyl, chlorine and fluorine; m is 0, 1, 2, 3, 4 or 5, en is 0, 1, 2, 3, 4 or 5; or a pharmaceutically acceptable salt thereof.

[022] The invention provides a compound having the structure shown in Formula IA: abd (Rb)m where: R' and R'' are selected independently from H, (C1-C6)alkyl, (C1-C6)alkenyl and (C1-C6)alkynyl, wherein the aforementioned (C1 Petition 870260002828, dated 12 / 01 / 2026, p. 18 / 237 9 / 211 (C1-C6)alkyl, (C1-C6)alkenyl and (C1-C6)alkynyl are optionally substituted with one to four substituents, independently selected from the group consisting of -OH, -O(C1-C4)alkyl, -O(C1-C4)alkenyl, -O(C1-C4)alkynyl, chlorine and fluorine, or R' and R'', together with the nitrogen to which they are attached, combine to form a (C1-C1-C1-heterocycloalkyl), wherein said (C1-C1-C1-heterocycloalkyl) is optionally substituted with one to four substituents, independently selected from the group consisting of -OH, -O(C1-C4)alkyl, -O(C1-C4)alkenyl, -O(C1-C4)alkynyl, chlorine and fluorine; each occurrence of Rbé -O(Ci-C4)alkyl, wherein said -O(Ci-C4)alkyl is optionally substituted with one or two substituents, selected independently from the group consisting of -OH, O(Ci-C4)alkyl, -O(Ci-C4)alkenyl, -O(Ci-C4)alkynyl, chlorine and fluorine; A is selected from . V(R“tx' X r1R.Rí(R>»-vj<R%--f “> p ,N° VΆ° Aim X ' V ' ' ' Rzen; each occurrence of Rz is independently H or (C1-C6)alkyl; each occurrence of Rdé selected independently from OH, (C1-C4)alkyl, -O(C1-C4)alkyl, chlorine and fluorine; H s iNCl·ζII < B is the ; D is a lipid chain selected from: Petition 870260002828, dated 12 / 01 / 2026, page 19 / 237 10 / 211 in which any carbon in the lipid chain is optionally substituted with -OH, -O(C1-C4)alkyl, -O(C1-C4)alkenyl, -O(C1-C4)alkynyl, chlorine and fluorine, where is the cis or trans stereochemistry; X1 is -O-, -C(R)2- or -NR-, and each occurrence of R is selected independently from H, (C1C4)alkyl, (C1-C4)alkenyl, (C1-C4)alkynyl, -OH, -O(C1-C4)alkyl, -O(C1C4)alkenyl, -O(C1-C4)alkynyl, chlorine and fluorine; m is 0, 1 or 2; n is 0, 1, 2 or 3; p is 0, 1 or 2; q is 0, 1, 2, 3, 4, 5, 6, 7, 8 or 9; s is 1, 2, 3, 4, 5, 6, 7 or 8, et is 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17 or 18; or a pharmaceutically acceptable salt thereof.

[023] The invention provides a compound having the structure shown in Formula II: Petition 870260002828, dated 12 / 01 / 2026, p. 20 / 237 11 / 211 where: R1 is (C1-C6)alkyl,wherein said (C1-Cg)alkyl is optionally substituted with one to four substituents selected from -OH and O(CH3); R2 is H, methyl or -O(CH3); each occurrence of R3 is independently H, (C1-C4)alkyl, (C1C4)alkenyl, (C1-C4)alkynyl or -O(C1-C4)alkyl, wherein said (C1C4)alkyl, (C1-C4)alkenyl, (C1-C4)alkynyl or -O(C1-C4)alkyl is optionally substituted with one or two substituents selected independently from -OH and -O(CH3); Each occurrence of R4 is independently H, (C1-C4)alkyl, (C1-C4)alkenyl, (C1-C4)alkynyl or -O(C1-C4)alkyl, wherein said (C1-C4)alkyl, (C1-C4)alkenyl, (C1-C4)alkynyl or -O(C1-C4)alkyl is optionally substituted with one or two substituents selected independently from -OH and -O(CH3); R5 is selected from (C6-C20)alkyl, (C6-C20)alkenyl and (C6C20)alkynyl, wherein said (C6-C20)alkyl,(C6-C20)alkenyl and (C6C20)alkynyl are optionally substituted with one to six substituents Petition 870260002828, dated 12 / 01 / 2026, page 21 / 237 12 / 211 independently selected from -OH, -O(C1-C4)alkyl, -O(C1C4)alkenyl, -O(C1-C4)alkynyl, chlorine and fluorine; and each occurrence of n is 4; or a pharmaceutically acceptable salt thereof.

[024] The invention provides a compound having the structure shown in Formula IIa: wherein: R1 is butyl, wherein said butyl is optionally substituted with one or two -OH; each occurrence of R3 is independently H or -O(CH3); and R5 is H; and R6 is selected from (C10-C20)alkyl, (C10-C20)alkenyl and (C10-C20)alkynyl; or a pharmaceutically acceptable salt thereof.

[025] The invention provides a compound having the structure shown in Formula III: Petition 870260002828, dated 12 / 01 / 2026, p. 22 / 237 13 / 211 where: R1 is (C11-C6)alkyl,wherein said (C1-C1)alkyl is optionally substituted with one to four substituents selected from -OH and O(CH3); R2 is H, methyl or -O(CH3); each occurrence of R3 is independently H, (C1-C4)alkyl, (C1C4)alkenyl, (C1-C4)alkynyl or -O(C1-C4)alkyl, wherein said (C1C4)alkyl, (C1-C4)alkenyl, (C1-C4)alkynyl or -O(C1-C4)alkyl is optionally substituted with one or two substituents selected from -OH and -O(CH3); R4 is selected from (C6-C20)alkyl, (C6-C20)alkenyl and (C6C20)alkynyl, wherein said (C6-C20)alkyl, (C6-C20)alkenyl and (C6C20)alkynyl are optionally substituted with one to six substituents selected from -OH, -O(C1-C4)alkyl, -O(C1-C4)alkenyl, -O(C1C4)alkynyl, chlorine and fluorine; or a pharmaceutically acceptable salt thereof.

[026] The invention provides a compound having the structure shown in Formula IIIa: Petition 870260002828, 12 / 01 / 2026, p. 23 / 237 14 / 211 R4 where: R1 is butyl,wherein said butyl is optionally substituted with one or two -OH; each occurrence of R3 is independently H or -O(CH3); and R4 is selected from (C10-C20)alkyl, (C10-C20)alkenyl and (C10C20)alkynyl; or a pharmaceutically acceptable salt thereof.

[027] The invention provides a compound having the structure shown in Formula IV: R4 R4 wherein: R1 is (C1-C6)alkyl, wherein said (C1-C6)alkyl is optionally substituted with one to four substituents selected from -OH and O(CH3); R2 is H, methyl or -O(CH3); Petition 870260002828, dated 12 / 01 / 2026, p. 24 / 237 15 / 211 each occurrence of R3 is independently H, (C1-C4)alkyl, (C1-C4)alkenyl, (C1-C4)alkynyl or -O(C1-C4)alkyl, wherein said (C1-C4)alkyl, (C1-C4)alkenyl, (C1-C4)alkynyl and -O(C1-C4)alkyl are optionally substituted with one or two substituents selected from -OH and -O(CH3); each occurrence of R4 is independently selected from (C6-C20)alkyl,(C6-C20)alkenyl and (C6-C20)alkynyl, wherein said (C6C20)alkyl, (C6-C20)alkenyl and (C6-C20)alkynyl are optionally substituted with one to six substituents selected from -OH, -O(C1C4)alkyl, -O(C1-C4)alkenyl, -O(C1-C4)alkynyl, chlorine or fluorine, or a pharmaceutically acceptable salt thereof.

[028] The invention provides a compound having the structure shown in Formula IVa: wherein: R1 is butyl, wherein said butyl is optionally substituted with one or two -OH; each occurrence of R3 is independently H or -O(CH3); and each occurrence of R4 is selected independently from (C10-C20)alkyl, (C10-C20)alkenyl and (C10-C20)alkynyl; Petition 870260002828, 12 / 01 / 2026, p. 25 / 237 16 / 211 or a pharmaceutically acceptable salt thereof.

[029] The invention provides the following compounds: (N-(5-(4-(4-((5-amino-7-(butylamino)-2H-pyrazolo[4,3-d]pyrimidin-2yl)methyl)-3,5-dimethoxyphenyl)piperazin-1-yl)-5-oxopentyl)stearamide,também denominado Compound A-1; (5)-N -(5-(4-(4-((5-amino-7-((1-hidroxipentan-2-il)amino)-2 H-pirazolo[4,3d ]pirimidin-2-il)metil)-3,5-dimetoxifenil)piperazin-1-il)-5oxopentil)estearamida, também denominado Compound A-2; (5 )-1-(4-(4-((5-amino-7-((1-hidroxipentan-2-il)amino)-2 H-pirazolo[4,3d ]pirimidin-2-il)metil)-3,5-dimetoxifenil)piperazin-1-il)octadecan-1-ona, também denominado Compound A-3; N -(5-(4-(4-((5-amino-7-(butylamino)-2 H-pyrazolo[4,3-d ]pyrimidin-2-yl)methyl)3-methoxiphenyl)piperazin-1-yl)-5-oxopentyl)estearamida, also called Compound B-1; N -(5-(4-(4-((5-amino-7-(butylamino)-2 H-pyrazolo[4,3-d ]pyrimidin-2-yl)methyl)3-methoxyphenyl)piperazin-1-yl)-5-oxopentyl)tetradecanamida, also called Compound B-2; N -(5-(4-(4-((5-amino-7-(butylamino)-2 H-pyrazolo[4,3-d ]pyrimidin-2-yl)methyl)3-methoxyphenyl)piperazin-1-yl)-5-oxopentyl)oleamida, also called Compound B-3; (9 Z,12 Z)-N -(5-(4-(4-((5-amino-7-(butylamino)-2 H-pyrazole[4,3-d]pyrimidin2-yl)methyl)-3-methoxyphenyl)piperazin-1-yl)-5-oxopentyl)octadeca-9,12-dienamida, também denominated Composto B-4; N -(5-(4-(4-((5-amino-7-(butylamino)-2 H-pyrazolo[4,3-d ]pyrimidin-2-yl)metil)3-methoxyphenyl)-1,4-diazepan-1-yl)-5-oxopentyl)estearamide, também denominated Composto B-5; N -(5-(4-(4-((5-amino-7-(butilamino)-2 H-pyrazolo[4,3-d ]pyrimidin-2-yl)metil)Petição 870260002828, de 12 / 01 / 2026, pág. 26 / 237 17 / 211 3-methoxyphenyl)piperidin-1-yl)-5-oxopentyl)esteramide, também denominated Composto B-6; N -(5-(3-(4-((5-amino-7-(butylamino)-2 H-pyrazolo[4,3-d ]pyrimidin-2-yl)metil)3-methoxyphenyl)azetidin-1-yl)-5-oxopentyl)estearamide, também denominated Composto B-7; 1-(4-((5-amino-7-(butylamino)-2 H -pyrazolo[4,3-d ]pyrimidin-2-yl)methyl)-3methoxyphenyl)-N-(3-stearamidopropyl)piperidine-4-carboxamide, also known as Compound B-8; (1 s ,3 s )-3-(2-(4-(4-((5-amino-7-(butylamino)-2 H--methoxyphenyl)-N-(3-stearamidopropyl)piperidine-4-carboxamide, also known as Compound B-8; (1 s3-d ]pirimidin-2il)metil)-3-metoxifenil)piperazin-1-il)-2-oxoetil)-N -octadecilciclobutano-1carboxamida, também denominado Compound B-9; (1 s ,3 s )-3-(2-(4-(4-((5-amino-7-(butylamino)-2 H-pyrazolo[4,3-d ]pirimidin-2il)metil)-3-metoxifenil)piperazin-1-il)-2-oxoetil)-N -hexadecilciclobutana-1carboxamida, também denominado Compound B-10; N -(3-(4-(4-((5-amino-7-(butylamino)-2 H-pyrazolo[4,3-d ]pyrimidin-2-yl)methyl)3-methoxyphenyl)piperazin-1-yl)-3-oxopropyl)estearamida, also called Compound B-11; N -(7-(4-(4-((5-amino-7-(butylamino)-2 H-pyrazolo[4,3-d ]pyrimidin-2-yl)methyl)3-methoxyphenyl)piperazin-1-yl)-7-oxo-heptyl)estearamida, also called Compound B-12; N -(3-(2-(4-(4-((5-amino-7-(butylamino)-2 H -pyrazolo[4,3-d ]pyrimidin-2yl)methyl)-3-methoxiphenyl)piperazin-1-yl)-2-oxoethyl)cyclobutyl)estearamida, also called Compound B-13; N -(5-(4-(4-((5-amino-7-(butylamino)-2 H-pyrazolo[4,3-d ]pyrimidin-2-yl)methyl)3-methoxyphenyl)piperazin-1-yl)-4,4-dimethyl-5-oxopentyl)estearamida,also called Compound B-14; N -(6-(4-(4-((5-amino-7-(butylamino)-2 H-pyrazolo[4,3-d ]pyrimidin-2-yl)methyl)Petition 870260002828, dated 12 / 01 / 2026, pág. 27 / 237 18 / 211 3-methoxyphenyl)piperazin-1-yl)-2-methyl-6-oxo-hexan-2-yl)estearamida, also called Compound B-15; 1-(4-(4-((5-amino-7-(butylamino)-2 H-pyrazolo[4,3-d ]pirimidin-2-yl)metil)-3metoxifenil)piperazin-1-yl)-5-(octadeciloxi)pentan-1-ona, também denominado Compound B-16; 1-(4-(4-((5-amino-7-(butylamino)-2 H-pyrazolo[4,3-d ]pirimidin-2-yl)metil)-3metoxifenil)piperazin-1-yl)-5-(octadecilamino)pentan-1-ona, também denominado Compound B-17; N -(5-(4-(4-((5-amino-7-(butylamino)-3-methyl-2 H-pyrazolo[4,3-d ]pyrimidin-2yl)methyl)-3-methoxiphenyl)piperazin-1-yl)-5-oxopentyl)estearamida, also called Compound B-18; (9 Z,12 Z)-N -(4-((4-((5-amino-7-(butylamino)-2 H -pyrazolo[4,3-d ]pyrimidin-2yl)methyl)-3,5-dimethoxybenzyl)(methyl)amino)butyl)octadeca-9,12-dienamida,also referred to as Compound C-1; N-(4-((4-((5-amino-7-(butylamino)-2H-pyrazolo[4,3-d]pyrimidin-2-yl)methyl)3,5-dimethoxybenzyl)(methyl)amino)butyl)tetradecanamide, also referred to as Compound C-2; N-(4-((4-((5-amino-7-(butylamino)-2H-pyrazolo[4,3-d]pyrimidin-2-yl)methyl)3,5-dimethoxybenzyl)(methyl)amino)butyl)oleamide, also referred to as Compound C-3; N-(4-((4-((5-amino-7-(butylamino)-2H-pyrazolo[4,3-d]pyrimidin-2-yl)methyl)3,5-dimethoxybenzyl)(methyl)amino)butyl)stearamide, also referred to as Compound C-4; N-(4-((4-((5-amino-7-(butylamino)-2H-pyrazolo[4,3-d]pyrimidin-2-yl)methyl)3,5-dimethoxybenzyl)(methyl)amino)-4-oxobutyl)stearamide, also called Compound C-5; (methyl)amino)butyl)carbamate (6Z,9Z,28Z,31Z)-heptatriacontaPetition 870260002828, of 01 / 12 / 2026, p. 28 / 237 19 / 211 6,9,28,31-tetraen-19-yl (4-((4-((5-amino-7-(butylamino)-2 H-pyrazolo[4,3d]pyrimidin-2-yl)methyl)-3,5-dimethoxybenzyl), also called Compound D1; 4-(4-((5-amino-7-(butylamino)-2 H -pyrazolo[4,3-d ]pyrimidin-2-yl)methyl)-3-methoxyphenyl)-N-(3-stearamidopropyl)piperazine-1-carboxamide, also known as Compound D-2; 4-(4-((5-amino-7-(butylamino)-2H-pyrazolo[4,3-d ]pyrimidin-2-yl)methyl)-3-methoxyphenyl)piperazine-1-carboxylate of 3-stearamidopropyl, also known as Compound D-3; N-(5-(4-(((5-amino-7-(butylamino)-2H-pyrazolo[4,3-d ]pyrimidin-2-yl)methyl)3-methoxyphenyl)piperazine-1-yl)-6,6,6-trifluorohexyl)stearamide, also known as Compound D-4; N-(4-((4-((7-(butylamino)-5-hydroxy-2H-pyrazolo[4,3-d]pyrimidin-2-yl)methyl)3,5-dimethoxybenzyl)(methyl)amino)butyl)stearamide, also referred to as Compound D-5, and (5-(4-(4-((5-amino-7-(butylamino)-2H-pyrazolo[4,3-d]pyrimidin-2-yl)methyl)-3-methoxyphenyl)piperazin-1-yl)-5-oxopentyl)carbamate of (6Z,9Z,28Z,31Z)heptatriaconta-6,9,28,31-tetraen-19-yl, also referred to as Compound D-6; or a pharmaceutically acceptable salt thereof.

[030] The invention provides the following compound: N-(5-(4-(4-((5-amino-7-(butylamino)-2 H-pyrazolo[4,3-d ]pirimidin-2-yl)methyl)3-methoxyphenyl)piperazin-1-yl)-5-oxopentyl)stearamide, also referred to as Compound B-1; or a pharmaceutically acceptable salt thereof.

[031] The invention also provides a stable nanoemulsion comprising: (i) one or more compounds having the structure shown in Formula I, I, Ia, II, IIa, III, IIIa, IV or IVa or pharmaceutically acceptable salt(s) Petition 870260002828, 12 / 01 / 2026, p. 29 / 237 20 / 211 thereof; ii) one or more emulsifiers, and iii) one or more terpenes.

[032] The invention also provides a stable nanoemulsion comprising: (i) one or more compounds having the structure shown in Formulas I, Ia, II, IIa, III, IIIa, IV or IVa or pharmaceutically acceptable salt(s) thereof; ii) one or more sorbitan-based surfactants; and iii) one or more terpenes.

[033] The invention also provides a stable nanoemulsion comprising: (i) N-(5-(4-(4-((5-amino-7-(butylamino)-2H-pyrazolo[4,3d]pyrimidin-2-yl)methyl)-3-methoxyphenyl)piperazin-1-yl)-5-oxopentyl)stearamide, or a pharmaceutically acceptable salt thereof; (ii) sorbitan trioleate (SPAN85); (iii) polysorbate-20 (PS-20) or polysorbate-80 (PS-80), and (iv) squalene.

[034] The invention also provides a stable nanoemulsion comprising: (i) at least one antigen; (ii) a compound having the structure shown in Formula I, Ia, II, IIa, III, IIIa, IV or IVa or a pharmaceutically acceptable salt thereof; (ii) SPAN-85; (iii) PS-20 or PS-80, and (iv) squalene.

[035] The invention also provides a stable nanoemulsion comprising: (i) at least one antigen; (ii) N-(5-(4-(4-((5-amino-7(butylamino)-2H-pyrazolo[4,3-d]pyrimidin-2-yl)methyl)-3-methoxyphenyl)piperazin-1yl)-5-oxopentyl)stearamide, or a pharmaceutically acceptable salt thereof; (ii) SPAN-85; (iii) PS-20 or PS-80,and (iv) squalene.

[036] The invention also provides a pharmaceutical composition comprising: (i) at least one antigen; (ii) a compound having the structure shown in Formula I, Ia, II, IIa, III, IIIa, IV or IVa or a pharmaceutically acceptable salt thereof; (iii) SPAN-85; (iv) PS-20 or PS-80; (v) squalene; and (vi) a pharmaceutically acceptable carrier.

[037] The invention also provides a pharmaceutical composition Petition 870260002828, dated 12 / 01 / 2026, p. 30 / 237 21 / 211 comprising: (i) at least one antigen; (ii) N-(5-(4-(4-((5-amino-7(butylamino)-2H-pyrazolo[4,3-d]pyrimidin-2-yl)methyl)-3-methoxyphenyl)piperazin-1yl)-5-oxopentyl)stearamide or a pharmaceutically acceptable salt thereof; (iii) SPAN-85; (iv) PS-20 or PS-80; (v) squalene; and (vi) a pharmaceutically acceptable carrier.

[038] The invention also provides an immunogenic composition comprising: (i) at least one antigen; (ii) a compound having the structure shown in Formula I, Ia, II, IIa, III, IIIa,IV or IVa or a pharmaceutically acceptable salt thereof; (iii) SPAN-85; (iv) PS-20 or PS-80; (v) squalene, and (vi) a pharmaceutically acceptable carrier.

[039] The invention also provides an immunogenic composition comprising: (i) at least one antigen; (ii) N-(5-(4-(4-((5-amino-7(butylamino)-2H-pyrazolo[4,3-d]pyrimidin-2-yl)methyl)-3-methoxyphenyl)piperazin-1yl)-5-oxopentyl)stearamide, or a pharmaceutically acceptable salt thereof; (iii) SPAN-85; (iv) PS-20 or PS-80; (v) squalene, and (vi) a pharmaceutically acceptable carrier.

[040] The invention also provides a single-dose vaccine composition comprising: (i) at least one antigen; (ii) a compound having the structure shown in Formula I, Ia, II, IIa, III, IIIa, IV or IVa or a pharmaceutically acceptable salt thereof; (iii) SPAN-85; (iv) PS-20; (v) squalene; and (vi) a pharmaceutically acceptable carrier.wherein a single dose of the vaccine composition is sufficient to elicit a desired immune response against at least one antigen.

[041] The invention also provides a single-dose vaccine composition comprising: (i) at least one antigen; (ii) N-(5-(4-(4-((5-amino-7(butylamino)-2H-pyrazolo[4,3-d]pyrimidin-2-yl)methyl)-3-methoxyphenyl)piperazin-1yl)-5-oxopentyl)stearamide, or a pharmaceutically acceptable salt thereof; Petition 870260002828, dated 12 / 01 / 2026, p. 31 / 237 22 / 211 (iii) SPAN-85; (iv) PS-20; (v) squalene, and (vi) a pharmaceutically acceptable carrier, wherein a single dose of the vaccine composition is sufficient to elicit a desired immune response against at least one antigen.

[042] The invention also provides a method for treating or preventing disease in a patient, comprising administering to the patient a pharmaceutical composition comprising: (i) at least one antigen; (ii) a compound having the structure presented in Formula I, Ia, II, IIa, III,IIIa, IV or IVa or a pharmaceutically acceptable salt thereof; (iii) SPAN-85; (iv) PS-20; (v) squalene, and (vi) a pharmaceutically acceptable carrier.

[043] The invention also provides a method for treating or preventing diseases in a patient, comprising administering to the patient a pharmaceutical composition comprising: (i) at least one antigen; (ii) N-(5-(4-(4-((5-amino-7-(butylamino)-2H-pyrazolo[4,3-d]pyrimidin-2-yl)methyl)-3-methoxyphenyl)piperazin-1-yl)-5-oxopentyl)stearamide, or a pharmaceutically acceptable salt thereof; (iii) SPAN-85; (iv) PS-20; (v) squalene, and (vi) a pharmaceutically acceptable carrier.

[044] In some embodiments of the methods disclosed in the present invention, the patient is a human being.

[045] In some embodiments of the methods disclosed in the present invention, the patient is a non-human animal.

[046] In some embodiments of i) stable nanoemulsions; ii) pharmaceutical compositions; iii) immunogenic compositions,and iv) single-dose vaccine compositions above, the concentration of the compound (i.e., (a) a compound having the structure shown in Formula I, Ia, II, IIa, III, IIIa, IV or IVa or a pharmaceutically acceptable salt thereof or (b) N-(5-(4-(4-((5-amino7-(butylamino)-2H-pyrazolo[4,3-d]pyrimidin-2-yl)methyl)-3-methoxypenyl)piperazin1-yl)-5-oxopentyl)stearamide, or a pharmaceutically acceptable salt thereof) is from 0.01 pg / mL to 1000 pg / mL or from 0.1 μg / mL to 100 μg / mL or 80 μg / mL or 16 μg / mL or 4 μg / mL.

[047] In some embodiments of the i) stable nanoemulsions; ii) pharmaceutical compositions; iii) immunogenic compositions, and iv) single-dose vaccine compositions above, the concentration of SPAN-85 is 0.001 mg / mL to 100 mg / mL or 0.01 mg / mL to 50 mg / mL or 0.1 mg / mL to 10 mg / mL or 0.001 mg / mL to 30 mg / mL or 0,2 mg / mL to 10 mg / mL.

[048] In some embodiments of the i) stable nanoemulsions; ii) pharmaceutical compositions; iii) immunogenic compositions, and iv) single-dose vaccine compositions above, the concentration of PS-20 or PS-80 is 0.001 mg / mL to 100 mg / mL or 0.01 mg / mL to 50 mg / mL or 0.1 mg / mL to 10 mg / mL or 0.001 mg / mL to 30 mg / mL or 0.2 mg / mL to 10 mg / mL.

[049] In some embodiments of the i) stable nanoemulsions; ii) pharmaceutical compositions; iii) immunogenic compositions, and iv) single-dose vaccine compositions above, the squalene concentration is 0.01 mg / mL to 100 mg / mL or 0.02 mg / mL to 20 mg / mL or 1 mg / mL to 20 mg / mL or 0.03 mg / mL to 30 mg / mL or 0.5 mg / mL to 20 mg / mL.

[050] In some embodiments of i) stable nanoemulsions; ii) pharmaceutical compositions; iii) immunogenic compositions, and iv) single-dose vaccine compositions above, the compound concentration is 80 pg / mL, the SPAN-85 concentration is 4.8 mg / mL, the PS-20 or PS-80 concentration is 4.8 mg / mL,and the squalene concentration is 16 mg / mL.

[051] In some embodiments of the i) stable nanoemulsions; ii) pharmaceutical compositions; iii) immunogenic compositions, and iv) single-dose vaccine compositions above, the compound concentration is 16 pg / mL, the SPAN-85 concentration is 4.8 mg / mL, the PS-20 or PS-80 concentration is 4.8 mg / mL, and the squalene concentration is 16 mg / mL. Petition 870260002828, dated 12 / 01 / 2026, p. 33 / 237 24 / 211

[052] In some embodiments of the i) stable nanoemulsions; ii) pharmaceutical compositions; iii) immunogenic compositions, and iv) single-dose vaccine compositions above, the compound concentration is 4 pg / mL, the SPAN-85 concentration is 4.8 mg / mL, the PS-20 or PS-80 concentration is 4.8 mg / mL, and the squalene concentration is 16 mg / mL.

[053] In some embodiments of i) stable nanoemulsions; ii) pharmaceutical compositions; iii) immunogenic compositions, and iv) single-dose vaccine compositions above,The nanoemulsions and / or compositions additionally comprise L-met and EDTA. DEFINITIONS

[054] The following abbreviations are used in the present invention: [Ni(dtbbpy)(H2Ü)4]Cl2 tetra-aquo[4,4'-bis(1,1-dimethylethyl)-2,2'-bipyridine]nickel(II) dichloride AcOH acetic acid Anh Anhydrous APA adjuvant aluminum phosphate Aq Aqueous(a) Bn Benzyl Boc or BOC tert-butoxycarbonyl BOP (Benzotriazol-1-yloxytris(dimethylamino)phosphonium hexafluorophosphate) Bs broad singlet BSI bloodstream infection BTMG 2-tert-butyl-1,1,3,3-tetramethylguanidine Bz Benzoyl calc'd Calculated Cbz Benzyloxycarbonyl CD3OD deuterated methanol CDCl3 deuterated chloroform CDI diimidazole carbonyl Celite terra Diatomaceous earth CH3CN Acetonitrile CMBP (cyanomethylene)tributylphosphorane CRAB Carbapenem-resistant Acinetobacter baumannii Petition 870260002828, dated 12 / 01 / 2026,page. 34 / 237 25 / 211 Cs2CO3 D Dba DBAB DBU DCE DCM DIEA or DIPEA DMAP DMF DMP DMSO DNA Dppf EDC ESI Et Et2O Et3N EtOAc EtOH FL GH HAP HATU Cesium carbonate Dibenzylidene azodicarboxylate Di-tert-butyl 1,8-diazabicyclo(5.4.0)undec-7-ene Dichloroethane Dichloromethane N,N-diisopropylethylamine 4-dimethylaminopyridine N,N-dimethylformamide Dess-Martin periodinane Dimethyl sulfoxide Deoxyribonucleic acid 1,1'-bis(diphenylphosphine)ferrocene 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide Electrospray ionization Ethyl diethyl ether Triethylamine ethyl acetate Ethanol Compound Gram Hour hospital-acquired pneumonia 1[bis(dimethylamino)methylene]-1H-1,2,3triazolo[4,5-b]pyridinium HCl Hex HMDS HPLC HPSEC hydrochloric acid Hexanes hexamethyldisilazane high-performance liquid chromatography high-performance size exclusion chromatography IBX IM Int IPA iPr 2-iodoxybenzoic acid inner membrane Intermediate Isopropanol Isopropyl Ir[df(CF3)ppy]2(dtbbpy)PF6 [4,4'-bis(1,1-dimethylethyl) hexafluorophosphate Petition 870260002828, dated 12 / 01 / 2026, page 35 / 237 26 / 211 2,2'-bipyridine-N1, N 1']bis[3,5-difluoro-2-[5(trifluoromethyl)-2-pyridinyl-N]phenyl-C]Iridium(III) K2CO3 LC LC / MS potassium carbonate liquid chromatography liquid chromatography coupled to mass spectrometry LED LOS LPS M MDR Me Me2S MeCN MeOH Mg MgSO4 Min mL Mmol MP-(OAc)3BH MS Mw Na2SO4 NaBH(OAc)3 NaBH4 NaN3 NaOH NaOMe NaOtBu n-Bu NCS NH4OH NMI NMR NMWCO OAc OM PCV Pd light-emitting diode Lipo-oligosaccharide Lipopolysaccharide Multiplex resistant to multiple drugs Methyl dimethyl sulfide Acetonitrile Methanol Milligrams magnesium sulfate Minutes Milliliters Millimoles MP-triacetoxyborohydride mass spectrometry molecular weight sodium sulfate triacetoxyborohydride Sodium borohydride, sodium azide, sodium hydroxide, sodium methoxide, tert-butoxide, n-butyl N-chlorosuccinimide, ammonium hydroxide, N-methylimidazole, nuclear magnetic resonance spectroscopy, nominal molecular weight cutoff, acetate outer membrane, pneumococcal conjugate vaccine, palladium, Petition 870260002828of 01 / 12 / 2026, p. 36 / 237 27 / 211 PD1 PD2 PD3 Pet. Ph PMe3 PnPs PPh3 Ppm prep-TLC Ps PS-20 PS-80 Psi Py Q RT or rt RuPhos RuPhos Pd G2 post-dose 1 post-dose 2 post-dose 3 Petroleum Phenyl Trimethylphosphine pneumococcal polysaccharide Triphenylphosphine parts per million preparative thin-layer chromatography Polysaccharide polysorbate-20 polysorbate-80 pounds per square inch Pyridine Quartet room temperature 2-dicyclohexylphosphino-2',6'-diisopropoxybiphenyl chloro(2-dicyclohexylphosphino-2',6'-diisopropoxy1,1'-biphenyl)[2-(2'-amino-1,1'-biphenyl)]palladium(II) S Sat SFC SNE SPAN-85 ST T TBAF TBDPS TBDPSCl TBS or TBDMS TBSCl t-Bu TCFH Saturated Singlet supercritical fluid chromatography stable nanoemulsion sorbitan-trioleate Serotype Triplet tert-butyl ammonium fluoride tert-butyldiphenylsilyl chloride tert-butyldiphenylsilyl chloride tert-butyldimethylsilyl chloride tert-butyldimethylsilyl chloride tert-butyl chlorine hexafluorophosphate-N,N,N',N'-tetramethylformandinium TEA TFA THF TLC TMS Triethylamine trifluoroacetic acid Tetrahydrofuran thin-layer chromatography Trimethylsilyl Petition 870260002828, dated 12 / 01 / 2026, page. 37 / 237 28 / 211 TMSBr trimethylsilyl bromide TMSCl Chlorotrimethylsilane TMSN3 trimethylsilyl azide Tris tris(hydroxymethyl)aminomethane UPLC ultra-high performance liquid chromatography w / v weight per volume pL Microliters

[055] As used throughout this descriptive report and in the appended claims, the singular forms “a”, “an”, and “the” include plural references unless the context clearly dictates otherwise.

[056] The term “about”, when used in the present invention in reference to a value, refers to a value that is equal to or, in the context, similar to the referenced value. In general, those skilled in the art and familiar with the context will appreciate the absolute amount and / or relative degree of difference encompassed by “about” in that context. For example, in some embodiments,the term “about” may encompass a range of values ​​that are within 25%, 20%, 19%, 18%, 17%, 16%, 15%, 14%, 13%, 12%, 11%, 10%, 9%, 8%, 7%, 6%, 5%, 4%, 3%, 2%, 1% or less of the reference value.

[057] An “adjuvant,” as defined in the present invention, refers to a compound or formulation or composition of compounds that serves to increase the immunogenicity of a composition of the invention. An adjuvant may i) increase the immune response to an antigen (e.g., a pneumococcal polysaccharide) that is weakly immunogenic when administered alone, for example, by inducing null or weak antibody titers or cell-mediated immune response; ii) increase antibody titers against the antigen, and / or iii) decrease the dose of the antigen effective to achieve an immune response in the individual.

[058] As used in the present invention, the term “administration” refers to the act of providing an active agent,composition or formulation to an individual. Exemplary routes of administration to the human body may be through the eyes (ophthalmic), mouth (oral), skin (transdermal), nose (nasal), lungs (inhalant), rectal, vaginal, oral mucosa (buccal), ear, by injection (e.g., intravenous (IV), subcutaneous, intratumoral, intraperitoneal, intramuscular (IM), intradermal (ID), etc.) and the like.

[059] As used in the present invention, an agent refers to a particle, compound, molecule, or entity of any chemical class.

[060] As used in the present invention, the term alkyl refers to a saturated aliphatic hydrocarbon of linear, cyclic, or branched chain having the specified number of carbon atoms. A numerical range, which refers to the total chain length, may be given. For example, a C1-C6 alkyl has a chain length of 1 to 6 atoms. An alkyl group may be optionally replaced by one or more substituents.which may be the same or different and are defined in the present invention below. Unless otherwise indicated, an alkyl group is unsubstituted.

[061] As used in the present invention, the term alkenyl means an unsaturated aliphatic hydrocarbon of a linear, cyclic or branched chain having the specified number of carbon atoms, including, but not limited to, unsaturated aliphatic hydrocarbons of dienes, trienes and tetraenes. An alkenyl group may optionally be substituted with one or more substituents, which may be the same or different and are defined in the present invention below. Unless otherwise indicated, an alkenyl group is unsubstituted.

[062] As used in the present invention, the term alkynyl means an unsaturated aliphatic hydrocarbon of a linear, cyclic or branched chain having the specified number of carbon atoms, including, but not limited to, unsaturated aliphatic hydrocarbons of dienes,triene and tetraene. An alkyl group may optionally be substituted with one or more substituents, which may be the same or different and are defined in the present invention below. Unless otherwise indicated, an alkyl group is unsubstituted.

[063] As used in the present invention, the term antigen refers to any antigen that can generate one or more immune responses. The antigen may be a protein, peptide, or polypeptide. In certain embodiments, the antigen is a lipid or a carbohydrate. In certain embodiments, the antigen is a polysaccharide. In certain embodiments, the antigen is a pneumococcal polysaccharide. In certain embodiments, the polysaccharide is an S. pneumoniae polysaccharide. The antigen may be one that generates a humoral and / or immune response from CTLs.

[064] As used in the present invention,The term aryl refers to a system of monocyclic or bicyclic aromatic carbocycle rings comprising from about 6 to about 14 carbon atoms. In one embodiment, an aryl group contains from about 6 to about 10 carbon atoms. An aryl group may optionally be substituted with one or more substituents of the ring system, which may be the same or different and are as defined in the present invention below. Non-limiting examples of aryl groups include phenyl and naphthyl. In one embodiment, an aryl group is phenyl. Unless otherwise indicated, an aryl group is unsubstituted.

[065] As used in the present invention, the term composition refers to a formulation containing an active pharmaceutical or biological ingredient (for example, a pneumococcal polysaccharide-carrier protein conjugate and a compound),together with one or more additional components. The term composition is used interchangeably with pharmaceutical composition and formulation. Compositions may be liquid or solid (e.g., lyophilized). Additional components that may be included, as appropriate, include pharmaceutically acceptable excipients, additives, diluents, buffers, sugars, amino acids, chelating agents, surfactants, polyols, bulking agents, stabilizers, lyophilized agents, solubilizers, emulsifiers, salts, adjuvants, tonicity-enhancing agents, delivery vehicles, and antimicrobial preservatives. The compositions are not toxic to receptors at the dosages and concentrations employed.

[066] As used in the present invention, the term “comprises”, when used with the composition of the invention, refers to the inclusion of any other components, such as adjuvants and excipients,or to the addition of one or more polysaccharide-carrier protein conjugates that are not specifically enumerated.

[067] As used in the present invention, the term “consisting of” and variations such as “consist of”, when used with a mixture of multivalent polysaccharides or a mixture of multivalent polysaccharide-carrier protein conjugates, refers to a mixture containing such S. pneumoniae-specific polysaccharides or S. pneumoniae polysaccharide-carrier protein conjugates and no other S. pneumoniae polysaccharides or S. pneumoniae polysaccharide-carrier protein conjugates of a different serotype.

[068] As used in the present invention, the term “consists essentially of” and variations such as “consist essentially of” or “consisting essentially of” indicate the inclusion of any enumerated elements or groups of elements, and the optional inclusion of other elements,of a similar or different nature from the enumerated elements, which do not materially alter the basic or innovative properties of the specified dosage regime, method, or composition. Petition 870260002828, dated 12 / 01 / 2026, page 41 / 237 32 / 211

[069] As used in the present invention, the term “O-deacetylated15B” or “de-O-acetyl-15B” or “de-O-Ac-15B” refers to an O-deacetylated 15B serotype, in which the O-acetyl content is less than 10% per repeat unit. In another embodiment, the O-acetyl content is less than 5% per repeat unit. In another embodiment, the O-acetyl content is less than about 1% per repeat unit. In another embodiment, the O-acetyl content is less than 1% per repeat unit. In another embodiment, the O-acetyl content is less than 0.5% per repeating unit. In another embodiment, the O-acetyl content is less than 0.1% per repeating unit. In another embodiment,The O-acetyl content is 0% per repeating unit. Processes for O-deacetylation are known in the art, for example, as described in Rajam et al., Clinical and Vaccine Immunology, 2007, 14(9):1223-1227.

[070] As used in the present invention, the term “dose” means an amount of an agent, API (active pharmaceutical ingredient), formulation, composition, pharmaceutical composition or immunogenic composition taken or recommended to be taken at a given time.

[071] As used in the present invention, the term “heteroaryl” refers to a system of monocyclic or multicyclic aromatic rings comprising from 5 to 14 ring atoms, wherein 1 to 4 of the ring atoms are independently O, N or S and the remaining ring atoms are carbon atoms. In one embodiment, a heteroaryl group has from 5 to 10 ring atoms. In another embodiment, a heteroaryl group is monocyclic and has 5 or 6 atoms in the ring. In yet another embodiment,A heteroaryl group is bicyclic. A heteroaryl group may optionally be substituted with one or more “ring system substituents,” which may be the same or different and are as defined in the present invention below. A heteroaryl group is linked via a carbon atom of the ring, and any nitrogen atom of a heteroaryl group may optionally be oxidized to the corresponding N-oxide. In one embodiment, a heteroaryl group is a 5-membered heteroaryl. In another embodiment, a heteroaryl group is a 6-membered heteroaryl. In another embodiment, a heteroaryl group comprises a 5- to 6-membered heteroaryl group fused to a benzene ring. Unless otherwise indicated, a heteroaryl group is unsubstituted.

[072] As used in the present invention, the term heterocycloalkyl means a monocyclic, bicyclic (including spirocyclic) or bridging carbocyclic ring or ring system,Saturated or partially unsaturated, non-aromatic, comprising from 3 to about 11 ring atoms, containing at least one heteroatom in the ring selected from N, S, and O, and the remaining ring atoms being carbon atoms. A heterocycloalkyl group may be attached via a carbon or nitrogen atom of the ring, unless otherwise specified. The heterocycloalkyl ring may be substituted at the ring carbons and / or at the ring nitrogen(s). In one embodiment, a heterocycloalkyl group is monocyclic and has from about 3 to about 7 ring atoms. In another embodiment, a heterocycloalkyl group is monocyclic and has from about 4 to about 7 ring atoms. In other embodiments, the heterocycloalkyl group is bicyclic and has from 7 to 10 ring atoms, from 8 to 10 ring atoms, or from 9 to 10 ring atoms. In yet another embodiment, a heterocycloalkyl group is monocyclic and has 5 or 6 atoms in the ring. In one embodiment,A heterocycloalkyl group is monocyclic. In another embodiment, a heterocycloalkyl group is bicyclic. Heterocycloalkyl groups can be substituted. In some embodiments, the heterocycloalkyl groups have 1 to 2 heteroatoms selected from nitrogen, sulfur, and oxygen atoms in the ring. In some embodiments, the heterocycloalkyl groups have 1 heteroatom selected from nitrogen, sulfur, and oxygen atoms in the ring. In some embodiments, the heteroatoms are selected from O, S, S(O), S(O)2 and —NH—, —N(alkyl)-. Non-limiting examples include ethers, thioethers, amines, hydroxymethyl, 3-hydroxypropyl, 1,2-dihydroxyethyl, 2-methoxyethyl, 2-aminoethyl, 2-dimethylaminoethyl and a similar aliphatic group containing a heteroatom.

[073] As used in the present invention, the term immunogenic or immunogenicity refers to the ability of an antigen (e.g.,a polysaccharide of 5. pneumoniae) to elicit an immune response in an individual. The term immunogenic composition refers to the ability of an agent, API, formulation, composition, or pharmaceutical compound to elicit an immune response in an individual.

[074] As used in the present invention, the expression in need of treatment includes those previously exposed to or infected by a disease-causing agent, those who have been previously vaccinated against a disease-causing agent, as well as those prone to infection or any person in whom it is desired to reduce the likelihood of infection, for example, immunocompromised individuals, the elderly, children, adults, or healthy individuals.

[075] As used in the present invention, the expression indicated for disease prevention means that a vaccine or composition is approved by one or more regulatory authorities, such as the U.S. Food and Drug Administration (FDA),for the prophylaxis of one or more diseases caused by an infectious agent or antigen. Infectious agents or antigens include HIV, HPV, CMV, VZV, EBV, adenovirus, coronavirus, and influenza, among other viruses. Diseases include bacterial diseases such as tuberculosis and pneumococcal pneumonia, among others. Petition 870260002828, dated 12 / 01 / 2026, p. 44 / 237 35 / 211

[076] As used in the present invention, the term “multiple dose” refers to a vaccine composition, pharmaceutical composition, or immunogenic composition that requires more than one dose, administration, or injection of its components in a clinical regimen to induce a durable immune response and provide protection against a disease or decrease the likelihood of infection by an infectious agent. A person skilled in the art would understand how to determine a durable immune response, for example, by measuring antibody titers over a specific period of time.

[077] As used in the present invention,A “patient” (alternatively referred to in this document as an “individual”) refers to a mammal capable of being infected by a disease-causing agent. In some embodiments, the patient is a human being. A patient may be treated prophylactically or therapeutically. Prophylactic treatment provides sufficient protective immunity to reduce the likelihood or severity of an infection or its effects. Therapeutic treatment may be performed to reduce the severity or prevent recurrence of an infection or its clinical effects. Prophylactic treatment may be performed using a composition, vaccine, or immunogenic composition of the invention, as described in the present invention. The compositions, vaccines, or immunogenic compositions of the invention may be administered to the general population or to persons at higher risk of infection, for example, the elderly or persons living with the elderly or their caregivers.

[078] As used in the present invention,The term “PCV1” refers to a monovalent pneumococcal conjugate vaccine or composition comprising a 5. pneumoniae polysaccharide-carrier protein conjugate, comprising a capsular polysaccharide of a 5. pneumoniae serotype conjugated to a carrier protein. In specific embodiments, Petition 870260002828, dated 12 / 01 / 2026, pp. 45 / 237 36 / 211, the carrier protein is CRM197.

[079] As used in the present invention, the term PCV24 refers to a 24-valent pneumococcal conjugate composition or vaccine comprising twenty-three 5. pneumoniae carrier protein polysaccharide conjugates, each comprising a capsular polysaccharide of a 5. pneumoniae serotype conjugated to a carrier protein, wherein the 5. pneumoniae serotypes are: 1, 3, 4, 5, 6A, 6B, 7F, 8, 9V, 10A, 11A, 12F, 14, 15A, 18C, 19A, 19F, 22F, 23B, 24F, 31, 33F and 35B, and at least one of the following serotypes of serogroup 15: 15B, 15C or O-deacetylated-15B. In a specific modality,The serotype of serogroup 15 is serotype 15C or 15B O-deacetylated. In another embodiment, the serotype of serogroup 15 is serotype 15B O-deacetylated. In specific embodiments, the carrier protein of one or more of the 5. pneumoniae polysaccharide-carrier protein conjugates is CRM197. In additional embodiments, the carrier protein of each of the 5. pneumoniae polysaccharide-carrier protein conjugates is CRM197.

[080] As used in the present invention, the term “PCV26” refers to a 26-valent pneumococcal conjugate composition or vaccine comprising twenty-five 5. pneumoniae polysaccharide-carrier protein conjugates, each comprising a capsular polysaccharide of a 5. pneumoniae serotype conjugated to a carrier protein, wherein the 5. pneumoniae serotypes are: 1, 3, 4, 5, 6A, 6B, 7F, 8, 9V, 10A, 11A, 12F, 14, 15A, 16F, 18C, 19A, 19F, 22F, 23A, 23B, 24F, 31, 33F and 35B, and at least one of the following serotypes of serogroup 15: 15B,15C or O-deacetylated-15B. In one specific embodiment, the serotype of serogroup 15 is serotype 15C or O-deacetylated 15B. In another embodiment, the serotype of serogroup 15 is O-deacetylated serotype 15B. In specific embodiments, the carrier protein of one or more of the S. pneumoniae polysaccharide-carrier protein conjugates is CRM197. In additional embodiments, the carrier protein of each of the S. pneumoniae polysaccharide-carrier protein conjugates is CRM197.

[081] As used in the present invention, the term “pharmaceutically acceptable”, in relation to a carrier, diluent or excipient of a pharmaceutical composition, indicates that a carrier, diluent or excipient must be compatible with the other ingredients of the composition and not harmful to its recipient.

[082] As used in the present invention,The term “pharmaceutical composition” refers to a composition containing an active pharmaceutical or biological ingredient, together with one or more additional components, for example, a composition in which an active agent is formulated together with one or more pharmaceutically acceptable carriers. As used in the present invention, the terms “pharmaceutical formulation” and “formulation” are used interchangeably with “pharmaceutical composition.” In some embodiments, the active agent is present in a unit dose amount appropriate for administration in a therapeutic regimen that shows a statistically significant probability of achieving a predetermined therapeutic effect when administered to a relevant population. Pharmaceutical compositions or formulations may be liquid or solid (e.g., lyophilized). Additional components that may be included, as appropriate, include pharmaceutically acceptable excipients, additives, diluents, buffers,Sugars, amino acids, chelating agents, surfactants, polyols, bulking agents, stabilizers, lipoprotectors, solubilizers, emulsifiers, salts, adjuvants, tonicity-enhancing agents, delivery vehicles, and antimicrobial preservatives. The pharmaceutical compositions or formulations are not toxic to receptors at the dosages and concentrations used. In some embodiments, a pharmaceutical composition may be specially formulated for administration in solid or liquid form, including those adapted for: oral administration, for example, drenches (aqueous or non-aqueous solutions or suspensions), tablets, for example, those intended for buccal, sublingual or systemic absorption, boluses, powders, granules, pastes for application to the tongue; parenteral administration, for example, by subcutaneous, intramuscular, intravenous or epidural injection, such as a sterile solution or suspension,or sustained-release formulation; topical application, for example, as a cream, ointment, or patch or controlled-release spray applied to the skin, lungs, or oral cavity; intravaginally or intrarectally, for example, as an ovule, cream, or foam; sublingually; ocularly; transdermally; or nasally, pulmonaryly, and on other mucous surfaces. In some embodiments, the term formulation refers to a single dose of vaccine, which may be included in any volume suitable for injection.

[083] As used in the present invention, the term “pneumococcal conjugate” or “pneumococcal polysaccharide-carrier protein conjugate” refers to a 5. pneumoniae polysaccharide conjugate carrier protein.

[084] As used in the present invention,The term “pneumococcal conjugate vaccine” (or “PCV”) is a pharmaceutical preparation or composition comprising one or more pneumococcal polysaccharide carrier protein conjugates that provide active immunity against diseases or pathological conditions caused by serotype(s) of S. pneumoniae.

[085] As used in the present invention, the term “ring system substituent” refers to a substituent group attached to an aromatic or non-aromatic ring system that, for example, replaces an available hydrogen in the ring system. Ring system substituents may be the same or different and are each selected independently. Examples of ring system substituents include alkyl, alkenyl, alkynyl, aryl, heteroaryl, -OH, hydroxyalkyl, haloalkyl, -O-alkyl, -Ohaloalkyl, -alkylene-O-alkyl, -O-aryl, -O-alkylene-aryl, acyl, -C(O)-aryl, halo, -NO2, -CN, -SF5, -C(O)OH,-C(O)O-alkyl, -C(O)O-aryl, -C(O)O-alkylenearyl, -S(O)-alkyl, -S(O)2-alkyl, -S(O)-aryl, -S(O)2-aryl, -S(O)-heteroaryl, S(O)2-heteroaryl, -S-alkyl, -S-aryl, -S-heteroaryl, -S-alkylene-aryl, -Salkylene-heteroaryl, -S(O)2-alkylene-aryl, -S(O)2-alkylene-heteroaryl, cycloalkyl, heterocycloalkyl, -OC(O)-alkyl, -OC(O)-aryl and -OC(O)cycloalkyl. An additional example of ring system substituents includes (C1-C4)alkyl, (C1-C4)alkenyl, (C1-C4)alkynyl, -OH, -O(C1-C4)alkyl, -O(C1C4)alkenyl, -O(C1-C4)alkynyl, chlorine, and fluorine.

[086] As used in the present invention, the term “single dose” refers to a vaccine composition that requires only one administration or injection in a clinical regimen to induce a durable immune response and provide protection against a disease (e.g., pneumococcal disease). A person skilled in the art would understand how to determine a durable immune response, for example,measuring antibody titers over a specified period of time.

[087] As used in the present invention, the term “substituent”, “optional substituent” or “optionally substituted” refers to a substituent group attached to an alkyl group, an alkenyl group or an alkynyl group that, for example, replaces an available hydrogen in the group. The substituents may be the same or different and are each selected independently. Examples of substituents include alkyl, alkenyl, alkynyl, aryl, heteroaryl, -OH, hydroxyalkyl, haloalkyl, -O-alkyl, -O-haloalkyl, -alkylene-O-alkyl, -O-aryl, -O-alkylene-aryl, acyl, -C(O)-aryl, Petition 870260002828, 12 / 01 / 2026, p. 49 / 237 40 / 211 halo, -NO2, -CN, -SF5, -C(O)OH, -C(O)O-alkyl, -C(O)O-aryl, -C(O)O-alkylenearyl, -S(O)-alkyl, -S(O)2-alkyl, -S(O)-aryl, -S(O)2-aryl, -S(O)-heteroaryl, S(O)2-heteroaryl, -S-alkyl, -S-aryl, -S-heteroaryl, -S-alkylenearyl, -Salkyleneheteroaryl,-S(O)2-alkylene-aryl, -S(O)2-alkylene-heteroaryl, cycloalkyl, heterocycloalkyl, -OC(O)-alkyl, -OC(O)-aryl and -OC(O)cycloalkyl. An additional example of substituents includes (C1-C4)alkyl, (C1C4)alkenyl, (C1-C4)alkynyl, -OH, -O(C1-C4)alkyl, -O(C1-C4)alkenyl, -O(C1C4)alkynyl, chlorine and fluorine.

[088] As used in the present invention, the term “therapeutically effective amount” refers to an amount of an active ingredient (antigen) sufficient to produce the desired therapeutic effect in a human or animal, for example, the amount needed to elicit an immune response, treat, cure,to prevent or inhibit the development and progression of a disease or its symptoms and / or the amount needed to alleviate symptoms or cause regression of a disease. The therapeutically effective amount may vary depending on the structure and potency of the active ingredient and the contemplated mode of administration. A person skilled in the art can easily determine a therapeutically effective amount of a given active ingredient in a vaccine.

[089] As used in the present invention, the term “valent” refers to the presence of a specified number of polysaccharides or polysaccharide-carrier protein conjugates in a composition.

[090] As used in the present invention, the term “vaccine” or “vaccine composition” refers to a biological preparation used to stimulate antibody production and provide immunity against an infectious disease.

[091] An “SNE”, for example, refers to a composition Petition 870260002828, dated 12 / 01 / 2026,Page 50 / 237 41 / 211 comprising a compound of the present invention, SPAN-85, PS-20 and squalene; wherein the composition is in the form of a nanoemulsion. In some embodiments, an SNE comprises from 0.01 pg / mL to 1,000 pg / mL of the compound, from 0.001 mg / mL to 60 mg / mL of SPAN-85, from 0.001 mg / mL to 60 mg / mL of PS-20 and from 0.01 mg / mL to 200 mg / mL of squalene. In one additional embodiment, an SNE comprises 100 pg / mL or 80 pg / mL of the compound, 0.01 mg / mL to 10 mg / mL of SPAN-85, 0.01 mg / mL to 10 mg / mL of PS-20, and 0.03 mg / mL to 30 mg / mL of squalene. In still other embodiments, an SNE comprises 80 pg / mL or 16 pg / mL or 4 pg / mL or 0.5 pg / mL of the compound, 0.2 mg / mL to 10 mg / mL of SPAN-85, 0.2 mg / mL to 10 mg / mL of PS-20, and 0.5 mg / mL to 20 mg / mL of squalene.

[092] A “B-1-SNE Compound”, for example, refers to a composition comprising Compound B-1, SPAN-85, PS-20 and squalene; wherein the composition is in the form of a nanoemulsion. In some embodiments, a B-1 SNE Compound comprises 0,From 0.01 pg / mL to 1000 pg / mL of Compound B-1, from 0.001 mg / mL to 60 mg / mL of SPAN-85, from 0.001 mg / mL to 60 mg / mL of PS-20, and from 0.01 mg / mL to 200 mg / mL of squalene. In further embodiments, a Compound B-1 SNE comprises 100 pg / mL or 80 pg / mL of Compound B-1, from 0.01 mg / mL to 10 mg / mL of SPAN-85, from 0.01 mg / mL to 10 mg / mL of PS-20, and from 0.03 mg / mL to 30 mg / mL of squalene. In still other embodiments, a Compound B-1 SNE comprises 80 pg / mL or 16 pg / mL or 4 pg / mL or 0.5 pg / mL of Compound B-1, 0.2 mg / mL to 10 mg / mL of SPAN-85, 0.2 mg / mL to 10 mg / mL of PS-20 and 0.5 mg / mL to 20 mg / mL of squalene.

[093] A “nanoemulsion”, also known as a nanometer-sized emulsion, is a fine oil-in-water (o / w) dispersion of two immiscible fluids. Nanoemulsions are a colloidal particulate system in the submicrometer size range that act as carriers of molecules of Petition 870260002828, dated 12 / 01 / 2026,pg. 51 / 237 42 / 211 drugs. Their size varies from 10 to 1,000 nm. These carriers are solid spheres and their surface is amorphous and lipophilic.

[094] As used in the present invention, the term “carbon- or nitrogen-linked spacer” refers to any chemistry that links a carbon (-C) or a nitrogen (-N) to the benzyl group of the Formulas of the invention (see appendix of variable “A” in Formulas I and Ia). Examples of carbon- or nitrogen-linked spacers are C1-C6 alkyl, heterocycloalkyl, aryl and heteroaryl, wherein said alkyl, heterocycloalkyl, aryl and heteroaryl are optionally substituted.

[095] Unless otherwise indicated, when describing a ligand throughout this disclosure, the first available bond in a ligand group connects to the portion of the compound flanking the ligand group on the left, and the terminal available bond of the ligand group connects to the terminal portion of the compound flanking the ligand group on the right. For example,If the ligand (L) is -CH2CF2-, the definition of L includes only A-CH2-CF2-B and does not include A-CF2-CH2-B.

[096] As used in the present invention, the term “functional group” refers to any chemistry that links the carbon- or nitrogen-bonded spacer to the lipid group. An example of a functional group is: ^'NT )n ' ' 4ν-O-ν4 , -hN-C-o4 -C-o4 , 4ç-N- - e 4c4 o 000 o , where n is 0, 1, 2, 3, 4 or 5.

[097] A further example of a functional group is 0 . Examples of lipids are represented by the variable D (as per Formulas I and Ia) and are selected from (C6-C20)alkyl, (C6-C20)alkenyl and Petition 870260002828, dated 12 / 01 / 2026, page 52 / 237 43 / 211 (C6-C2o)alkynyl, wherein said alkyl,Alkenyl and alkynyl are optionally substituted.

[099] A further example of a lipid is where any carbon in the lipid chain is optionally substituted, S is cis or trans stereochemistry, X is O, C(R)2 or NR, and R is independently selected from H, (C1-C4)alkyl, (C1C4)alkenyl, (C1-C4)alkynyl, OH, O(C1-C4)alkyl, O(C1-C4)alkenyl, O(C1C4)alkynyl, chlorine and fluorine.

[100] A further example of a lipid is represented by the variable l-oZ D (as in Formulas I and Ia), where D is z, where Z is selected from (C6-C20)alkyl, (C6-C20)alkenyl and (C6-C20)alkynyl, where said (C6-C20)alkyl, (C6-C20)alkenyl and (C6-C20)alkynyl are optionally substituted.

[101] A compound of the invention having one or more asymmetric centers may occur as a mixture of the stereoisomers or as a substantially pure individual diastereoisomer or enantiomer.Unless expressly stated otherwise, the invention encompasses all stereoisomeric forms of the compounds of Formulas I, Ia, II, IIa, III, IIIa, IV, and IVa. Unless a specific stereochemistry is indicated, the invention is intended to include all such isomeric forms of these compounds. The asymmetry centers present in the compounds of Formulas I, Ia, II, IIa, III, IIIa, IV, and IVa may independently have either (R) or (S) configuration. When the bonds to the chiral carbon are depicted as straight lines in the structural formulas of the invention, it is understood that both (R) and (S) configurations of the chiral carbon, and therefore both enantiomers and mixtures thereof, are encompassed by the formula. Similarly, when the name of a compound is listed without a chiral designation for a chiral carbon, it is understood that both the (R) and (S) configurations of the chiral carbon are present, and therefore,The enantiomers, diastereomers, and individual mixtures thereof are encompassed by the name. The production of specific stereoisomers or mixtures thereof can be identified in examples where such stereoisomers or mixtures have been obtained, but this in no way limits the inclusion of all stereoisomers and mixtures thereof within the scope of this invention.

[102] When any variable (e.g., n, Rb, etc.) occurs more than once in any constituent or in Formulas I, Ia, II, IIa, III, IIIa, IV, and IVa, its definition in each occurrence is independent of its definition in all other occurrences. Furthermore,Combinations of substituents and / or variables are permitted only if such combinations result in stable compounds.

[103] A stable compound is a compound that can be prepared and isolated and whose structure and properties remain or can be maintained essentially unchanged for a period of time sufficient to permit the use of the compound for the purposes described in the present invention (e.g., use as an adjuvant in an immunogenic composition to be administered to an individual). The compounds of the present invention are limited to stable compounds covered by Formulas I, Ia, II, IIa, III, IIIa, IV and IVa. Petition 870260002828, 12 / 01 / 2026, p. 54 / 237 45 / 211

[104] A wavy line, as used in the present invention, indicates a point of attachment to the remainder of the compound. Lines drawn in a ring system, for example: ,They indicate that the linkage can be attached to any of the replaceable atoms of the ring. Compounds

[105] The compounds of the invention are useful in the adjuvant formulations described in the present invention. These adjuvant formulations are useful for enhancing the immune response of a vaccine formulation. For example, the adjuvant formulations described in the present invention are useful for enhancing the immune response of an adenovirus vaccine, an anthrax vaccine, a cholera vaccine, a dengue vaccine, a diphtheria vaccine, a hepatitis vaccine, a Haemophilus influenzae type b (Hib) vaccine, a human papillomavirus (HPV) vaccine, a seasonal influenza (flu) vaccine, a Japanese encephalitis vaccine, a measles vaccine, a meningococcal vaccine, a mumps vaccine, a pertussis vaccine, a pneumococcal vaccine, a polio vaccine, a rabies vaccine, a rotavirus vaccine,a rubella vaccine, a herpes zoster vaccine, a smallpox vaccine, a tetanus vaccine, a tuberculosis vaccine, a typhoid fever vaccine, a varicella vaccine and a yellow fever vaccine. For example, the adjuvant formulations described in this invention are useful for enhancing the immune response of a pneumococcal composition, a pneumococcal conjugate composition, a pneumococcal vaccine (PV) or a pneumococcal conjugate vaccine (PCV).

[106] In some embodiments, a compound of the invention is represented by the structure shown in Formula I: Petition 870260002828, dated 12 / 01 / 2026, p. 55 / 237 46 / 211 where: Rae selected from H, -OH, (Ci-C6)alkyl, (Ci-C6)alkenyl, (C1C6)alkynyl -O(C1-C6)alkyl, -O(C1-C6)alkenyl, -O(C1-C6)alkynyl, chlorine, fluorine and NR'R'', where the aforementioned (C1-C6)alkyl, (C1-C6)alkenyl, (C1C6)alkynyl, -O(C1-C6)alkyl,-O(C1-C6)alkenyl and -O(C1-C6)alkynyl are optionally substituted with one to four substituents, selected independently from the group consisting of -OH, -O(C1-C4)alkyl, -O(C1-C4)alkenyl, -O(C1-C4)alkynyl, chlorine and fluorine; Ra' is selected from H, -OH, (C1-C6)alkyl, (C1-C6)alkenyl, (C1C6)alkynyl, -O(C1-C6)alkyl, -O(C1-C6)alkenyl, -O(C1-C6)alkynyl, chlorine, fluorine and -NR'R'', wherein said (C1-C6)alkyl, (C1-C6)alkenyl, (C1C6)alkynyl, -O(C1-C6)alkyl, -O(C1-C6)alkenyl and -O(C1-C6)alkynyl are optionally substituted with one to four substituents, selected independently from the group consisting of -OH, -O(C1-C4)alkyl, -O(C1-C4)alkenyl, -O(C1-C4)alkynyl, chlorine and fluorine; Ra'' is selected from H, -OH, (C1-C6)alkyl, (C1-C6)alkenyl, (C1-C6)alkynyl -O(C1-C6)alkyl, -O(C1-C6)alkenyl, -O(C1-C6)alkynyl, chlorine, fluorine and - NR'R'', wherein said (C1-C6)alkyl, (C1-C6)alkenyl, (C1-C6)alkynyl,-O(C1-C6)alkyl, -O(C1-C6)alkenyl and -O(C1-C6)alkynyl are optionally substituted with one to four substituents, selected independently from the group consisting of -OH, -O(C1-C4)alkyl, -O(C1-C4)alkenyl, -O(C1-C4)alkynyl, chlorine and fluorine; R' and R'' are independently selected from H, (C1-C6)alkyl, (C1-C6)alkenyl and (C1-C6)alkynyl, wherein said (C1-C6)alkyl, (C1-C6)alkenyl and (C1-C6)alkynyl are optionally substituted with one to four substituents, independently selected from the group consisting of -OH, -O(C1-C4)alkyl, -O(C1-C4)alkenyl, -O(C1-C4)alkynyl, chlorine and fluorine, or R' and R'', together with the nitrogen to which they are attached, combine to form a (C3-C6)heterocycloalkyl, wherein said (C3-C6)heterocycloalkyl is optionally substituted with one to four substituents, selected independently from the -OH group.-O(CiC4)alkyl, -O(Ci-C4)alkenyl, -O(Ci-C4)alkynyl, chloro and fluorine; each occurrence of Rbé independently selected from H, -OH, (Ci-Ce)alkyl, (Ci-Ce)alkenyl, (Ci-C6)alkynyl, -O(Ci-C6)alkyl, -O(Ci-C6)alkenyl, -O(Ci-C6)alkynyl, chlorine, fluorine or NR'R'', wherein said (Ci-C6)alkyl, (Ci-C6)alkenyl, (Ci-C6)alkynyl, -O(Ci-C6)alkyl, -O(CiC6)alkenyl and -O(Ci-C6)alkynyl are optionally substituted with one to four substituents, independently selected from the group consisting of -OH, -O(Ci-C4)alkyl, -O(Ci-C4)alkenyl, -O(CiC4)alkynyl, chlorine and fluorine; A is a carbon- or nitrogen-bonded spacer selected from (C1-C6)alkyl, heterocycloalkyl, heterocycloalkyl-C(O)-Rz-, (C1-C4)alkyl-N(Rz)-Rz-, aryl and heteroaryl, wherein said (C1-C6)alkyl, heterocycloalkyl, aryl and heteroaryl are optionally substituted with one to six substituents, selected independently from the group consisting of -OH,(Ci-C6)alkyl, (Ci-C6)alkenyl, (Ci-C6)alkynyl, -O(Ci-C6)alkyl, -O(Ci-C6)alkenyl, -O(Ci-C6)alkynyl, chlorine, fluorine and NR'R, wherein the aforementioned (Ci-C6)alkyl, (Ci-C6)alkenyl, (Ci-C6)alkynyl, -O(Ci-C6)alkyl, -O(Ci-C6)alkenyl and -O(Ci-C6)alkynyl are optionally Petition 870260002828, dated 12 / 01 / 2026, page. 57 / 237 48 / 211 substituted with one to six substituents, selected independently from the group consisting of -OH, -O(C1-C4)alkyl, -O(C1-C4)alkenyl, -O(C1-C4)alkynyl, chlorine and fluorine; each occurrence of Rz is independently H or (C1-C6)alkyl; B is a functional group selected from . lN-cl , 4-N-C-n1 , -^NC-ol ,^co, -^C-NψeFçl OO ooo · ; D is a lipid selected from (C6-C20)alkyl, (C6-C20)alkenyl and (C6-C20)alkynyl, wherein said (C6-C20)alkyl, (C6-C20)alkenyl and (C6-C20)alkynyl are optionally substituted with one to six substituents, selected independently from the group consisting of -OH.-O(C1-C4)alkyl, -O(C1-C4)alkenyl, -O(C1-C4)alkynyl, chlorine and fluorine; or D is z; each occurrence of Z is independently selected from (C6C20)alkyl, (C6-C20)alkenyl and (C6-C20)alkynyl, wherein said (C6C20)alkyl, (C6-C20)alkenyl and (C6-C20)alkynyl are optionally substituted with one to six substituents, independently selected from the group consisting of -OH, -O(C1-C4)alkyl, -O(C1-C4)alkenyl, -O(C1-C4)alkynyl, chlorine and fluorine; m is 0, 1, 2, 3, 4 or 5, en is 0, 1, 2, 3, 4 or 5.

[107] In some embodiments, a compound of the invention is represented by the structure shown in Formula I, where m is 0, 1, 2, 3, 4 or 5.

[108] In some embodiments, a compound of the invention is represented by the structure shown in Formula I, where m is 0, 1, 2, 3 or 4. Petition 870260002828, dated 12 / 01 / 2026, p. 58 / 237 49 / 211

[109] In some embodiments, a compound of the invention is represented by the structure shown in Formula I, where m is 0, 1,2 or 3.

[110] In some embodiments, a compound of the invention is represented by the structure presented in Formula I, where m is 0, 1, or 2.

[111] In some embodiments, a compound of the invention is represented by the structure presented in Formula I, where m is 2.

[112] In some embodiments, a compound of the invention is represented by the structure presented in Formula I, where m is 1.

[113] In some embodiments, a compound of the invention is represented by the structure presented in Formula I, where m is 0.

[114] In some embodiments, a compound of the invention is represented by the structure presented in Formula I, where n is 0, 1, 2, 3, 4, or 5.

[115] In some embodiments, a compound of the invention is represented by the structure presented in Formula I, where n is 0, 1, 2, 3, or 4.

[116] In some embodiments, a compound of the invention is represented by the structure presented in Formula I, where n is 0, 1, 2 or 3.

[117] In some modes,A compound of the invention is represented by the structure shown in Formula I, where n is 0, 1 or 2.

[118] In some embodiments, a compound of the invention is represented by the structure shown in Formula I, where n is 2.

[119] In some embodiments, a compound of the invention is represented by the structure shown in Formula I, where n is 1.

[120] In some embodiments, a compound of the invention is represented by the structure shown in Formula I, where n is 0.

[121] In some embodiments, a compound of the invention is Petition 870260002828, dated 12 / 01 / 2026, p. 59 / 237 50 / 211 represented by the structure shown in Formula I, wherein R' and R'' are independent H, (C1-C6)alkyl, (C1-C6)alkenyl or (C1-C6)alkynyl, wherein said (C1-C6)alkyl, (C1-C6)alkenyl and (C1-C6)alkynyl are optionally substituted with one to four substituents, selected independently from the group consisting of -OH, -O(CC)alkyl, -O(CC)alkenyl, -O(CC)alkynyl,Chlorine and fluorine. [i22] In some embodiments, a compound of the invention is represented by the structure shown in Formula I, wherein R' and R'' are independently H, (CC)alkyl, (CC)alkenyl or (CC)alkynyl, wherein said (CC)alkyl, (CC)alkenyl and (CC)alkynyl are optionally substituted with one to four -OH or -O(CH), independently selected. [i23] In some embodiments, a compound of the invention is represented by the structure shown in Formula I, wherein R' and R'' are independently H, (CC)alkyl, (CC)alkenyl or (CC)alkynyl, wherein said (CC)alkyl, (CC)alkenyl and (CC)alkynyl are optionally substituted with one or two -OH or -O(CH), independently selected. [i24] In some embodiments, a compound of the invention is represented by the structure shown in Formula I, wherein R' and R'' are independently H, (C1-C4)alkyl, wherein said (C1-C4)alkyl is optionally substituted with one or two -OH or -O(CH3),independently selected. [i25] In some embodiments, a compound of the invention is represented by the structure shown in Formula I, in which R' and R'' are independently H and (C1-C4)alkyl. [i26] In some embodiments, a compound of the invention is represented by the structure shown in Formula I, in which R' and R'', together with the nitrogen to which they are attached, combine to form a Petition 870260002828, dated 12 / 01 / 2026, p. 60 / 237 51 / 211 (C1-C6)heterocycloalkyl, wherein said (C3-C6)heterocycloalkyl is optionally substituted with one to four substituents, independently selected from the group consisting of -OH, -O(C1-C4)alkyl, O(C1-C4)alkenyl, -O(C1-C4)alkynyl, chlorine and fluorine.

[127] In some embodiments, a compound of the invention is represented by the structure shown in Formula I, in which Rae is H, -OH, (C1-C6)alkyl, (C1-C6)alkenyl, -O(C1-C6)alkynyl, -O(C1-C6)alkynyl, chlorine, fluorine or NR'R'',wherein the aforementioned (C1-Ce)alkyl, (C1-C6)alkenyl, (C1-C6)alkynyl, -O(C1-C6)alkyl, -O(C1-C6)alkenyl and -O(C1-C6)alkynyl are optionally substituted with one to four substituents, selected independently from the group consisting of -OH, -O(C1-C4)alkyl, -O(C1-C4)alkenyl, -O(C1-C4)alkynyl, chlorine and fluorine.

[128] In some embodiments, a compound of the invention is represented by the structure shown in Formula I, wherein Rae H, -OH, (C1-C4)alkyl, (C1-C4)alkenyl, (C1-C4)alkynyl, -O(C1-C4)alkyl, -O(C1-C4)alkenyl, O(C1-C4)alkynyl, chlorine, fluorine or NR'R, wherein said (C1-C4)alkyl, (C1-C4)alkenyl, (C1-C4)alkynyl, -O(C1-C4)alkyl, -O(C1-C4)alkenyl and -O(C1-C4)alkynyl are optionally substituted with one or two substituents, selected independently from the group consisting of -OH, -O(C1-C4)alkyl, -O(C1-C4)alkenyl, -O(C1-C4)alkynyl, chlorine and fluorine.

[129] In some embodiments,One compound of the invention is represented by the structure shown in Formula I, in which Ra is H, -OH, (C1-C4)alkyl, (C1-C4)alkenyl, (C1-C4)alkynyl, -O(C1-C4)alkyl, -O(C1-C4)alkenyl, O(C1-C4)alkynyl, chlorine, fluorine or NR'R.

[130] In some embodiments, a compound of the invention is represented by the structure shown in Formula I, wherein R' is H and R'' is pentyl.

[131] In some embodiments, a compound of the invention is represented by the structure shown in Formula I, wherein R' is H and R'' is butyl.

[132] In some embodiments, a compound of the invention is represented by the structure shown in Formula I, wherein R' is H and R'' is butyl.

[133] In some embodiments, a compound of the invention is represented by the structure shown in Formula I, wherein R' is H and R'' is propyl.where R' is H and R'' is ethyl.

[135] In some embodiments, a compound of the invention is represented by the structure shown in Formula I, where R' is H and R'' is methyl.

[136] In some embodiments, a compound of the invention is represented by the structure shown in Formula I, wherein R' is H and R'' is H.

[137] In some embodiments, a compound of the invention is represented by the structure shown in Formula I, wherein Ra is H, -OH, (C1Ce)alkyl, (C1-C6)alkenyl, (C1-C6)alkynyl, -O(C1-C6)alkyl, -O(C1-C6)alkenyl, O(C1-C6)alkynyl, chlorine, fluorine or NR'R'', wherein said (C1-C6)alkyl, (C1C6)alkenyl, (C1-C6)alkynyl, -O(C1-C6)alkyl, -O(C1-C6)alkenyl and -O(C1C6)alkynyl are optionally substituted with one or two substituents, selected independently from the group consisting of -OH, -O(C1-C4)alkyl, -O(C1-C4)alkenyl, -O(C1-C4)alkynyl, chlorine and fluorine.

[138] In some embodiments,One compound of the invention is represented by the structure shown in Formula I, wherein Ra' is H, -OH, (C1-C4)alkyl, (C1-C4)alkenyl, (C1-C4)alkynyl, -O(C1-C4)alkyl, -O(C1-C4)alkenyl, Petition 870260002828, dated 12 / 01 / 2026, p. 62 / 237 53 / 211 O(Ci-C4)alkynyl, chlorine, fluorine or NR'R'', wherein said (Ci-C4)alkyl, (CiC4)alkenyl, (Ci-C4)alkynyl, -O(Ci-C4)alkyl, -O(Ci-C4)alkenyl and -O(CiC4)alkynyl are optionally substituted with one or two substituents, selected independently from the group consisting of -OH, -O(CiC4)alkyl, -O(Ci-C4)alkenyl, -O(Ci-C4)alkynyl, chlorine and fluorine.

[139] In some embodiments, a compound of the invention is represented by the structure shown in Formula I, wherein Ra' is H, -OH, (C1-C4)alkyl, (C1-C4)alkenyl, (C1-C4)alkynyl, -O(C1-C4)alkyl, -O(C1-C4)alkenyl, O(C1-C4)alkynyl, chlorine, fluorine or NR'R''.

[140] In some embodiments, a compound of the invention is represented by the structure shown in Formula I,wherein Ra' is NR'R”. [i4i] In some embodiments, a compound of the invention is represented by the structure shown in Formula I, wherein R' is H and R'' is pentyl. [i42] In some embodiments, a compound of the invention is represented by the structure shown in Formula I, wherein R' is H and R'' is butyl. [i43] In some embodiments, a compound of the invention is represented by the structure shown in Formula I, wherein R' is H and R'' is propyl. [i44] In some embodiments, a compound of the invention is represented by the structure shown in Formula I, wherein R' is H and R'' is ethyl. [i45] In some embodiments, a compound of the invention is represented by the structure shown in Formula I, wherein R' is H and R'' is methyl. 63 / 237 54 / 211 represented by the structure shown in Formula I, wherein R' is H and R is H.

[147] In some embodiments,One compound of the invention is represented by the structure shown in Formula I, wherein Rae H, -OH, (C1-C6)alkyl, (C1-C6)alkenyl, (C1-C6)alkynyl, -O(C1-C6)alkyl, -O(C1-C6)alkenyl, O(C1-C6)alkynyl, chlorine, fluorine or NR'R'', wherein said (C1-C6)alkyl, (C1-C6)alkenyl, (C1-C6)alkynyl, -O(C1-C6)alkyl, -O(C1-C6)alkenyl and -O(C1C6)alkynyl are optionally substituted with one or two substituents, independently selected from the group consisting of -OH, -O(C1C4)alkyl, -O(C1-C4)alkenyl, -O(C1-C4)alkynyl, chlorine and fluorine.

[148] In some embodiments, a compound of the invention is represented by the structure shown in Formula I, wherein Rae is H, -OH, (C1-C4)alkyl, (C1-C4)alkenyl, (C1-C4)alkynyl, -O(C1-C4)alkyl, -O(C1-C4)alkenyl, O(C1-C4)alkynyl, chlorine, fluorine or NR'R'', wherein said (C1-C4)alkyl, (C1-C4)alkenyl, (C1-C4)alkynyl, -O(C1-C4)alkyl,-O(C1-C4)alkenyl and -O(C1C4)alkynyl are optionally substituted with one or two substituents, selected independently from the group consisting of -OH, -O(C1C4)alkyl, -O(C1-C4)alkenyl, -O(C1-C4)alkynyl, chlorine and fluorine.

[149] In some embodiments, a compound of the invention is represented by the structure shown in Formula I, wherein Ra'' is H, -OH, (C1C4)alkyl, (C1-C4)alkenyl, (C1-C4)alkynyl, -O(C1-C4)alkyl, -O(C1-C4)alkenyl, O(C1-C4)alkynyl, chlorine, fluorine or NR'R''.

[150] In some embodiments, a compound of the invention is represented by the structure shown in Formula I, wherein Ra'' is NR'R”.

[151] In some embodiments, a compound of the invention is represented by the structure shown in Formula I, wherein R' is H and R'' is pentyl.

[152] In some embodiments, a compound of the invention is Petition 870260002828, dated 12 / 01 / 2026, p. 64 / 237 55 / 211 represented by the structure shown in Formula I,where R' is H and R'' is butyl.

[153] In some embodiments, a compound of the invention is represented by the structure shown in Formula I, where R' is H and R'' is propyl.

[154] In some embodiments, a compound of the invention is represented by the structure shown in Formula I, where R' is H and R'' is ethyl.

[155] In some embodiments, a compound of the invention is represented by the structure shown in Formula I, where R' is H and R'' is methyl.

[156] In some embodiments, a compound of the invention is represented by the structure shown in Formula I, wherein R' is H and R'' is H.

[157] In some embodiments, a compound of the invention is represented by the structure shown in Formula I, wherein Ra'' is H.

[158] In some embodiments, a compound of the invention is represented by the structure shown in Formula I, wherein R' is H, -OH, (C1Ce)alkyl, (C1-C6)alkenyl, (C1-C6)alkynyl, -O(C1-C6)alkyl, -O(C1-C6)alkenyl, O(C1-C6)alkynyl, chlorine, fluorine or NR'R'',wherein the aforementioned (C1-C6)alkyl, (C1C6)alkenyl, (C1-C6)alkynyl, -O(C1-C6)alkyl, -O(C1-C6)alkenyl and -O(C1C6)alkynyl are optionally substituted with one or two substituents, selected independently from the group consisting of -OH, -O(C1C4)alkyl, -O(C1-C4)alkenyl, -O(C1-C4)alkynyl, chlorine and fluorine.

[159] In some embodiments, a compound of the invention is represented by the structure shown in Formula I, wherein Rbé H, -OH, (C1-C4)alkyl, (C1-C4)alkenyl, (C1-C4)alkynyl, -O(C1-C4)alkyl, -O(C1-C4)alkenyl, O(C1-C4)alkynyl, chlorine, fluorine or NR'R'', wherein said (C1-C4)alkyl, (C1 Petition 870260002828, dated 12 / 01 / 2026, p. 65 / 237 56 / 211 C4)alkenyl, (C1-C4)alkynyl, -O(C1-C4)alkyl, -O(C1-C4)alkenyl and -O(C1C4)alkynyl are optionally substituted with one or two substituents, selected independently from the group consisting of -OH, -O(C1-C4)alkyl, -O(C1-C4)alkenyl, -O(C1-C4)alkynyl,chlorine and fluorine.

[160] In some embodiments, a compound of the invention is represented by the structure shown in Formula I, in which Rbé independently H, -OH, (C1-C6)alkyl, (C1-C6)alkenyl, (C1-C6)alkynyl, O(C1-C6)alkyl, -O(C1-C6)alkenyl, -O(C1-C6)alkynyl, chlorine, fluorine or NR'R.

[161] In some embodiments, a compound of the invention is represented by the structure shown in Formula I, in which each occurrence of Rbé independently H, -OH, (C1-C4)alkyl, -O(C1-C4)alkyl, chlorine, fluorine or NH2.

[162] In some embodiments, a compound of the invention is represented by the structure shown in Formula I, in which each occurrence of Rbé independently H and O(CH3).

[163] In some embodiments, a compound of the invention is represented by the structure shown in Formula I, wherein A is a (C1C6)alkyl or heterocycloalkyl, wherein said alkyl or heterocycloalkyl is optionally substituted with one to four substituents,selected independently from the group consisting of -OH, oxo, (C1-C6)alkyl, (C1-C6)alkenyl, (C1-C6)alkynyl, -O(C1-C6)alkyl, -O(C1-C6)alkenyl, -O(C1-C6)alkynyl, chlorine, fluorine and NR'R, wherein said (C1-C6)alkyl, (C1-C6)alkenyl, (C1-C6)alkynyl, -O(C1-C6)alkyl, -O(C1-C6)alkenyl and -O(C1C6)alkynyl are optionally substituted with one to four substituents, selected independently from the group consisting of -OH, -O(C1-C4)alkyl, -O(C1-C4)alkenyl, -O(C1-C4)alkynyl, chlorine and fluorine.

[164] In some embodiments, a compound of the invention is represented by the structure shown in Formula I, in which A is a (C1-C4)alkyl or heterocycloalkyl, wherein said alkyl or heterocycloalkyl is optionally substituted with one to four substituents, independently selected from the group consisting of -OH, oxo, (C1-C4)alkyl, (C1-C4)alkenyl, (C1-C4)alkynyl,-O(C1-C4)alkyl, -O(C1-C4)alkenyl, -O(C1-C4)alkynyl, chlorine, fluorine and NR'R, wherein said (C1-C4)alkyl, (C1-C4)alkenyl, (C1-C4)alkynyl, -O(C1-C4)alkyl, -O(C1-C4)alkenyl and -O(C1C4)alkynyl are optionally substituted with one to six substituents, selected independently from the group consisting of -OH, -O(C1-C4)alkyl, -O(C1-C4)alkenyl, -O(C1-C4)alkynyl, chlorine and fluorine.

[165] In some embodiments, a compound of the invention is represented by the structure shown in Formula I, wherein A is heterocycloalkyl-C(O)-Rz- or (C1-C4)alkyl-N(Rz)2-; wherein each occurrence of Rz is independently H or (C1-C6)alkyl.

[166] In some embodiments, a compound of the invention is represented by the structure shown in Formula I, wherein A is selected from ZRZT 7=X / =\ RZ^ N'^ , ΉV / F-Rz, Trze ΉV VN ZΎ R t- %% RZ , wherein Rz is independently selected from H, (C1-C6)alkyl, (C1-C6)alkenyl, (C1-C6)alkynyl, O(C1-C6)alkyl,O(C1-C6)alkenyl and O(C1C6)alkynyl, X is CH or N, R is selected independently of H, -OH, oxo, (C1-C4)alkyl, (C1-C4)alkenyl, (C1-C4)alkynyl, -OH, -O(C1-C4)alkyl, -O(C1-C4)alkenyl, O(C1-C4)alkynyl, chlorine and fluorine, n is 0, i, 2, 3 or 4, and p is 0, i, 2, 3 or 4. [i67] In some embodiments, a compound of the invention is represented by the structure shown in Formula I, where A is selected from Rz?N Rz hRz where Rz is selected independently of H, (C1-C6)alkyl, (C1-C6)alkenyl and (C1-C6)alkynyl, X is CH or N, R is independently selected from -OH, (C1-C4)alkyl, -O(C1-C4)alkyl, chlorine and fluorine, n is 0, i, 2 or 3, and e is 0, i or 2. [i68] In some embodiments, a compound of the invention is represented by the structure shown in Formula I, wherein A is selected Petition 870260002828, 12 / 01 / 2026, p. 68 / 237 59 / 211 of ZRZ RZ / =\ / =\RZ N'RZ / , ' Ή}-R' ,-^-Rz eM where Rz is independently H or (C1-C6)alkyl, X is CH or N, R is independently selected from -OH, (C1-C4)alkyl, -O(C1C4)alkyl, chlorine and fluorine, n is 0, 1, 2 or 3, and p is 0, 1 or 2.

[169] In some embodiments, a compound of the invention is represented by the structure shown in Formula I, where A is selected from RzRze in which Rz is independently H or (C1-C6)alkyl, R is independently selected from -OH, (C1-C4)alkyl, -O(C1C4)alkyl, chlorine and fluorine, where n is 0, 1, 2 or 3, and where p is 0, 1 or 2.

[170] In some embodiments, a compound of the invention is Petition 870260002828, of 12 / 01 / 2026, p. 69 / 237 60 / 211 represented by the structure shown in Formula I, wherein A is selected Rz7 .. , ' and ' from where Rz is independently H or (C1-C6)alkyl.

[171] In some embodiments, a compound of the invention is represented by the structure shown in Formula I, wherein B is selected s H ss H H ς5H s, h -hN-Ch , -ÉN-CN-É ,-ÉN-C-θψand|ca de oo oo , in some embodiments, a compound of the invention is represented by the structure shown in Formula I, where B is 0.

[172] In some embodiments, a compound of the invention is represented by the structure shown in Formula I, wherein D is (C6C20)alkyl, (C6-C20)alkenyl or (C6-C20)alkynyl, wherein said (C6C20)alkyl, (C6-C20)alkenyl or (C6-C20)alkynyl is optionally substituted with one to six substituents, selected independently from -OH, O(CH3), chlorine and fluorine, or , z -^θ( D is z, where Z is selected from (C6-C20)alkyl (C6-C20)alkenyl and (C6-C20)alkynyl, wherein said (C6-C20)alkyl (C6-C20)alkenyl and (C6C20)alkynyl are optionally substituted with one to six substituents, selected independently from -OH, -O(CH3), chlorine and fluoride.(C6-C20)alkenyl or (C6-C20)alkynyl, or -Hz D is z, wherein Z is selected from (C6-C20)alkyl, (C6-C20)alkenyl and (C6-C20)alkynyl.

[174] In some embodiments, a compound of the invention is represented by the structure shown in Formula I, wherein D is selected from where any carbon in the lipid chain is optionally substituted with -OH, -O(CH3), chlorine or fluorine, S is cis or trans stereochemistry, X is O, C(R)2 or NR, and R is independently selected from H, (C1-C4)alkyl, (C1C4)alkenyl, (C1-C4)alkynyl, -OH, -O(C1-C4)alkyl, -O(C1-C4)alkenyl, -O(C1C4)alkynyl, chlorine and fluorine.

[175] In some embodiments, a compound of the invention is represented by the structure shown in Formula I, wherein D is selected from the chain of lipids in which any carbon is optionally replaced with -OH, -O(CH3), chlorine or fluorine, Petition 870260002828, dated 12 / 01 / 2026,p. 71 / 237 62 / 211 is cis or trans stereochemistry, X1 is -O-, -C(R)2- or -NR-, and each occurrence of R is independently selected from H, (C1C4)alkyl, (C1-C4)alkenyl, (C1-C4)alkynyl, -OH, -O(C1-C4)alkyl, -O(C1C4)alkenyl, -O(C1-C4)alkynyl, chlorine and fluorine; n is 0, 1, 2, 3, 4 or 5; q is 0, 1, 2, 3, 4, 5, 6, 7, 8 or 9; s is 1, 2, 3, 4, 5, 6, 7 or 8, et is 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17 or 18.

[176] In some embodiments, a compound of the invention is represented by the structure shown in Formula Ia: ABD wherein: R' and R'' are independently selected from H, (C1C6)alkyl, (C1-C6)alkenyl and (C1-C6)alkynyl, wherein said (C1C6)alkyl, (C1-C6)alkenyl and (C1-C6)alkynyl are optionally substituted with one to four substituents, independently selected from the group consisting of -OH, -O(C1C4)alkyl, -O(C1-C4)alkenyl, -O(C1-C4)alkynyl, chlorine and fluorine, or R' and R, together with the nitrogen to which they are attached,combine to form a (C3-C6)heterocycloalkyl, in which said (C3-C6)heterocycloalkyl is optionally substituted with one to four substituents, selected independently from the group consisting of -OH, -O(C1-C4)alkyl, -O(C1-C4)alkenyl, -O(C1-C4)alkynyl, chlorine and fluorine; Petition 870260002828, dated 12 / 01 / 2026, p. 72 / 237 63 / 211 each occurrence of Rbé -O(C1-C4)alkyl, in which said -O(C1-C4)alkyl is optionally substituted with one or two substituents, selected independently from the group consisting of -OH, O(C1-C4)alkyl, -O(C1-C4)alkenyl, -O(C1-C4)alkynyl, chlorine and fluorine; A is selected from each occurrence of Rz independently of H or (C1-C6)alkyl; each occurrence of Rd is selected independently of OH, (C1-C4)alkyl, -O(C1-C4)alkyl, chlorine, and fluorine; D is a lipid chain selected from: where any carbon in the lipid chain is optionally substituted with -OH, -O(C1-C4)alkyl,-O(C1-C4)alkenyl, -O(C1-C4)alkynyl, chlorine and fluorine, where is cis or trans stereochemistry; X1 is -O-, -C(R)2- or -NR-, and each occurrence of R is selected independently of H, (C1 Petition 870260002828, 12 / 01 / 2026, p. 73 / 237 64 / 211 C4)alkyl, (C1-C4)alkenyl, (C1-C4)alkynyl, -OH, -O(C1-C4)alkyl, -O(C1C4)alkenyl, -O(C1-C4)alkynyl, chlorine and fluorine; m is 0, 1 or 2; n is 0, 1, 2 or 3; p is 0, 1 or 2; q is 0, 1, 2, 3, 4, 5, 6, 7, 8 or 9; s is 1, 2, 3, 4, 5, 6, 7 or 8, et is 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17 or 18.

[177] In some embodiments, a compound of the invention is represented by the structure shown in Formula Ia, where m is 2.

[178] In some embodiments, a compound of the invention is represented by the structure shown in Formula Ia, where m is 1.

[179] In some embodiments, a compound of the invention is represented by the structure shown in Formula Ia, where m is 0.

[180] In some embodiments,A compound of the invention is represented by the structure shown in Formula Ia, wherein R' and R'' are independently selected from H and (C1-C6)alkyl, wherein said alkyl is optionally substituted with one to four -OH and / or -O(CH3).

[181] In some embodiments, a compound of the invention is represented by the structure shown in Formula Ia, wherein R' and R'' are independently H, (C1-C4)alkyl, wherein said alkyl is optionally substituted with one or four -OH and -O(CH3).

[182] In some embodiments, a compound of the invention is represented by the structure shown in Formula Ia, wherein R' is H and R'' is pentyl.

[183] ​​In some embodiments, a compound of the invention is represented by the structure shown in Formula Ia, wherein R' is H and R'' is Petition 870260002828, dated 12 / 01 / 2026, p. 74 / 237 65 / 211 butyl.

[184] In some embodiments, a compound of the invention is represented by the structure shown in Formula Ia,where R' is H and R'' is propyl.

[185] In some embodiments, a compound of the invention is represented by the structure shown in Formula Ia, where R' is H and R'' is ethyl.

[186] In some embodiments, a compound of the invention is represented by the structure shown in Formula Ia, where R' is H and R'' is methyl.

[187] In some embodiments, a compound of the invention is represented by the structure shown in Formula Ia, where R' is H and R'' is H.

[188] In some embodiments, a compound of the invention is represented by the structure shown in Formula Ia, where Ra'' is H or (C1C4)alkyl, wherein said alkyl is optionally substituted with one or two -OH and / or -O(CH3).

[189] In some embodiments, a compound of the invention is represented by the structure shown in Formula Ia, wherein Ra'' is H or (C1C4)alkyl.

[190] In some embodiments, a compound of the invention is represented by the structure shown in Formula Ia, where Ra'' is H.

[191] In some embodiments,A compound of the invention is represented by the structure shown in Formula Ia, wherein Rbé -O(C1-C4)alkyl, wherein said -O(C1-C4)alkyl is optionally substituted with one or two -OH and / or -O(CH3).

[192] In some embodiments, a compound of the invention is represented by the structure shown in Formula Ia, wherein Rbé -O(CH3). Petition 870260002828, 12 / 01 / 2026, p. 75 / 237 66 / 211

[193] In some embodiments, a compound of the invention is represented by the structure shown in Formula Ia, where A is selected and R% . , ' and ' of , where Rz is independently H or (C1-C6)alkyl.

[194] In some embodiments, a compound of the invention is represented by the structure shown in Formula II: wherein: R1 is (C1-C6)alkyl, wherein said (C1-C6)alkyl is optionally substituted with one to four substituents selected from -OH and O(CH3); R2 is H, methyl or -O(CH3); each occurrence of R3 is independently H, (C1-C4)alkyl, (C1-C4)alkenyl,(C1-C4)alkynyl or -O(C1-C4)alkyl, wherein said (C1-C4)alkyl, (C1-C4)alkenyl, (C1-C4)alkynyl or -O(C1-C4)alkyl is optionally substituted with one or two substituents selected from -OH and -O(CH3); each occurrence of R4 is independently H, (C1-C4)alkyl, (C1-C4)alkenyl, (C1-C4)alkynyl or -O(C1-C4)alkyl, wherein said (C1-C4)alkyl, (C1-C4)alkenyl, (C1-C4)alkynyl or -O(C1-C4)alkyl is optionally substituted with one or two substituents selected from Petition 870260002828, dated 12 / 01 / 2026, page. 76 / 237 67 / 211 of -OH and -O(CHa); R5 and R6 are selected from (C6-C20)alkyl, (C6-C20)alkenyl and (C6C20)alkynyl, wherein said (C6-C20)alkyl, (C6-C20)alkenyl and (C6C20)alkynyl are optionally substituted with one to six substituents selected independently from -OH, -O(C1-C4)alkyl, -O(C1C4)alkenyl, -O(C1-C4)alkynyl, chlorine and fluorine; and each occurrence of n is 4.

[195] In some embodiments,A compound of the invention is represented by the structure shown in Formula II, where n is independently 0, 1, 2, or 3.

[196] In some embodiments, a compound of the invention is represented by the structure shown in Formula II, where n is independently 0, 1, or 2.

[197] In some embodiments, a compound of the invention is represented by the structure shown in Formula II, where n is independently 0 or 1.

[198] In some embodiments, a compound of the invention is represented by the structure shown in Formula II, where n is absent.

[199] In some embodiments, a compound of the invention is represented by the structure shown in Formula II, where R1 is ethyl, butyl (branched or linear chain), or pentyl (branched or linear chain), wherein said ethyl, butyl, or pentyl is optionally substituted with one to four substituents selected independently from -OH, -O(CHa), chlorine, and fluorine.

[200] In some embodiments,A compound of the invention is represented by the structure shown in Formula II, wherein R1 is butyl (branched or linear chain), wherein said butyl is optionally substituted with one to four substituents, selected independently from -OH, -O(CH3), chlorine and fluorine.

[201] In some embodiments, a compound of the invention is represented by the structure shown in Formula II, wherein R1 is ethyl, butyl (branched or linear chain) or pentyl (branched or linear chain), wherein said ethyl, butyl or pentyl is optionally substituted with one to two substituents, selected independently from -OH and -O(CH3).

[202] In some embodiments, a compound of the invention is represented by the structure shown in Formula II, wherein R1 is butyl (branched or linear chain), wherein said butyl is optionally substituted with one or two substituents,

[203] In some embodiments, a compound of the invention is represented by the structure shown in Formula II, in which R2 is H or methyl.

[204] In some embodiments, a compound of the invention is represented by the structure shown in Formula II, in which R2 is H.

[205] In some embodiments, a compound of the invention is represented by the structure shown in Formula II, in which R3 is independently (C1-C4)alkyl, (C1-C4)alkenyl or -O(C1-C4)alkyl, in which said C1-C4)alkyl, (C1-C4)alkenyl or -O(C1-C4)alkyl is optionally substituted with one to four substituents, selected independently from -OH or -O(CH3).

[206] In some embodiments, a compound of the invention is represented by the structure shown in Formula II, wherein R3 is independently (C1-C4)alkyl or -O(C1-C4)alkyl, wherein said (C1 Petition 870260002828, dated 12 / 01 / 2026,pg. 78 / 237 69 / 211 C4)alkyl or -O(C1-C4)alkyl is optionally substituted with one to four substituents, selected independently from -OH or -O(CH3).

[207] In some embodiments, a compound of the invention is represented by the structure shown in Formula II, wherein R3 is independently (C1-C4)alkyl or -O(C1-C4)alkyl, wherein said (C1C4)alkyl or -O(C1-C4)alkyl is optionally substituted with one to two substituents, selected independently from -OH or -O(CH3).

[208] In some embodiments, a compound of the invention is represented by the structure shown in Formula II, wherein R3 is independently methyl or -O(CH3).

[209] In some embodiments, a compound of the invention is represented by the structure shown in Formula II, wherein R3 is independently -O(CH3).

[210] In some embodiments, a compound of the invention is represented by the structure shown in Formula II, in which R4 is independently (C1-C4)alkyl or -O(C1-C4)alkyl,wherein said (C1-C4)alkyl or -O(C1-C4)alkyl is optionally substituted with one to four substituents, selected independently from -OH, -O(CH3), chlorine and fluorine.

[211] In some embodiments, a compound of the invention is represented by the structure shown in Formula II, in which R4 is independently (C1-C4)alkyl or -O(C1-C4)alkyl.

[212] In some embodiments, a compound of the invention is represented by the structure shown in Formula II, in which R6 is selected from (C6-C2u)alkyl and (C6-C2u)alkenyl, in which said (C6-C2u)alkyl and (C6-C2u)alkenyl are optionally substituted with one to six -OH and -O(CH3).

[213] In some embodiments, a compound of the invention is Petition 870260002828, dated 12 / 01 / 2026, p. 79 / 237 70 / 211 represented by the structure shown in Formula II, in which R6 is selected from (C8-C20)alkyl and (C8-C20)alkenyl,in which said (C8-C20)alkyl and (C8-C20)alkenyl are optionally substituted with one to six -OH and -O(CH3).

[214] In some embodiments, a compound of the invention is represented by the structure shown in Formula II, wherein R6 is selected from (C10-C20)alkyl and (C10-C20)alkenyl, wherein said (C10C20)alkyl and (C10-C20)alkenyl are optionally substituted with one to six -OH and -O(CH3).

[215] In some embodiments, a compound of the invention is represented by the structure shown in Formula II, wherein R6 is selected from (C12-C20)alkyl and (C12-C20)alkenyl, wherein said (C12C20)alkyl and (C12-C20)alkenyl are optionally substituted with one to six OH and -O(CH3).

[216] In some embodiments, a compound of the invention is represented by the structure shown in Formula II, wherein R6 is selected from (C14-C20)alkyl and (C14-C20)alkenyl,in which the aforementioned (C14-C20)alkyl and (C14-C20)alkenyl groups are optionally substituted with one to six -OH and -O(CH3).

[217] In some embodiments, a compound of the invention is represented by the structure shown in Formula II, wherein R6 is selected from (C16-C20)alkyl and (C16-C20)alkenyl groups, wherein the aforementioned (C16-C20)alkyl and (C16-C20)alkenyl groups are optionally substituted with one to six -OH and -O(CH3).

[218] In some embodiments, a compound of the invention is represented by the structure shown in Formula II, wherein R6 is selected from (C6-C20)alkyl and (C6-C20)alkenyl groups.

[219] In some embodiments, a compound of the invention is represented by the structure shown in Formula II, in which R6 is selected from (C8-C20)alkyl and (C8-C20)alkenyl.

[220] In some embodiments, a compound of the invention is represented by the structure shown in Formula II,

[221] In some embodiments, a compound of the invention is represented by the structure shown in Formula II, in which R6 is selected from (C10-C20)alkyl and (C10-C20)alkenyl.

[222] In some embodiments, a compound of the invention is represented by the structure shown in Formula II, in which R6 is selected from (C12-C20)alkyl and (C12-C20)alkenyl.

[223] In some embodiments, a compound of the invention is represented by the structure shown in Formula II, in which R6 is selected from (C16-C20)alkyl and (C16-C20)alkenyl.

[224] The invention further provides a compound having the structure shown in Formula IIa: wherein: R1 is butyl, wherein said butyl is optionally substituted with one or two -OH; each occurrence of R3 is independently H or -O(CH3); and Petition 870260002828, dated 12 / 01 / 2026, p. 81 / 237 72 / 211 R5 is ο Ν R6 H ; and R6 is selected from (C1o-C2o)alkyl,(C1o-C2o)alkenyl and (C10C2o)alkynyl.

[225] In some embodiments, a compound of the invention is represented by the structure shown in Formula IIa, wherein R6 is selected from (C1o-C2o)alkyl and (C1o-C2o)alkenyl, wherein said (C1o-C2o)alkyl and (C1o-C2o)alkenyl are optionally substituted with one or two -OH and -O(CH3).

[226] In some embodiments, a compound of the invention is represented by the structure shown in Formula IIa, wherein R6 is selected from (C12-C2o)alkyl and (C12-C2o)alkenyl, wherein said (C12-C2o)alkyl and (C12-C2o)alkenyl are optionally substituted with one or two -OH and -O(CH3).

[227] In some embodiments, a compound of the invention is represented by the structure shown in Formula IIa, wherein R6 is selected from (C14-C2o)alkyl and (C14-C2o)alkenyl, wherein said (C14-C2o)alkyl and (C14-C2o)alkenyl are optionally substituted with one or two -OH and -O(CH3).

[228] In some embodiments,A compound of the invention is represented by the structure shown in Formula IIa, wherein R6 is selected from (C16-C2o)alkyl and (C16-C2o)alkenyl, wherein said (C16-C2o)alkyl and (C16-C2o)alkenyl are optionally substituted with one or two -OH and -O(CH3).

[229] In some embodiments, a compound of the invention is represented by the structure shown in Formula IIa, wherein R6 is selected from (C1o-C2o)alkyl and (C1o-C2o)alkenyl. Petition 870260002828, dated 12 / 01 / 2026, p. 82 / 237 73 / 211

[230] In some embodiments, a compound of the invention is represented by the structure shown in Formula IIa, in which R6 is selected from (C12-C20)alkyl and (C12-C20)alkenyl.

[231] In some embodiments, a compound of the invention is represented by the structure shown in Formula IIa, in which R6 is selected from (C14-C20)alkyl and (C14-C20)alkenyl.

[232] In some embodiments,One compound of the invention is represented by the structure shown in Formula IIa, in which R6 is selected from (C16-C20)alkyl and (C16-C20)alkenyl.

[233] The invention provides a compound having the structure shown in Formula III: wherein: R1 is (C1-C6)alkyl, in which said (C1-C6)alkyl is optionally substituted with one to four substituents selected from -OH and O(CH3); R2 is H, methyl or -O(CH3); Each occurrence of R3 is independently H, (C1-C4)alkyl, (C1-C4)alkenyl, (C1-C4)alkynyl or -O(C1-C4)alkyl, wherein said (C1-C4)alkyl, (C1-C4)alkenyl, (C1-C4)alkynyl or -O(C1-C4)alkyl is optionally substituted with one or two substituents selected from -OH and -O(CH3); Petition 870260002828, dated 12 / 01 / 2026, p. 83 / 237 74 / 211 R4 is selected from (Ce-C2o)alkyl, (C6-C2o)alkenyl and (Ce-C2o)alkynyl, wherein said (Ce-C2o)alkyl,(Ce-C2o)alkenyl and (CeC2o)alkynyl are optionally substituted with one to six substituents selected from -OH, -O(C1-C4)alkyl, -O(C1-C4)alkenyl, -O(C1C4)alkynyl, chlorine and fluorine; en is 4.

[234] In some embodiments, a compound of the invention is represented by the structure shown in Formula III, where n is 0, 1, 2 or 3.

[235] In some embodiments, a compound of the invention is represented by the structure shown in Formula III, where n is 0, 1 or 2.

[236] In some embodiments, a compound of the invention is represented by the structure shown in Formula III, where n is 0 or 1.

[237] In some embodiments, a compound of the invention is represented by the structure shown in Formula III, where n is absent.

[238] In some embodiments, a compound of the invention is represented by the structure shown in Formula III, wherein R1 is ethyl, butyl (branched or linear chain) or pentyl (branched or linear chain), wherein said ethyl,butyl or pentyl is optionally substituted with one to four substituents selected independently of -OH, -O(CH3), chlorine and fluorine.

[239] In some embodiments, a compound of the invention is represented by the structure shown in Formula III, wherein R1 is butyl (branched or linear chain), wherein said butyl is optionally substituted with one to four substituents, selected independently of -OH, -O(CH3), chlorine and fluorine. [24o] In some embodiments, a compound of the invention is represented by the structure shown in Formula III, wherein R1 is ethyl, butyl (branched or linear chain) or pentyl (branched or linear chain), wherein said ethyl, butyl or pentyl is optionally substituted with one to two substituents, selected independently of -OH and -O(CH3).

[241] In some embodiments, a compound of the invention is represented by the structure shown in Formula III,

[242] In some embodiments, a compound of the invention is represented by the structure shown in Formula III, in which R1 is butyl (branched or linear chain), wherein said butyl is optionally substituted with one to two substituents, selected independently of -OH and -O(CH3).

[243] In some embodiments, a compound of the invention is represented by the structure shown in Formula III, wherein R2 is H or methyl.

[244] In some embodiments, a compound of the invention is represented by the structure shown in Formula III, wherein each occurrence of R3 is independently (C1-C4)alkyl, (C1-C4)alkenyl or -O(C1-C4)alkyl, wherein said (C1-C4)alkyl, (C1-C4)alkenyl or -O(C1-C4)alkyl is optionally substituted with one to four substituents, selected independently of -OH and -O(CH3).

[245] In some embodiments, a compound of the invention is represented by the structure shown in Formula III,wherein each occurrence of R3 is independently (C1-C4)alkyl or -O(C1-C4)alkyl, wherein said (C1-C4)alkyl or -O(C1-C4)alkyl is optionally substituted with one to four substituents, selected independently of -OH and O(CH3).

[246] In some embodiments, a compound of the invention is represented by the structure shown in Formula III, wherein each occurrence of R3 is independently (C1-C4)alkyl or -O(C1-C4)alkyl, wherein said (C1-C4)alkyl or -O(C1-C4)alkyl is optionally substituted with one to two substituents, selected independently of -OH and -O(CH3). Petition 870260002828, dated 12 / 01 / 2026, p. 85 / 237 76 / 211

[247] In some embodiments, a compound of the invention is represented by the structure shown in Formula III, wherein each occurrence of R3 is independently methyl or -O(CH3).

[248] In some embodiments, a compound of the invention is represented by the structure shown in Formula III,where each occurrence of R3 is -O(CH3).

[249] In some embodiments, a compound of the invention is represented by the structure shown in Formula III, wherein R4 is selected from (C6-C20)alkyl and (C6-C20)alkenyl, wherein said (C6C20)alkyl and (C6-C20)alkenyl are optionally substituted with one to six substituents, selected independently from -OH and -O(CH3).

[250] In some embodiments, a compound of the invention is represented by the structure shown in Formula III, wherein R4 is selected from (C8-C20)alkyl and (C8-C20)alkenyl, wherein said (C8C20)alkyl and (C8-C20)alkenyl are optionally substituted with one to six substituents, selected independently from -OH and -O(CH3).

[251] In some embodiments, a compound of the invention is represented by the structure shown in Formula III, in which R4 is selected from (C10-C20)alkyl and (C10-C20)alkenyl,in which said (C10-C20)alkyl and (C10-C20)alkenyl are optionally substituted with one to six substituents, selected independently of -OH and -O(CH3).

[252] In some embodiments, a compound of the invention is represented by the structure shown in Formula III, wherein R4 is selected from (C12-C20)alkyl and (C12-C20)alkenyl, wherein said (C12-C20)alkyl and (C12-C20)alkenyl are optionally substituted with one to six substituents, selected independently of -OH and -O(CH3).

[253] In some embodiments, a compound of the invention is Petition 870260002828, dated 12 / 01 / 2026, p. 86 / 237 77 / 211 represented by the structure shown in Formula III, wherein R4 is selected from (C14-C20)alkyl and (C14-C20)alkenyl, wherein said (C14-C20)alkyl and (C14-C20)alkenyl are optionally substituted with one to six substituents, selected independently from -OH and -O(CH3).

[254] In some embodiments,A compound of the invention is represented by the structure shown in Formula III, wherein R4 is selected from (C16-C20)alkyl and (C16-C20)alkenyl, wherein said (C16-C20)alkyl and (C16-C20)alkenyl are optionally substituted with one to six substituents, selected independently from -OH and -O(CH3).

[255] In some embodiments, a compound of the invention is represented by the structure shown in Formula III, wherein R4 is selected from (C6-C20)alkyl and (C6-C20)alkenyl.

[256] In some embodiments, a compound of the invention is represented by the structure shown in Formula III, wherein R4 is selected from (C8-C20)alkyl and (C8-C20)alkenyl.

[257] In some embodiments, a compound of the invention is represented by the structure shown in Formula III, in which R4 is selected from (C10-C20)alkyl and (C10-C20)alkenyl.

[258] In some embodiments, a compound of the invention is represented by the structure shown in Formula III,in which R4 is selected from (C12-C20)alkyl and (C12-C20)alkenyl.

[259] In some embodiments, a compound of the invention is represented by the structure shown in Formula III, in which R4 is selected from (C14-C20)alkyl and (C14-C20)alkenyl.

[260] In some embodiments, a compound of the invention is represented by the structure shown in Formula III, in which R4 is selected from (C16-C20)alkyl and (C16-C20)alkenyl. Petition 870260002828, 12 / 01 / 2026, p. 87 / 237 78 / 211

[261] The invention also provides a compound having the structure shown in Formula IIIa: in which: R1 is butyl, in which said butyl is optionally substituted with one or two -OH; each occurrence of R3 is independently H or -O(CH3); and R4 is selected from (C10-C20)alkyl, (C10-C20)alkenyl and (C10C20)alkynyl.

[262] In some embodiments, a compound of the invention is represented by the structure shown in Formula IIIa,in which R4 is selected from (C6-C20)alkyl and (C6-C20)alkenyl, wherein said (C6C20)alkyl and (C6-C20)alkenyl are optionally substituted with one to six -OH and -O(CH3).

[263] In some embodiments, a compound of the invention is represented by the structure shown in Formula IIIa, wherein R4 is selected from (C8-C20)alkyl and (C8-C20)alkenyl, wherein said (C8C20)alkyl and (C8-C20)alkenyl are optionally substituted with one to six substituents, selected independently from -OH and -O(CH3).

[264] In some embodiments, a compound of the invention is Petition 870260002828, dated 12 / 01 / 2026, p. 88 / 237 79 / 211 represented by the structure shown in Formula IIIa, wherein R4 is selected from (C10-C20)alkyl and (C10-C20)alkenyl, wherein said (C10-C20)alkyl and (C10-C20)alkenyl are optionally substituted with one to six substituents, selected independently from -OH and -O(CH3).

[265] In some embodiments,A compound of the invention is represented by the structure shown in Formula IIIa, wherein R4 is selected from (C12-C20)alkyl and (C12-C20)alkenyl, wherein said (C12-C20)alkyl and (C12-C20)alkenyl are optionally substituted with one to six substituents, selected independently from -OH and -O(CH3).

[266] In some embodiments, a compound of the invention is represented by the structure shown in Formula IIIa, wherein R4 is selected from (C14-C20)alkyl and (C14-C20)alkenyl, wherein said (C14-C20)alkyl and (C14-C20)alkenyl are optionally substituted with one to six substituents, selected independently from -OH and -O(CH3).

[267] In some embodiments, a compound of the invention is represented by the structure shown in Formula IIIa, wherein R4 is selected from (C16-C20)alkyl and (C16-C20)alkenyl, wherein said (C16-C20)alkyl and (C16-C20)alkenyl are optionally substituted with one to six substituents,

[268] In some embodiments, a compound of the invention is represented by the structure shown in Formula IIIa, in which R4 is selected independently of -OH and -O(CH3).

[269] In some embodiments, a compound of the invention is represented by the structure shown in Formula IIIa, in which R4 is selected from (C6-C20)alkyl and (C6-C20)alkenyl.

[270] In some embodiments, a compound of the invention is represented by the structure shown in Formula IIIa, in which R4 is selected from (C6-C20)alkyl and (C8-C20)alkenyl.

[271] In some embodiments, a compound of the invention is represented by the structure shown in Formula IIIa, in which R4 is selected from (C6-C20)alkyl and (C6-C20)alkenyl.

[271] In some embodiments, a compound of the invention is represented by the structure shown in Formula IIIa, in which R4 is selected from (C12-C2o)alkyl and (C12-C2o)alkenyl.

[272] In some embodiments, a compound of the invention is represented by the structure shown in Formula IIIa,wherein R4 is selected from (C14-C2o)alkyl and (C14-C2o)alkenyl.

[273] In some embodiments, a compound of the invention is represented by the structure shown in Formula IIIa, wherein R4 is selected from (C16-C2o)alkyl and (C16-C2o)alkenyl.

[274] The invention provides a compound having the structure shown in Formula IV: R4 wherein: R1 is (C1-C6)alkyl, wherein said (C1-C6)alkyl is optionally substituted with one to four substituents selected independently from -OH and -O(CH3); R2 is H, methyl or -O(CHa); each occurrence of R3 is independently H, (C1-C4)alkyl, (C1-C4)alkenyl, (C1-C4)alkynyl or -O(C1-C4)alkyl, wherein the said (C1-C4)alkyl, (C1-C4)alkenyl, (C1-C4)alkynyl and -O(C1-C4)alkyl are Petition 870260002828, dated 12 / 01 / 2026,p. 90 / 237 81 / 211 optionally substituted with one or two substituents selected independently of -OH and -O(CH3); each occurrence of R4 is independently selected from (C6-C20)alkyl, (C6-C20)alkenyl and (C6-C20)alkynyl, wherein said (C6C20)alkyl, (C6-C20)alkenyl and (C6-C20)alkynyl are optionally substituted with one to six substituents selected independently of -OH, -O(C1-C4)alkyl, -O(C1-C4)alkenyl, -O(C1-C4)alkynyl, chlorine or fluorine;

[275] In some embodiments, a compound of the invention is represented by the structure shown in Formula IV, where n is 0, 1, 2 or 3.

[276] In some embodiments, a compound of the invention is represented by the structure shown in Formula IV, where n is 0, 1 or 2.

[277] In some embodiments, a compound of the invention is represented by the structure shown in Formula IV, where n is 0 or 1.

[278] In some embodiments,A compound of the invention is represented by the structure shown in Formula IV, where n is absent.

[279] In some embodiments, a compound of the invention is represented by the structure shown in Formula IV, wherein R1 is ethyl, butyl (branched or linear chain) or pentyl (branched or linear chain), wherein said ethyl, butyl or pentyl is optionally substituted with one to four substituents selected independently from -OH, -O(CH3), chlorine and fluorine.

[280] In some embodiments, a compound of the invention is represented by the structure shown in Formula IV, wherein R1 is butyl (branched or linear chain), wherein said butyl is optionally substituted with one to four substituents, selected independently from -OH, -O(CH3), chlorine and fluorine. Petition 870260002828, dated 12 / 01 / 2026, p. 91 / 237 82 / 211

[281] In some embodiments, a compound of the invention is represented by the structure shown in Formula IV, in which R1 is ethyl,butyl (branched or linear chain) or pentyl (branched or linear chain), wherein said ethyl, butyl or pentyl is optionally substituted with one or two substituents, selected independently from -OH and -O(CH3).

[282] In some embodiments, a compound of the invention is represented by the structure shown in Formula IV, wherein R1 is butyl (branched or linear chain), wherein said butyl is optionally substituted with one or two substituents, selected independently from -OH and -O(CH3).

[283] In some embodiments, a compound of the invention is represented by the structure shown in Formula IV, wherein R2 is H or methyl.

[284] In some embodiments, a compound of the invention is represented by the structure shown in Formula IV, wherein R2 is H.

[285] In some embodiments, a compound of the invention is represented by the structure shown in Formula IV, wherein each occurrence of R3 is independently (C1-C4)alkyl,(C1-C4)alkenyl or -O(C1-C4)alkyl, wherein said C1-C4)alkyl, (C1-C4)alkenyl or -O(C1-C4)alkyl is optionally substituted with one to four substituents, selected independently from -OH or -O(CH3).

[286] In some embodiments, a compound of the invention is represented by the structure shown in Formula IV, wherein each occurrence of R3 is independently (C1-C4)alkyl or -O(C1-C4)alkyl, wherein said (C1-C4)alkyl or -O(C1-C4)alkyl is optionally substituted with one to four substituents, selected independently from -OH or O(CH3).

[287] In some embodiments, a compound of the invention is Petition 870260002828, dated 12 / 01 / 2026, p. 92 / 237 83 / 211 represented by the structure shown in Formula IV, wherein each occurrence of R3 is independently (C1-C4)alkyl or -O(C1-C4)alkyl, wherein said (C1-C4)alkyl or -O(C1-C4)alkyl is optionally substituted with one or two substituents,

[288] In some embodiments, a compound of the invention is represented by the structure shown in Formula IV, wherein each occurrence of R3 is independently methyl or -O(CH3).

[289] In some embodiments, a compound of the invention is represented by the structure shown in Formula IV, wherein each occurrence of R3 is independently -O(CH3).

[290] In some embodiments, a compound of the invention is represented by the structure shown in Formula IV, wherein each occurrence of R4 is independently selected from (C6-C20)alkyl and (C6C20)alkenyl, wherein said (C6-C20)alkyl and (C6-C20)alkenyl are optionally substituted with one to six -OH and -O(CH3).

[291] In some embodiments, a compound of the invention is represented by the structure shown in Formula IV, in which each occurrence of R4 is independently selected from (C8-C20)alkyl and (C8C20)alkenyl,in which said (C8-C20)alkyl and (C8-C20)alkenyl are optionally substituted with one to six -OH and -O(CH3).

[292] In some embodiments, a compound of the invention is represented by the structure shown in Formula IV, wherein each occurrence of R4 is selected independently from (C10-C20)alkyl and (C10C20)alkenyl, wherein said (C10-C20)alkyl and (C10-C20)alkenyl are optionally substituted with one to six -OH and -O(CH3).

[293] In some embodiments, a compound of the invention is represented by the structure shown in Formula IV, wherein each occurrence Petition 870260002828, 12 / 01 / 2026, p. 93 / 237 84 / 211 of R4 is independently selected from (C12-C20)alkyl and (C12C20)alkenyl, wherein said (C12-C20)alkyl and (C12-C20)alkenyl are optionally substituted with one to six -OH and -O(CH3).

[294] In some embodiments, a compound of the invention is represented by the structure shown in Formula IV,wherein each occurrence of R4 is selected independently from (C14-C20)alkyl and (C14C20)alkenyl, wherein said (C14-C20)alkyl and (C14-C20)alkenyl are optionally substituted with one to six -OH and -O(CH3).

[295] In some embodiments, a compound of the invention is represented by the structure shown in Formula IV, wherein each occurrence of R4 is selected independently from (C16-C20)alkyl and (C16C20)alkenyl, wherein said (C16-C20)alkyl and (C16-C20)alkenyl are optionally substituted with one to six -OH and -O(CH3).

[296] In some embodiments, a compound of the invention is represented by the structure shown in Formula IV, in which each occurrence of R4 is selected independently from (C6-C20)alkyl and (C6C20)alkenyl.

[297] In some embodiments, a compound of the invention is represented by the structure shown in Formula IV,in which each occurrence of R4 is selected independently of (C8-C20)alkyl and (C8C20)alkenyl.

[298] In some embodiments, a compound of the invention is represented by the structure shown in Formula IV, in which each occurrence of R4 is selected independently of (C10-C20)alkyl and (C10C20)alkenyl.

[299] In some embodiments, a compound of the invention is represented by the structure shown in Formula IV, in which each occurrence of R4 is selected independently of (C12-C20)alkyl and (C12C20)alkenyl.

[300] In some embodiments, a compound of the invention is represented by the structure shown in Formula IV, in which each occurrence of R4 is selected independently from (C14-C20)alkyl and (C14C20)alkenyl.

[301] In some embodiments, a compound of the invention is represented by the structure shown in Formula IV,wherein each occurrence of R4 is selected independently from (C16-C20)alkyl and (C16C20)alkenyl.

[302] The invention provides a compound having the structure shown in Formula IVa: R4 wherein: R1 is butyl, wherein said butyl is optionally substituted with one or two -OH; each occurrence of R3 is independently H or -O(CH3); and each occurrence of R4 is selected independently from (C10-C20)alkyl, (C10-C20)alkenyl and (C10-C20)alkynyl.

[303] In some embodiments, a compound of the invention is represented by the structure shown in Formula IVa, wherein R4 is Petition 870260002828, dated 12 / 01 / 2026, p. 95 / 237 86 / 211 selected independently of (C6-C2o)alkyl and (C6-C2o)alkenyl, wherein said (C6-C2o)alkyl and (C6-C2o)alkenyl are optionally substituted with one to six substituents, selected independently of -OH and -O(CH3).

[304] In some embodiments,A compound of the invention is represented by the structure shown in Formula IVa, wherein R4 is independently selected from (C8-C20)alkyl and (C8-C20)alkenyl, wherein said (C8-C20)alkyl and (C8-C20)alkenyl are optionally substituted with one to six substituents, independently selected from -OH and -O(CH3).

[305] In some embodiments, a compound of the invention is represented by the structure shown in Formula IVa, wherein R4 is independently selected from (C10-C20)alkyl and (C10-C20)alkenyl, wherein said (C10-C20)alkyl and (C10-C20)alkenyl are optionally substituted with one to six substituents, independently selected from -OH and -O(CH3).

[306] In some embodiments, a compound of the invention is represented by the structure shown in Formula IVa, in which R4 is independently selected from (C12-C20)alkyl and (C12-C20)alkenyl,in which said (C12-C20)alkyl and (C12-C20)alkenyl are optionally substituted with one to six substituents, selected independently of -OH and -O(CH3).

[307] In some embodiments, a compound of the invention is represented by the structure shown in Formula IVa, wherein R4 is selected independently of (C14-C20)alkyl and (C14-C20)alkenyl, wherein said (C14-C20)alkyl and (C14-C20)alkenyl are optionally substituted with one to six substituents, selected independently of Petition 870260002828, dated 12 / 01 / 2026, page 96 / 237 87 / 211 of -OH and -O(CH3).

[308] In some embodiments, a compound of the invention is represented by the structure shown in Formula IVa, wherein R4 is independently selected from (C16-C20)alkyl and (C16-C20)alkenyl, wherein said (C16-C20)alkyl and (C16-C20)alkenyl are optionally substituted with one to six substituents,

[309] In some embodiments, a compound of the invention is represented by the structure shown in Formula IVa, wherein each occurrence of R4 is independently selected from (C6-C20)alkyl and (C6-C20)alkenyl.

[310] In some embodiments, a compound of the invention is represented by the structure shown in Formula IVa, wherein each occurrence of R4 is independently selected from (C8-C20)alkyl and (C8-C20)alkenyl.

[311] In some embodiments, a compound of the invention is represented by the structure shown in Formula IVa, wherein each occurrence of R4 is independently selected from (C10-C20)alkyl and (C10-C20)alkenyl.

[312] In some embodiments, a compound of the invention is represented by the structure shown in Formula IVa, wherein each occurrence of R4 is selected independently from (C12-C20)alkyl and (C12-C20)alkenyl.

[313] In some embodiments,A compound of the invention is represented by the structure shown in Formula IVa, wherein each occurrence of R4 is independently selected from (C14-C20)alkyl and (C14-C20)alkenyl. Petition 870260002828, dated 12 / 01 / 2026, page 97 / 237 88 / 211

[314] In some embodiments, a compound of the invention is represented by the structure shown in Formula IVa, wherein each occurrence of R4 is independently selected from (C16-C20)alkyl and (C16-C20)alkenyl.

[315] In some embodiments, the invention provides a compound selected from: (N -(5-(4-(4-((5-amino-7-(butylamino)-2 H -pyrazolo[4,3-d]pyrimidin-2yl)methyl)-3,5-dimethoxyphenyl)piperazin-1-yl)-5-oxopentyl)stearamide; (5)-N -(5-(4-(4-((5-amino-7-((1-hydroxypentan-2-yl)amino)-2H-pyrazolo[4,3d]pyrimidin-2-yl)methyl)-3,5-dimethoxyphenyl)piperazin-1-yl)-5oxopentyl)stearamide (5); )-1-(4-(4-((5-amino-7-((1-hydroxypentan-2-yl)amino)-2 H-pyrazolo[4,3d ]pirimidin-2-yl)methyl)-3,5-dimethoxyphenyl)piperazin-1-yl)octadecan-1-one; N -(5-(4-(4-((5-amino-7-(butylamino)-2 H-pyrazolo[4,3-d ]pyrimidin-2-yl)methyl)3-methoxyphenyl)piperazin-1-yl)-5-oxopentyl)stearamide; N -(5-(4-(4-((5-amino-7-(butylamino)-2 H-pyrazolo[4,3-d ]pyrimidin-2-yl)methyl)3-methoxyphenyl)piperazin-1-yl)-5-oxopentyl)tetradecanamida; N -(5-(4-(4-((5-amino-7-(butylamino)-2 H-pyrazolo[4,3-d ]pyrimidin-2-yl)methyl)3-methoxyphenyl)piperazin-1-yl)-5-oxopentyl)oleamide; (9 Z,12 Z)-N -(5-(4-(4-((5-amino-7-(butylamino)-2 H-pyrazolo[4,3-d ]pyrimidin-2-yl)methyl)-3-methoxyphenyl)piperazin-1-yl)-5-oxopentyl)octadeca-9,12-dienamide; N -(5-(4-(4-((5-amino-7-(butylamino)-2 H-pyrazolo[4,3-d ]pyrimidin-2-yl)methyl)3-methoxyphenyl)-1,4-diazepan-1-yl)-5-oxopentyl)stearamide; N -(5-(4-(4-((5-amino-7-(butylamino)-2 H-pyrazolo[4,3-d ]pyrimidin-2-yl)methyl)3-methoxyphenyl)piperidin-1-yl)-5-oxopentyl)stearamide; N -(5-(3-(4-((5-amino-7-(butylamino)-2 H-pyrazolo[4,3-d ]pyrimidin-2-yl)methyl)3-methoxyphenyl)azetidin-1-yl)-5-oxopentyl)stearamide; Petition 870260002828, of 12 / 01 / 2026, pág. 98 / 237 89 / 211 1-(4-((5-amino-7-(butylamino)-2 H -pyrazolo[4,3-d ]pyrimidin-2-yl)methyl)-3methoxyphenyl)-N-(3-stearamidopropyl)piperidine-4-carboxamide; (1 s ,3 s )-3-(2-(4-(4-((5-amino-7-(butylamino)-2 H-pyrazolo[4,3-d ]pyrimidin-2-yl)methyl)-3-methoxyphenyl)piperazin-1-yl)-2-oxoethyl)-N -octadecylcyclobutano-1carboxamide; (1 s ,3 s )-3-(2-(4-(4-((5-amino-7-(butylamino)-2 H-pyrazolo[4,3-d ]pyrimidin-2-yl)methyl)-3-methoxyphenyl)piperazin-1-yl)-2-oxoethyl)-N -hexadecylcyclobutane-1carboxamide; N -(3-(4-(4-((5-amino-7-(butylamino)-2 H-pyrazolo[4,3-d ]pyrimidin-2-yl)methyl)3-methoxyphenyl)piperazin-1-yl)-3-oxopropyl)stearamide; N -(7-(4-(4-((5-amino-7-(butylamino)-2 H-pyrazolo[4,3-d ]pyrimidin-2-yl)methyl)3-methoxyphenyl)piperazin-1-yl)-7-oxo-heptyl)stearamide; N -(3-(2-(4-(4-((5-amino-7-(butylamino)-2H-pyrazolo[4,3-d ]pyrimidin-2yl)methyl)-3-methoxyphenyl)piperazin-1-yl)-2-oxoethyl)cyclobutyl)stearamide; N -(5-(4-(4-((5-amino-7-(butylamino)-2 H-pyrazolo[4,3-d ]pyrimidin-2-yl)methyl)3-methoxyphenyl)piperazin-1-yl)-4,4-dimethyl-5-oxopentyl)stearamide; N -(6-(4-(4-((5-amino-7-(butylamino)-2 H-pyrazolo[4,3-d ]pyrimidin-2-yl)methyl)3-methoxyphenyl)piperazin-1-yl)-2-methyl-6-oxo-hexan-2-yl)stearamide; 1-(4-(4-((5-amino-7-(butylamino)-2 H-pyrazolo[4,3-d]pyrimidin-2-yl)methyl)-3methoxyphenyl)piperazin-1-yl)-5-(octadecyloxy)pentan-1-one; 1-(4-(4-((5-amino-7-(butylamino)-2H-pyrazolo[4,3-d]pyrimidin-2-yl)methyl)-3methoxyphenyl)piperazin-1-yl)-5-(octadecylamino)pentan-1-one; N-(5-(4-(4-((5-amino-7-(butylamino)-3-methyl-2H-pyrazolo[4,3-d]pyrimidin-2-yl)methyl)-3-methoxyphenyl)piperazin-1-yl)-5-oxopentyl)stearamide; (9 Z,12 Z)-N -(4-((4-((5-amino-7-(butilamino)-2 H -pyrazolo[4,3-d ]pyrimidin-2yl)metil)-3,5-dimethoxybenzil)(metil)amino)butil)octadeca-9,12-dienamide; N-(4-((4-((5-amino-7-(butylamino)-2H-pyrazolo[4,3-d]pyrimidin-2-yl)methyl)Petição 870260002828, de 12 / 01 / 2026, pág. 99 / 237 90 / 211 3,5-dimethoxybenzyl)(methyl)amino)butyl)tetradecanamida; N -(4-((4-((5-amino-7-(butylamino)-2 H -pyrazolo[4,3-d ]pyrimidin-2-yl)methyl)3,5-dimethoxybenzyl)(methyl)amino)butyl)oleamide; N -(4-((4-((5-amino-7-(butylamino)-2 H -pyrazolo[4,3-d ]pyrimidin-2-yl)methyl)3,5-dimethoxybenzyl)(methyl)amino)butyl)stearamide; N -(4-((4-((5-amino-7-(butylamino)-2 H -pyrazolo[4,3-d ]pyrimidin-2-yl)methyl)3,5-dimethoxybenzyl)(methyl)amino)-4-oxobutyl)stearamide; (methyl)amino)butyl)carbamate of (6 Z,9 Z,28 Z,31Z )-heptatriaconta6,9,28,31-tetraen-19-yl (4-((4-((5-amino-7-(butylamino)-2 H-pyrazolo[4,3-d]pyrimidin-2-yl)methyl)-3,5-dimethoxybenzyl); 4-(4-((5-amino-7-(butylamino)-2H-pyrazolo[4,3-d]pyrimidin-2-yl)methyl)-3methoxyphenyl)-N-(3-stearamidopropyl)piperazine-1-carboxamide; 4-(4-((5-amino-7-(butylamino)-2 H -pyrazolo[4,3-d]pyrimidin-2-yl)methyl)-3methoxyphenyl)-N-(3-stearamidopropyl)piperazine-1-carboxamide;3-d ]pyrimidine-2-yl)methyl)-3methoxyphenyl)piperazine-1-carboxylate of 3-stearamidopropyl; N -(5-(4-(4-((5-amino-7-(butylamino)-2 H-pyrazolo[4,3-d ]pyrimidin-2-yl)methyl)3-methoxyphenyl)piperazin-1-yl)-6,6,6-trifluoro-hexyl)stearamide; N-(4-((4-((7-(butylamino)-5-hydroxy-2H-pyrazolo[4,3-d]pyrimidin-2-yl)methyl)3,5-dimethoxybenzyl)(methyl)amino)butyl)stearamide; (5-(4-(4-((5-amino-7-(butylamino)-2 H -pyrazole[4,3-d ]pyrimidin-2-yl)methyl)-3methoxyphenyl)piperazin-1-yl)-5-oxopentyl)carbamate of (6 Z,9 Z,28 Z,31Z)heptatriaconta-6,9,28,31-tetraene-19; or a pharmaceutically acceptable salt of the same.

[316] In some embodiments, a compound of the invention is (N -(5-(4-(4((5-amino-7-(butylamino)-2 H -pyrazole[4,3-d ]pyrimidin-2-yl)methyl)-3,5dimethoxyphenyl)piperazin-1-yl)-5-oxopentyl) or pharmaceutically salt acceptable of the same

[317] In some embodiments, a compound of the invention is (N -(5-(4-(4- Petition 870260002828, dated 12 / 01 / 2026,).pg. 100 / 237 91 / 211 ((5-amino-7-(butylamino)-2 H -pyrazolo[4,3-d ]pyrimidin-2-yl)methyl)-3,5-dimethoxyphenyl)piperazin-1-yl)-5-oxopentil)stearamide, or a pharmaceutically acceptable salt thereof.

[318] In some embodiments, a compound of the invention is (5)-N -(5-(4(4-((5-amino-7-((1-hydroxypentan-2-yl)amino)-2 H -pyrazolo[4,3-d ]pyrimidin-2-yl)methyl)-3,5-dimethoxyphenyl)piperazin-1-yl)-5-oxopentil)stearamide, or a pharmaceutically acceptable salt thereof.

[319] In some embodiments, a compound of the invention is (5)-1-(4-(4((5-amino-7-((1-hydroxypentan-2-yl)amino)-2H-pyrazolo[4,3-d]pyrimidin-2-yl)methyl)-3,5-dimethoxyphenyl)piperazin-1-yl)octadecan-1-one, or a pharmaceutically acceptable salt thereof.

[320] In some embodiments, a compound of the invention is N-(5-(4-(4((5-amino-7-(butylamino)-2H-pyrazolo[4,3-d]pyrimidin-2-yl)methyl)-3-methoxyphenyl)piperazin-1-yl)-5-oxopentyl)stearamide, or a pharmaceutically acceptable salt thereof.

[321] In some embodiments,One compound of the invention is N-(5-(4-(4((5-amino-7-(butylamino)-2H-pyrazolo[4,3-d]pyrimidin-2-yl)methyl)-3-methoxyphenyl)piperazin-1-yl)-5-oxopentil)tetradecanamide, or a pharmaceutically acceptable salt thereof.

[322] In some embodiments, one compound of the invention is N-(5-(4-(4((5-amino-7-(butylamino)-2H-pyrazolo[4,3-d]pyrimidin-2-yl)methyl)-3-methoxyphenyl)piperazin-1-yl)-5-oxopentil)oleamide, or a pharmaceutically acceptable salt thereof.

[323] In some embodiments, a compound of the invention is (9 Z,12 Z)-N (5-(4-(4-((5-amino-7-(butylamino)-2 H -pyrazolo[4,3-d ]pyrimidin-2-yl)methyl)-3-methoxyphenyl)piperazin-1-yl)-5-oxopentyl)octadeca-9,12-dienamide, or a pharmaceutically acceptable salt thereof. Petition 870260002828, dated 12 / 01 / 2026, p. 101 / 237 92 / 211

[324] In some embodiments, a compound of the invention is N-(5-(4-(4((5-amino-7-(butylamino)-2H-pyrazolo[4,3-d]pyrimidin-2-yl)methyl)-3-methoxyphenyl)1,4-diazepan-1-yl)-5-oxopentyl)stearamide,or a pharmaceutically acceptable salt thereof.

[325] In some embodiments, a compound of the invention is N-(5-(4-(4((5-amino-7-(butylamino)-2H-pyrazolo[4,3-d]pyrimidin-2-yl)methyl)-3methoxyphenyl)piperidin-1-yl)-5-oxopentyl)stearamide, or a pharmaceutically acceptable salt thereof.

[326] In some embodiments, a compound of the invention is N-(5-(3-(4((5-amino-7-(butylamino)-2H-pyrazolo[4,3-d]pyrimidin-2-yl)methyl)-3methoxyphenyl)azetidin-1-yl)-5-oxopentyl)stearamide, or a pharmaceutically acceptable salt thereof.

[327] In some embodiments, a compound of the invention is 1-(4-((5-amino-7-(butylamino)-2H-pyrazolo[4,3-d]pyrimidin-2-yl)methyl)-3-methoxyphenyl)-N-(3-stearamidopropyl)piperidine-4-carboxamide, or a pharmaceutically acceptable salt thereof.

[328] In some embodiments, a compound of the invention is (1s,3s)-3-(2(4-(4-((5-amino-7-(butylamino)-2H-pyrazolo[4,3-d]pyrimidin-2-yl)methyl)-3-methoxyphenyl)piperazin-1-yl)-2-oxoethyl)-N-octadecylcyclobutane-1-carboxamide,or a pharmaceutically acceptable salt thereof.

[329] In some embodiments, a compound of the invention is (1s,3s)-3-(2(4-(4-((5-amino-7-(butylamino)-2H-pyrazolo[4,3-d]pyrimidin-2-yl)methyl)-3methoxyphenyl)piperazin-1-yl)-2-oxoethyl)-N-hexadecylcyclobutane-1-carboxamide, or a pharmaceutically acceptable salt thereof.

[330] In some embodiments, a compound of the invention is N-(3-(4-(4((5-amino-7-(butylamino)-2H-pyrazolo[4,3-d]pyrimidin-2-yl)methyl)-3-methoxyphenyl)piperazin-1-yl)-3-oxopropyl)stearamide, or a pharmaceutically acceptable salt thereof. Petition 870260002828, dated 12 / 01 / 2026, p. 102 / 237 93 / 211

[331] In some embodiments, a compound of the invention is N-(7-(4-(4((5-amino-7-(butylamino)-2H-pyrazolo[4,3-d]pyrimidin-2-yl)methyl)-3-methoxyphenyl)piperazin-1-yl)-7-oxo-heptyl)stearamide, or a pharmaceutically acceptable salt thereof.

[332] In some embodiments, a compound of the invention is N-(3-(2-(4(4-((5-amino-7-(butylamino)-2H-pyrazolo[4,3-d]pyrimidin-2-yl)methyl)-3-methoxyphenyl)piperazin-1-yl)-2-oxoethyl)cyclobutyl)stearamide, or a pharmaceutically acceptable salt thereof.

[333] In some embodiments, a compound of the invention is N-(5-(4-(4((5-amino-7-(butylamino)-2H-pyrazolo[4,3-d]pyrimidin-2-yl)methyl)-3-methoxyphenyl)piperazin-1-yl)-4,4-dimethyl-5-oxopentyl)stearamide, or a pharmaceutically acceptable salt thereof.

[334] In some embodiments, a compound of the invention is N-(6-(4-(4((5-amino-7-(butylamino)-2H-pyrazolo[4,3-d]pyrimidin-2-yl)methyl)-3-methoxyphenyl)piperazin-1-yl)-2-methyl-6-oxo-hexan-2-yl)stearamide, or a pharmaceutically acceptable salt thereof.

[335] In some embodiments, a compound of the invention is 1-(4-(4-((5-amino-7-(butylamino)-2H-pyrazolo[4,3-d]pyrimidin-2-yl)methyl)-3-methoxyphenyl)piperazin-1-yl)-5-(octadecyloxy)pentan-1-one, or a pharmaceutically acceptable salt thereof.

[336] In some embodiments, a compound of the invention is 1-(4-(4-((5amino-7-(butylamino)-2H-pyrazolo[4,3-d]pirimidin-2-yl)methyl)-3-methoxyphenyl)piperazin-1-yl)-5-(octadecylamino)pentan-1-one, or a pharmaceutically acceptable salt thereof.

[337] In some embodiments, a compound of the invention is N-(5-(4-(4((5-amino-7-(butylamino)-3-methyl-2H-pyrazolo[4,3-d]pirimidin-2-yl)methyl)-3-methoxyphenyl)piperazin-1-yl)-5-oxopentyl)stearamide, or a pharmaceutically acceptable salt thereof.

[338] In some embodiments, a compound of the invention is (9Z,12Z)-N-(4-((4-((5-amino-7-(butylamino)-2H-pyrazolo[4,3-d]pyrimidin-2-yl)methyl)-3,5-dimethoxybenzyl)(methyl)amino)butyl)octadeca-9,12-dienamide, or a pharmaceutically acceptable salt thereof.

[339] In some embodiments, a compound of the invention is N-(4-((4-((5-amino-7-(butylamino)-2H-pyrazolo[4,3-d]pyrimidin-2-yl)methyl)-3,5-dimethoxybenzyl)(methyl)amino)butyl)tetradecanamide, or a pharmaceutically acceptable salt thereof.

[340] In some embodiments,One compound of the invention is N-(4-((4-((5amino-7-(butylamino)-2H-pyrazolo[4,3-d]pyrimidin-2-yl)methyl)-3,5-dimethoxybenzyl)(methyl)amino)butyl)oleamide, or a pharmaceutically acceptable salt thereof.

[341] In some embodiments, one compound of the invention is N-(4-((4-((5amino-7-(butylamino)-2H-pyrazolo[4,3-d]pyrimidin-2-yl)methyl)-3,5-dimethoxybenzyl)(methyl)amino)butyl)stearamide, or a pharmaceutically acceptable salt thereof.

[342] In some embodiments, a compound of the invention is N-(4-((4-((5amino-7-(butylamino)-2H-pyrazolo[4,3-d]pyrimidin-2-yl)methyl)-3,5-dimethoxybenzyl)(methyl)amino)4-oxobutyl)stearamide, or a pharmaceutically acceptable salt thereof.

[343] In some embodiments, a compound of the invention is (6Z,9Z,28Z,31Z)-heptatriaconta-6,9,28,31-tetraen-19-yl)(4-((((5amino-7-(butylamino)-2H-pyrazolo[4,3-d]pyrimidin-2-yl)methyl)-3,5-dimethoxybenzyl)(methyl)amino)butyl)carbamate, or a pharmaceutically acceptable salt thereof. Petition 870260002828, dated 12 / 01 / 2026,pg. 104 / 237 95 / 211

[344] In some embodiments, a compound of the invention is 4-(4-((5amino-7-(butylamino)-2H-pyrazolo[4,3-d]pyrimidin-2-yl)methyl)-3-methoxyphenyl)-N-(3-stearamidopropyl)piperazine-1-carboxamide, or a pharmaceutically acceptable salt thereof.

[345] In some embodiments, a compound of the invention is 3-stearamidopropyl 4-(4-((5amino-7-(butylamino)-2H-pyrazolo[4,3-d]pyrimidin-2-yl)methyl)-3-methoxyphenyl)piperazine-1-carboxylate, or a pharmaceutically acceptable salt thereof.

[346] In some embodiments, a compound of the invention is (N-(5-(4-(4((5-amino-7-(butylamino)-2H-pyrazolo[4,3-d]pyrimidin-2-yl)methyl)-3-methoxyphenyl)piperazin-1-yl)-6,6,6-trifluorohexyl)stearamide, or a pharmaceutically acceptable salt thereof.

[347] In some embodiments, a compound of the invention is N-(4-((4-((7(butylamino)-5-hydroxy-2H-pyrazolo[4,3-d]pyrimidin-2-yl)methyl)-3,5-dimethoxybenzyl)(methyl)amino)butyl)stearamide,or a pharmaceutically acceptable salt thereof.

[348] In some embodiments, a compound of the invention is (5-(4-(4-((5amino-7-(butylamino)-2H-pyrazolo[4,3-d]pyrimidin-2-yl)methyl)-3-methoxyphenyl)piperazin-1-yl)-5-oxopentyl)carbamate of (6Z,9Z,28Z,31Z)-heptatriaconta-6,9,28,31-tetraen-19-yl, or a pharmaceutically acceptable salt thereof. Adjuvants

[349] Adjuvant-based approaches are being investigated to increase the immunogenicity of vaccines and help meet unmet residual medical needs, particularly for populations with increased susceptibility to infectious diseases (i.e., immunocompromised populations, the elderly, or children). Petition 870260002828, dated 12 / 01 / 2026, page 105 / 237 96 / 211

[350] For example, although the incidence of invasive pneumococcal disease (IPD) has decreased dramatically in both children and adults after the introduction of pneumococcal conjugate vaccines,Residual disease caused by persistent vaccine-type serotypes still persists. Furthermore, serotype-specific immune responses vary, and the introduction of PCVs with expanded valence has resulted in an overall decrease in serotype-specific immune responses. Adjuvant-based strategies to enhance the immunogenicity of PCVs may increase vaccine efficacy against challenging serotypes, provide more durable immune responses, or allow for a reduction in the dosing schedule.

[351] Preclinical data indicate that a toll-like receptor 7 / 8 (TLR7 / 8) agonist may enhance the immunogenicity of PCVs. [Dowling, DJ et al.] reported accelerated and enhanced serotype-specific antibody responses, including both binding antibody titers and functional opsonophagocytic killing,in neonatal and infant rhesus monkeys immunized with PCV13 plus the TLR7 / 8 agonist 3M-052 compared to PCV13 alone (PCV13 contains aluminum adjuvant). The addition of the TLR7 / 8 agonist to PCV13 also induced Th1-polarized CD4 CRM197-specific T cells and B cells specific for 5. pneumoniae antigens in infant rhesus monkeys, and increased the production of type II IFN and Th1-polarizing cytokines after in vitro stimulation of human neonatal umbilical cord blood (Dowling, DJ et al., JCI Insight 2017; 2(2) e91020). Adjuvant Formulations

[352] The disclosure provides an adjuvant formulation comprising: 1) one or more compounds of the invention or pharmaceutically acceptable salt(s) thereof; 2) one or more sorbitan-based surfactants, and 3) one or more terpenes. The adjuvant formulations of the invention are also Petition 870260002828, dated 12 / 01 / 2026,pg. 106 / 237 97 / 211 called stable nanoemulsions or SNEs.

[353] The present disclosure provides an adjuvant formulation comprising: 1) one or more compounds of the invention or pharmaceutically acceptable salt(s) thereof; 2) sorbitan trioleate (SPAN85); 3) polysorbate-20 (PS-20) or polysorbate-80 (PS-80), and 4) squalene.

[354] The disclosure provides an adjuvant formulation comprising: 1) one or more compounds of the invention or pharmaceutically acceptable salt(s) thereof; 2) SPAN-85; 3) PS-20, and 4) squalene.

[355] The disclosure provides an adjuvant formulation comprising: 1) a compound of the invention or a pharmaceutically acceptable salt thereof; 2) SPAN-85; 3) PS-20 or PS-80, and 4) squalene.

[356] The disclosure provides an adjuvant formulation comprising: 1) a compound of the invention or a pharmaceutically acceptable salt thereof; 2) SPAN-85; 3) PS-20, and 4) squalene. General Methods of Production of SNE Formulations

[357] Generally, SNEs can be formed,For example, initially combining and mixing the components. Once mixed and combined, an aqueous buffer is added and mixed with the initial components of the compound to form a combined emulsion mixture. In some embodiments, the components of the combined emulsion are first subjected to coarse homogenization, followed by fine homogenization. Then, the resulting formulation is subjected to a final filtration step and stored at 4 °C. The solution may include one or more compounds; one or more sorbitan-based surfactants (e.g., PS-20; PS-80; SPAN-85), and one or more terpenes (e.g., squalene) in specific molar ratios.

[358] Alternatively, a process for preparing an SNE of the invention consists of 4 main steps: 1) preparation of a solution of a Petition 870260002828, dated 12 / 01 / 2026,pg. 107 / 237 98 / 211 mixture of components including functional and non-functional ingredients and an aqueous buffer; 2) formation of SNE by means of split-flow mixing; 3) ultrafiltration, and 4) filtration.

[359] Generally, the components are dissolved in ethanol before being sterilely filtered to form a mixture. Several aqueous buffers are also prepared. The mixture and buffer streams are then combined using a T- or Y-tube mixer and, immediately after outlet, are diluted and mixed with an aqueous buffer to form an SNE intermediate. An SNE intermediate is then subjected to ultrafiltration or dialysis to concentrate the material and also to exchange the material with a suitable buffer to remove residual ethanol. After diafiltration, a final concentration step is performed to achieve the final target concentration. The SNE volume is then filtered with a sterilizing filter. SNE formulations

[360] In some modalities,A formulation of SNE is provided comprising: 1) about 10 to 14 mol% of a compound of Formulas I, Ia, II, IIa, III, IIIa, IV and IVa or a pharmaceutically acceptable salt thereof; 2) about 1 to 4 mol% of SPAN-85; 3) about 1 to 4 mol% of PS-20 or PS80; and 4) about 50 to 80 mol% of squalene.

[361] In some embodiments, a formulation of SNE is provided comprising: 1) about 30 to 65 mol% of a compound of Formulas I, Ia, II, IIa, III, IIIa, IV and IVa or a pharmaceutically acceptable salt thereof; 2) about 5 to 30 mol% of SPAN-85; 3) about 0.5 to 4 mol% of PS-20 or PS-80, and 4) about 10 to 40 mol% of squalene.

[362] In some embodiments, an SNE formulation is provided comprising: 1) about 55 to 65 mol% of a compound of Formulas I, Petition 870260002828, 12 / 01 / 2026, p. 108 / 237 99 / 211 Ia, II, IIa, III, IIIa, IV and IVa or a pharmaceutically acceptable salt thereof; 2) about 5 to 15 mol% of SPAN-85; 3) about 1 to 2,5 mol% of PS-20 or PS-80, and 4) about 25 to 35 mol% of squalene.

[363] In some embodiments, an SNE formulation is provided comprising: 1) about 13 to 45 mol% of a compound of Formulas I, Ia, II, IIa, III, IIIa, IV and IVa or a pharmaceutically acceptable salt thereof; 2) about 2 to 4 mol% of SPAN-85; 3) about 1.5 to 3 mol% of PS-20 or PS-80, and 4) about 50 to 82 mol% of squalene.

[364] In some embodiments, an SNE formulation is provided comprising: 1) about 13 to 14 mol% of a compound of Formulas I, Ia, II, IIa, III, IIIa, IV and IVa or a pharmaceutically acceptable salt thereof; 2) about 1 to 2 mol% of SPAN-85; 3) about 1 to 2 mol% of PS-20 or PS80; and 4) about 79 to 81 mol% of squalene.

[365] In some embodiments, an SNE formulation comprising: about 1 to 60 mol% of a compound of Formulas I, Ia, II, IIa, III, IIIa,IV and IVa or a pharmaceutically acceptable salt thereof; 2) about 1 to 4 mol% of SPAN-85; 3) about 1 to 4 mol% of PS-20 or PS-80, and 4) about 32 to 97 mol% of squalene.

[366] In some embodiments, an SNE formulation is provided comprising: 1) about 0 to 45 mol% of a compound of Formulas I, Ia, II, IIa, III, IIIa, IV and IVa or a pharmaceutically acceptable salt thereof; 2) about 1 to 10 mol% of a nonionic surfactant, and 3) about 50 to 85 mol% of squalene. In one embodiment of this embodiment, the nonionic surfactant comprises a mixture of SPAN-85 and PS-20 or PS-80.

[367] In some embodiments, an SNE formulation is provided comprising: 1) about 10 to 14 mol% of a compound of Formulas I, Ia, II, IIa, III, IIIa, IV and IVa or a pharmaceutically acceptable salt thereof; 2) Petition 870260002828, dated 12 / 01 / 2026, pp. 109 / 237 100 / 211 about 1 to 4 mol% of SPAN-85; 3) about 1 to 4 mol% of PS-20,and 4) about 50 to 80 mol% of squalene.

[368] In some embodiments, an SNE formulation is provided comprising: 1) about 30 to 65 mol% of a compound of Formulas I, Ia, II, IIa, III, IIIa, IV and IVa or a pharmaceutically acceptable salt thereof; 2) about 5 to 30 mol% of SPAN-85; 3) about 0.5 to 4 mol% of PS-20, and 4) about 10 to 40 mol% of squalene.

[369] In some embodiments, an SNE formulation is provided comprising: 1) about 55 to 65 mol% of a compound of Formulas I, Ia, II, IIa, III, IIIa, IV and IVa or a pharmaceutically acceptable salt thereof; 2) about 5 to 15 mol% of SPAN-85; 3) about 1 to 2.5 mol% of PS-20, and 4) about 25 to 35 mol% of squalene.

[370] In some embodiments, an SNE formulation is provided comprising: 1) about 13 to 45 mol% of a compound of Formulas I, Ia, II, IIa, III, IIIa, IV and IVa or a pharmaceutically acceptable salt thereof; 2) about 2 to 4 mol% of SPAN-85; 3) about 1,5 to 3 mol% of PS-20, and 4) about 50 to 82 mol% of squalene.

[371] In some embodiments, an SNE formulation is provided comprising: 1) about 13 to 14 mol% of a compound of Formulas I, Ia, II, IIa, III, IIIa, IV and IVa or a pharmaceutically acceptable salt thereof; 2) about 1 to 2 mol% of SPAN-85; 3) about 1 to 2 mol% of PS-20, and 4) about 79 to 81 mol% of squalene.

[372] In some embodiments, an SNE formulation is provided comprising: about 1 to 60 mol% of a compound of Formulas I, Ia, II, IIa, III, IIIa, IV and IVa or a pharmaceutically acceptable salt thereof; 2) about 1 to 4 mol% of SPAN-85; 3) about 1 to 4 mol% of PS-20, and 4) about 32 to 97 mol% of squalene. Petition 870260002828, dated 12 / 01 / 2026, p. 110 / 237 101 / 211

[373] In some embodiments, an SNE formulation comprising: 1) about 0 to 45 mol% of a compound of Formulas I, Ia, II, Ia, III, IIIa,IV and IVa or a pharmaceutically acceptable salt thereof; 2) about 1 to 10 mol% of a nonionic surfactant, and 3) about 50 to 85 mol% of squalene. In one aspect of this embodiment, the nonionic surfactant comprises a mixture of SPAN-85 and PS-20.

[374] In some embodiments, an SNE formulation is provided comprising: 1) 0.01 to 0.1 mol% of a compound of Formulas I, Ia, II, IIa, III, IIIa, IV and IVa or a pharmaceutically acceptable salt thereof; 2) 1.5 to 15.0 mol% of SPAN-85; 3) 1 to 10.0 mol% of PS-20, and 4) 80.0 to 98.0 mol% of squalene.

[375] In some embodiments, an SNE formulation is provided comprising: 1) 0.1 to 1.0 mol% of a compound of Formulas I, Ia, II, IIa, III, IIIa, IV and IVa or a pharmaceutically acceptable salt thereof; 2) 8.0 to 11.9 mol% of SPAN-85; 3) 6 to 10 mol% of PS-20; and 4) 70 to 85 mol% of squalene.

[376] In some embodiments, an EMS formulation comprising: 0.01 to 0,1 mol% of a compound of Formulas I, Ia, II, IIa, III, IIIa, IV and IVa or a pharmaceutically acceptable salt thereof; 2) 8.0 to 11.9 mol% of SPAN-85; 3) 6 to 10 mol% of PS-20; and 4) 78 to 85 mol% of squalene.

[377] In some embodiments, an SNE formulation is provided comprising: 200 to 400 pg of a compound of Formulas I, Ia, II, IIa, III, IIIa, IV and IVa or a pharmaceutically acceptable salt thereof; 2) 8 to 16 mg of SPAN-85; 3) 8 to 16 mol% of PS-20; and 4) 40 to 80 mg of squalene.

[378] In some embodiments, an SNE formulation is provided comprising: 1) 10 to 20 pg of a compound of Formulas I, Ia, II, IIa, III, IIIa, Petition 870260002828, 12 / 01 / 2026, p. 111 / 237 102 / 211 IV and IVa or a pharmaceutically acceptable salt thereof; 2) 8 to 16 mg of SPAN-85; 3) 8 to 16 mg of PS-20; and 4) 40 to 80 mg of squalene.

[379] In some embodiments, an EMS formulation comprising: 0.5 to 3,0 pg of a compound of Formulas I, Ia, II, IIa, III, IIIa, IV and IVa or a pharmaceutically acceptable salt thereof; 2) 0.6 to 3.6 mg of SPAN-85; 3) 0.6 to 3.6 mg of PS-20, and 4) 2.0 to 12.0 mg of squalene.

[380] In some embodiments, an SNE formulation is provided comprising: 0.5 to 3.0 pg of a compound of Formulas I, Ia, II, IIa, III, IIIa, IV and IVa or a pharmaceutically acceptable salt thereof; 2) 0.15 to 0.18 mg of SPAN-85; 3) 0.15 to 0.18 mg of PS-20, and 4) 0.5 to 0.6 mg of squalene.

[381] In some embodiments, an SNE formulation is provided comprising: 1) 0.5 to 3.0 pg of a compound of Formulas I, Ia, II, IIa, III, IIIa, IV and IVa or a pharmaceutically acceptable salt thereof; 2) 0.15 to 0.95 mg of SPAN-85; 3) 0.15 to 0.95 mg of PS-20; and 4) 0.5 to 3.0 mg of squalene.

[382] In some embodiments, an SNE formulation comprising: 4.0 to 20 pg of a compound of Formulas I, Ia, II, IIa, III, IIIa,IV and IVa or a pharmaceutically acceptable salt thereof; 2) 0.24 to 1.3 mg of SPAN-85; 3) 0.24 to 1.3 mg of PS-20, and 4) 0.8 to 4.0 mg of squalene.

[383] In some embodiments, an SNE formulation is provided comprising: 4.0 to 20 pg of a compound of Formulas I, Ia, II, IIa, III, IIIa, IV and IVa or a pharmaceutically acceptable salt thereof; 2) 1.2 to 6.5 mg of SPAN-85; 3) 1.2 to 6.5 mg of PS-20, and 4) 4.0 to 20.0 mg of squalene.

[384] In some embodiments, an SNE formulation is provided comprising: 20 to 100 pg of a compound of Formulas I, Ia, II, IIa, III, IIIa, IV and IVa or a pharmaceutically acceptable salt thereof; 2) 1.2 to 6.5 mg of SPAN-85; 3) 1.2 to 6.5 mg of PS-20; and 4) 4.0 to 20.0 mg of squalene.

[385] In some embodiments, an SNE formulation is provided Petition 870260002828, dated 12 / 01 / 2026, p. 112 / 237 103 / 211 comprising: 20 to 40 pg of a compound of Formulas I, Ia, II, IIa, III, IIIa,IV and IVa or a pharmaceutically acceptable salt thereof; 2) 5 to 8.0 mg of SPAN-85; 3) 5 to 8.0 mg of PS-20; and 4) 20.0 to 40.0 mg of squalene.

[386] In some embodiments, any of the formulations provided above comprises a specific compound selected from: (N-(5-(4-(((5-amino-7-(butylamino)-2H-pyrazolo[4,3-d]pyrimidin-2-yl)methyl)-3,5-dimethoxyphenyl)piperazin-1-yl)-5-oxopentyl)stearamide, also referred to as Compound A-1; (5)-N-(5-(4-((5-amino-7-((1-hydroxypentan-2-yl)amino)-2H-pyrazolo[4,3d]pyrimidin-2-yl)methyl)-3,5-dimethoxyphenyl)piperazin-1-yl)-5oxopentyl)stearamide, also referred to as Compound A-2; (5)-1-(4-((5-amino-7-((1-hydroxypentan-2-yl)amino)-2 H-pyrazolo[4,3d]pyrimidin-2-yl)methyl)-3,5-dimethoxyphenyl)piperazin-1-yl)octadecan-1-one, also called Compound A-3; N -(5-(4-(4-((5-amino-7-(butylamino)-2H-pyrazolo[4,3-d]pyrimidin-2-yl)methyl)3-methoxyphenyl)piperazin-1-yl)-5-oxopentyl)stearamide,also called Compound B-1; N -(5-(4-(4-((5-amino-7-(butylamino)-2 H-pyrazolo[4,3-d ]pyrimidin-2-yl)methyl)3-methoxyphenyl)piperazin-1-yl)-5-oxopentyl)tetradecanoamide, also called Compound B-2; N -(5-(4-(4-((5-amino-7-(butylamino)-2 H-pyrazolo[4,3-d ]pyrimidin-2-yl)methyl)3-methoxyphenyl)piperazin-1-yl)-5-oxopentyl)oleamide, also called Compound B-3; (9 Z,12 Z)-N -(5-(4-(4-((5-amino-7-(butilamino)-2 H-pyrazolo[4,3-d ]pyrimidin2-yl)metil)-3-methoxyphenyl)piperazin-1-yl)-5-oxopentyl)octadeca-9,12-dienamida, també denominated Composto B-4; N -(5-(4-(4-((5-amino-7-(butylamino)-2 H-pyrazolo[4,3-d ]pyrimidin-2-yl)metil)Petição 870260002828, de 12 / 01 / 2026, pág. 113 / 237 104 / 211 3-methoxyphenyl)-1,4-diazepan-1-yl)-5-oxopentyl)esteramide, também denominated Composto B-5; N -(5-(4-(4-((5-amino-7-(butylamino)-2 H-pyrazolo[4,3-d ]pyrimidin-2-yl)methyl)3-methoxyphenyl)piperidin-1-yl)-5-oxopentyl)stearamide, also known as Compound B-6; N -(5-(3-(4-((5-amino-7-(butylamino)-2 H-pyrazolo[4,3-d ]pyrimidin-2-yl)methyl)3-methoxyphenyl)piperidin-1-yl)-5-oxopentyl)stearamide, also known as Compound B-6;3-d]pyrimidin-2-yl)metil)3-methoxyphenyl)azetidin-1-yl)-5-oxopentyl)estearamide, também denominated Composto B-7; 1-(4-((5-amino-7-(butylamino)-2 H -pyrazolo[4,3-d ]pyrimidin-2-yl)metil)-3methoxyphenyl)-N-(3-estearamidopropyl)piperidina-4-carboxamida, também denominated Composto B-8; (1 s ,3 s )-3-(2-(4-(4-((5-amino-7-(butilamino)-2 H-pyrazolo[4,3-d ]pyrimidin-2yl)metil)-3-methoxyphenyl)piperazin-1-yl)-2-oxoetil)-N -octadecylciclobutano-1carboxamide, també denominated Composto B-9; (1 s ,3 s )-3-(2-(4-(4-((5-amino-7-(butilamino)-2 H-pyrazolo[4,3-d ]pyrimidin-2yl)metil)-3-methoxyphenyl)piperazin-1-yl)-2-oxoetil)-N -hexadecylciclobutana-1carboxamide, també denominated Composto B-10; N -(3-(4-(4-((5-amino-7-(butylamino)-2 H-pyrazolo[4,3-d ]pyrimidin-2-yl)metil)3-methoxyphenyl)piperazin-1-yl)-3-oxopropyl)estearamide, também denominated Composto B-11; N -(7-(4-(4-((5-amino-7-(butylamino)-2 H-pyrazolo[4,3-d ]pyrimidin-2-yl)methyl)3-methoxyphenyl)piperazin-1-yl)-7-oxo-heptyl)stearamide,also called Compound B-12; N -(3-(2-(4-(4-((5-amino-7-(butylamino)-2 H -pyrazolo[4,3-d ]pyrimidin-2yl)methyl)-3-methoxiphenyl)piperazin-1-yl)-2-oxoethyl)cyclobutyl)estearamida, also called Compound B-13; N -(5-(4-(4-((5-amino-7-(butylamino)-2 H-pyrazolo[4,3-d ]pyrimidin-2-yl)methyl)Petition 870260002828, dated 12 / 01 / 2026, pág. 114 / 237 105 / 211 3-methoxyphenyl)piperazin-1-yl)-4,4-dimethyl-5-oxopentyl)estearamida, also called Compound B-14; N -(6-(4-(4-((5-amino-7-(butylamino)-2 H-pyrazolo[4,3-d ]pirimidin-2-yl)metil)3-metoxifenil)piperazin-1-yl)-2-metil-6-oxo-hexan-2-yl)estearamida, também denominado Compound B-15; 1-(4-(4-((5-amino-7-(butylamino)-2 H-pyrazolo[4,3-d ]pirimidin-2-yl)metil)-3metoxifenil)piperazin-1-yl)-5-(octadeciloxi)pentan-1-ona, também denominado Compound B-16; 1-(4-(4-((5-amino-7-(butylamino)-2 H-pyrazolo[4,3-d ]pyrimidin-2-yl)methyl)-3methoxyphenyl)piperazin-1-yl)-5-(octadecylamino)pentan-1-one,also referred to as Compound B-17; N-(5-(4-(4-((5-amino-7-(butylamino)-3-methyl-2H-pyrazolo[4,3-d]pyrimidin-2yl)methyl)-3-methoxyphenyl)piperazin-1-yl)-5-oxopentyl)stearamide, also referred to as Compound B-18; (9Z,12Z)-N-(4-((4-((5-amino-7-(butylamino)-2H-pyrazolo[4,3-d]pyrimidin-2yl)methyl)-3,5-dimethoxybenzyl)(methyl)amino)butyl)octadeca-9,12-dienamide, also referred to as Compound C-1; N-(4-((4-((5-amino-7-(butylamino)-2H-pyrazolo[4,3-d]pyrimidin-2-yl)methyl)3,5-dimethoxybenzyl)(methyl)amino)butyl)tetradecanamide, also referred to as Compound C-2; N-(4-((4-((5-amino-7-(butylamino)-2H-pyrazolo[4,3-d]pyrimidin-2-yl)methyl)3,5-dimethoxybenzyl)(methyl)amino)butyl)oleamide, also referred to as Compound C-3; N-(4-((4-((5-amino-7-(butylamino)-2H-pyrazolo[4,3-d]pyrimidin-2-yl)methyl)3,5-dimethoxybenzyl)(methyl)amino)butyl)stearamide, also referred to as Compound C-4; N-(4-((4-((5-amino-7-(butylamino)-2H-pyrazolo[4,3-d]pyrimidin-2-yl)methyl) Petition 870260002828, dated 12 / 01 / 2026,pg. 115 / 237 106 / 211 3,5-dimethoxybenzyl)(methyl)amino)-4-oxobutyl)stearamide, also known as Compound C-5; (methyl)amino)butyl)carbamate (6Z,9Z,28Z,31Z)-heptatriaconta6,9,28,31-tetraen-19-yl (4-((4-((5-amino-7-(butylamino)-2 H-pyrazolo[4,3d]pyrimidin-2-yl)methyl)-3,5-dimethoxybenzyl), also called Compound D1; 4-(4-((5-amino-7-(butylamino)-2 H -pyrazolo[4,3-d]pyrimidin-2-yl)methyl)-3methoxyphenyl)-N-(3-stearamidopropyl)piperazine-1-carboxamide, also called Compound D-2; 3-stearamidopropyl pyrimidin-2-yl)methyl)-3-methoxyphenyl)piperazine-1-carboxylate, also referred to as Compound D-3; N-(5-(4-(((5-amino-7-(butylamino)-2H-pyrazolo[4,3-d]pyrimidin-2-yl)methyl)3-methoxyphenyl)piperazine-1-yl)-6,6,6-trifluorohexyl)stearamide, also referred to as Compound D-4; N-(4-((4-((7-(butylamino)-5-hydroxy-2H-pyrazolo[4,3-d]pyrimidin-2-yl)methyl)3,5-dimethoxybenzyl)(methyl)amino)butyl)stearamide, also referred to as Compound D-5,and (5-(4-(4-((5-amino-7-(butylamino)-2H-pyrazolo[4,3-d]pyrimidin-2-yl)methyl)-3-methoxyphenyl)piperazin-1-yl)-5-oxopentyl)carbamate of (6Z,9Z,28Z,31Z)heptatriaconta-6,9,28,31-tetraen-19-yl, also called Compound D-6; or a pharmaceutically acceptable salt thereof.

[387] In some embodiments of the invention, a formulation is provided in which the SNE further comprises one or more additional components that are selected from a surfactant, a mixture of surfactants, a phospholipid, a terpene, a terpenoid, a triterpene or a combination thereof. Petition 870260002828, dated 12 / 01 / 2026, p. 116 / 237 107 / 211

[388] In some embodiments of the invention, the surfactant includes, but is not limited to: polyoxyethylene sorbitan ester surfactants (commonly called Tweens), particularly PS-20 and PS-80; ethylene oxide (EO), propylene oxide (PO) and / or butylene oxide (BO) copolymers, sold under the DOWFAX™ brand,such as linear EO / PO block copolymers; octoxinols, which may vary in the number of repeating ethoxy groups (oxy-1,2-ethanedi-yl), with octoxinol-9 (Triton X-100 or t-octylphenoxypolyethoxyethanol) being of particular interest; (octylphenoxy)polyethoxyethanol (IGEPAL CA-630 / NP-40); nonylphenol ethoxylates, such as the Tergitol™ NP series; Polyoxyethylene fatty ethers derived from lauric, cetyl, stearyl and oleyl alcohols (known as Brij surfactants), such as triethylene glycol monolauryl ether (Brij 30), and sorbitan esters (commonly known as SPANs), such as sorbitan trioleate (Span-85, Tween-85 or [2[(2R,3S,4R)-4-hydroxy-3-[(Z)-octadec-9-enoyl]oxyoxolan-2-yl]-2-[(Z)-octadec-9enoyl]oxyethyl]) and sorbitan monolaurate.

[389] In some embodiments of the invention, mixtures of surfactants are used, for example, mixtures of PS-20 / Span 85. A combination of a polyoxyethylene sorbitan ester,such as polyoxyethylene sorbitan monooleate (PS-80), and an octoxinol, such as t-octylphenoxypolyethoxyethanol (Triton X-100), is also suitable. Another useful combination comprises laureth 9 plus a polyoxyethylene sorbitan ester and / or an octoxinol.

[390] In some embodiments of the invention, the amounts of surfactants or emulsifiers are: polyoxyethylene sorbitan esters (such as PS-20) from 0.01 to 10 mol%, in particular about 1 to 4 mol%; octyl- or nonylphenoxy polyoxyethanols (such as Triton X-100 or other detergents of the Triton series) from 0.001 to 10 mol%, in particular about 1 to 4 mol%; w / v, in particular from 0.01 to 0.1% w / v; polyoxyethylene ethers (such as laureth 9) from 0.1 to 20 mol%, preferably from 0.5 to 10 mol% and, in particular, from 1 to 4 mol% or about 10% by mass.

[391] In some embodiments of the invention, the phospholipid is selected from a natural phospholipid,including phosphatidylcholine (PC), phosphatidylethanolamine (PE) and phosphatidylglycerol (PG), phosphatidylserine (PS), phosphatidylinositol (PI), phosphatidic acid (phosphatidate) (PA), dipalmitoylphosphatidylcholine, monoacyl-phosphatidylcholine (Lyso PC), l-palmitoyl-2-oleoylsn-glycero-3-phosphocholine (POPC), N-Acyl-PE, a phosphoinositide and a phosphosphingolipid. Phospholipid derivatives include phosphatidic acid (DMPA, DPPA, DSPA), phosphatidylcholine (DDPC, DLPC, DMPC, DPPC, DSPC, DOPC, POPC, DEPC), phosphatidylglycerol (DMPG, DPPG, DSPG, POPG), phosphatidylethanolamine (DMPE, DPPE, DSPE, DOPE), and phosphatidylserine (DOPS). Fatty acids include C14:0, palmitic acid (C16:0), stearic acid (C18:0), oleic acid (C18:1), linoleic acid (C18:2), linolenic acid (C18:3), arachidonic acid (C20:4), C20:0, C22:0, and lecithin. In certain embodiments of the invention, the phospholipid is phosphatidylserine, l,2-Distearolyl-sn-glycero-3-phosphocholine (DSPC), l,2-dipalmitoleoyl-sn-glycero-3-phosphocholine, 1,2-dimyristoyl-sn-glycero-3-phosphocholine (DMPC), dilauroylphosphatidylcholine (DLPC), 1,2-dieicosenoyl-sn-glycero-3-phosphocholine or 1,2-dioleoyl-sn-glycero-3-phosphocholine (DOPC).

[392] In some embodiments of the invention, the terpene is selected from a monoterpene, such as geraniol, terpeneol, limonene, myrcene, linalool or pinene. In some embodiments, the formulation comprises a sesquiterpene consisting of humulene, a farnesene or farnesol; a diterpene, such as cafestol, kahweol, cembrene or taxadiene; a triterpene, such as squalene or squalant; a tetraterpene, such as acyclic lycopene, monocyclic gamma-carotene or bicyclic alpha- and beta-carotenes; a polyterpene or a norisoprenoid. Petition 870260002828, dated 12 / 01 / 2026, pp. 118 / 237 109 / 211 Vaccine Compositions

[393] Vaccines (vaccine compositions or immunogenics) are well known in the art and include adenovirus vaccines, anthrax vaccines, cholera vaccines, dengue vaccines,vaccines against diphtheria, vaccines against hepatitis, vaccines against Haemophilus influenzae type b (Hib), vaccines against human papillomavirus (HPV), vaccines against seasonal influenza (flu), vaccines against Japanese encephalitis, vaccines against measles, vaccines against meningococcal diseases, vaccines against mumps, vaccines against pertussis, pneumococcal vaccines, vaccines against poliomyelitis, vaccines against rabies, vaccines against rotavirus, vaccines against rubella, vaccines against herpes zoster, vaccines against smallpox, vaccines against tetanus, vaccines against tuberculosis, vaccines against typhoid fever, vaccines against varicella, and vaccines against yellow fever.

[394] Pneumococcal vaccines or compositions are well known (e.g., PNEUMOVAX®, Merck & Co., Inc., Rahway, NJ, USA). Pneumococcal conjugate vaccines or compositions have been previously disclosed. Consult the international publication documents WO2011 / 100151, WO2019 / 139692 and WO2020 / 131763.

[395] Bacterial capsular polysaccharides,Particularly those that have been used as antigens are suitable for use in the invention and can be easily identified by methods for identifying immunogenic and / or antigenic polysaccharides. Exemplary bacterial capsular polysaccharides of S. pneumoniae are serotypes: 1, 2, 3, 4, 5, 6A, 6B, 6C, 7C, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15A, 15B, 15C, 16F, 17F, 18C, 19A, 19F, 20 (20A and 20B), 22F, 23A, 23B, 23F, 24F, 33F, 35B, 35F or 38, among others. Administration / Dosage

[396] The compositions and formulations of the invention can be used to protect or treat a patient susceptible to infection by administering the composition, formulation or vaccine systemically or via mucosal route to the patient. In one embodiment, the invention provides a method for inducing an immune response to an antigen,comprising administering to a patient an immunologically effective amount of an immunogenic composition of the invention. In another embodiment, the invention provides a method for vaccinating against an infection, comprising the step of administering to the patient an immunologically effective amount of an immunogenic composition, formulation or vaccine of the invention.

[397] In some embodiments of the above methods, the patient is a human being.

[398] In other embodiments of the above methods, the patient is a non-human animal.

[399] The ideal amounts of components for a given composition, formulation or vaccine can be verified by standard studies involving the observation of appropriate immune responses in individuals. For example, in one embodiment, the dosage for human vaccination is determined by extrapolation from animal studies to human data. In another embodiment,The dosage is determined empirically.

[400] The methods of the invention can be used for the prevention and / or reduction of primary clinical syndromes caused by infectious agents in an individual; that is, a human being or a non-human animal.

[401] Administration of the compositions, formulations or vaccines of the invention may include one or more of the following: intramuscular, intraperitoneal, intradermal or subcutaneous injection; or mucosal administration in the oral / alimentary, respiratory or genitourinary tracts. In one embodiment, intranasal administration is used for the treatment of the disease.

[402] According to any of the methods of the invention and in Petition 870260002828, dated 12 / 01 / 2026, pp. 120 / 237 111 / 211 some embodiments, the individual is human. In certain embodiments, the human patient is a young infant (less than 1 year old),an older infant (approximately 12 to 24 months old) or a preschool child (approximately 2 to 5 years old). In other embodiments, the human patient is an elderly patient (over 65 years old). The compositions of the invention are also suitable for use in older children, adolescents, and adults (e.g., aged 18 to 45 years or 18 to 65 years).

[403] In one embodiment of the methods of the invention, a composition, formulation, or vaccine of the invention is administered to the individual as a single inoculation. In another embodiment, the composition, formulation, or vaccine is administered two, three, four, or more times, with suitable intervals between them. For example, the composition, formulation, or vaccine may be administered at intervals of 1, 2, 3, 4, 5, or 6 months, or any combination of these intervals. Formulations

[404] In the embodiments of the formulations below,A composition refers to a pharmaceutical composition and / or an immunogenic composition and / or a single-dose vaccine composition. In some embodiments, a composition is provided that includes one or more compounds as described in this document and one or more antigens.

[405] In some embodiments, a composition is provided that includes about 1 pg to about 200 mg of a compound of the invention, or a pharmaceutically acceptable salt thereof, and at least one antigen, wherein the antigen is present at a concentration of about 0.01 pg to about 100 pg per 0.5 mL of the vaccine formulation.

[406] In some embodiments, wording is provided that includes Petition 870260002828, dated 12 / 01 / 2026, p. 121 / 237 112 / 211 approximately 0.02 pg to approximately 40 mg of a compound of the invention, or a pharmaceutically acceptable salt thereof, and at least one antigen, wherein the antigen is present in a concentration of approximately 0.002 pg to approximately 20 pg per 0.1 mL of the vaccine formulation.

[407] In some embodiments, a composition is provided that includes about 50 pg to about 2.1 mg of a compound of the invention, or a pharmaceutically acceptable salt thereof, and at least one antigen, wherein the antigen is present at a concentration of about 0.002 pg to about 20 pg per 0.5 mL of the vaccine formulation.

[408] In some embodiments, a composition is provided that includes about 50 pg to about 10 mg of a compound of the invention, or a pharmaceutically acceptable salt thereof, and at least one antigen, wherein the antigen is present at a concentration of about 0.002 pg to about 20 pg per 0.5 mL of the vaccine formulation.

[409] In some embodiments, a composition is provided that includes from about 50 pg to about 10 mg of a compound of the invention, or a pharmaceutically acceptable salt thereof, and at least one antigen, wherein the antigen is present at a concentration of from about 0.002 pg to about 20 pg per 0.5 mL of the vaccine formulation.

[410] In some embodiments, a composition is provided that includes from about 1 pg to about 200 mg of a compound of the invention, or a pharmaceutically acceptable salt thereof, and at least one antigen, wherein the antigen is present at a concentration of from about 0.01 pg to about 100 pg per 0.5 mL of the vaccine formulation prepared as a lyophilized formulation.

[411] In some embodiments, a composition is provided that includes from about 1 pg to about 200 mg of a compound of the invention, or a salt Petition 870260002828, dated 12 / 01 / 2026, p. 122 / 237 113 / 211 pharmaceutically acceptable of the same, from 1 pg to about 1 mg of Aluminum in the form of APA and at least one antigen, wherein the antigen is present at a concentration of about 0.01 pg to about 100 pg per 0.5 mL of the vaccine formulation prepared as a lyophilized formulation.

[412] In some embodiments, a composition is provided, as highlighted in the various embodiments above,which includes from about 0.05 pg to about 200 mg of a compound of the invention, or a pharmaceutically acceptable salt thereof, and additionally includes SPAN-85, PS-20 or PS-80 and squalene. In some embodiments, a composition is provided, as highlighted in the various embodiments above, which includes from about 0.05 pg to about 200 mg of a compound of the invention, or a pharmaceutically acceptable salt thereof, and additionally includes SPAN-85, PS-20 and squalene. In some embodiments, the compound is Compound A-1, or A-2, or A-3. In another embodiment, the compound is Compound B-1, or B-2, or B-3, or B-4, or B-5, or B-6, or B-7, or B-8, or B-9, or B-10, or B-11, or B-12, or B-13, or B-14, or B-15, or B-16, or B-17, or B-18. In another embodiment, the compound is Compound C-1, or C-2, or C-3, or C-4, or C-5. In another embodiment, the compound is Compound D-1, or D-2, or D-3, or D4, or D-5, or D-6.

[413] In some embodiments, a composition of the invention is administered subcutaneously,The compositions are administered topically, orally, via mucosal injection, intravenously, or intramuscularly. The compositions are administered in sufficient quantity to elicit a protective response. The compositions may also be administered by various other routes, for example, orally, parenterally, subcutaneously, via mucosal injection, or intramuscularly. The administered dose may vary depending on the patient's general condition, sex, weight, and age, as well as the route of administration.

[414] The compositions of the invention, as highlighted in the various embodiments above, may be referred to as immunogenic compositions.

[415] The compositions of the invention, as highlighted in the various embodiments above, may be referred to as vaccines or vaccine compositions.

[416] In each of the embodiments described above,The composition further comprises one or more antigens.

[417] The invention provides methods for treating or preventing diseases by administering the compositions described above.

[418] The invention provides the use of the compositions described above for treating or preventing diseases.

[419] All publications mentioned in the present invention are incorporated by reference for the purpose of describing and disclosing methodologies and materials that can be used in connection with the invention. Nothing in the present invention should be construed as an admission that the invention does not have the right to anticipate such disclosure by virtue of a prior invention.

[420] Having described certain embodiments of the invention with reference to the accompanying drawings, it should be understood that the invention is not limited to these precise embodiments, and that various alterations and modifications may be used by a person skilled in the art, without departing from the scope or spirit of the invention.as defined in the appended claims.

[421] The following examples illustrate, but do not limit, the invention. EXAMPLE 1 General Methods for Producing the Compounds of Formulas I, Ia, II, IIa, III, IIIa, IV and IVa

[422] The compounds can be prepared from known or readily prepared starting materials by following methods known to a person skilled in the art of organic synthesis. Useful representative methods for producing the compounds are presented in the Examples below. Alternative synthetic methods and analogous structures will be apparent to those skilled in the art of organic synthesis.

[423] A person skilled in the art of organic synthesis will recognize that the synthesis of multicyclic and / or heterocyclic nuclei contained in the compounds of the invention may require the protection of certain functional groups (i.e.,derivatization with the aim of chemical compatibility with a given reaction condition). Suitable protecting groups for the various functional groups of these compounds and methods for their installation and removal are well known in the field of organic chemistry. A summary of many of these methods can be found in Greene et al., Protective Groups in Organic Synthesis, Wiley-Interscience, New York, (1999).

[424] A person skilled in the art of organic synthesis will also recognize that a route for the synthesis of the multicyclic heterocyclic cores of the compounds of the invention may be more desirable depending on the choice of attached substituents.

[425] Furthermore, a person skilled in the art will recognize that, in some cases, the order of reactions may differ from that presented in the present invention to avoid functional group incompatibilities and thus,Adjust the synthetic pathway accordingly.

[426] The preparation of useful multicyclic intermediates for the production of the multicyclic and / or heterocyclic nuclei of the compounds of the invention has been described in the literature and in compendia such as “Comprehensive Heterocyclic Chemistry” editions I, II and III, published by Elsevier and edited by AR Katritzky & R. JK Taylor. The manipulation of the necessary substitution patterns has also been described in the available chemical literature, as summarized in compendia such as “Comprehensive Organic Chemistry”, published by Elsevier and edited by DH R. Barton and WD Ollis; “Comprehensive Organic Functional Group Transformations”, edited by AR Katritzky & RJK Taylor and “Comprehensive Organic Transformation,published by Wiley-CVH and edited by RC Larock.

[427] The starting materials used and the intermediates prepared using the methods presented in the Examples below can be isolated and purified, if desired, using conventional techniques, including but not limited to filtration, distillation, crystallization, chromatography and the like. Such materials can be differentiated using conventional means, including physical constants and spectral data.

[428] A person skilled in the art will be familiar with standard formulation techniques as presented in the scientific literature as well as in textbooks such as Zheng, “Formulation and Analytical Development for Low-Dose Oral Drug Products, Wiley, 2009, ISBN. Preparation of Compounds and Intermediates

[429] The invention is illustrated by the following Examples. For all Examples, standard processing and purification methods known to those skilled in the art can be used. Unless otherwise indicated,All temperatures are expressed in °C (degrees Celsius). All reactions are conducted at room temperature unless otherwise indicated. The synthetic methodologies illustrated in the present invention are intended to exemplify applicable chemistry through the use of specific examples and are not indicative of the scope of disclosure. General Methods

[430] Commercially available solvents, reagents, and intermediates were used as received. Intermediates that are not commercially available were prepared as described below. 1H NMR spectra are reported in ppm relative to Me4Si, with the number of protons, multiplicities, and coupling constants in Hertz indicated in parentheses. When LC / MS data are presented,The observed precursor ion is indicated. Flash column chromatography was performed using pre-packed normal phase silica or bulk silica. EXAMPLE 2 Methods for Producing the Intermediates of Compounds of the Invention Intermediate 1-1 Preparation of the Compound Int. 1-1 O SMe O h2n MeO2C 1. 2. NaOMe MeO NN OMe H . AcOH:MeOH DMSO n-BuNH2, BOP, DBU Int. 1-1 (7-(butylamino)-1 H -pyrazolo[4,3-d ]pyrimidin-5-yl)carbamate methyl H MeO. _N. YY YY ON^· IH Step 1: Methyl (7-hydroxy-1H-pyrazolo[4,3-d]pyrimidin-5-yl)carbamate

[431] To a stirred mixture of methyl 4-amino-1H-pyrazol-5-carboxylate (2 g, 14.17 mmol) and 1,3-bis(methoxycarbonyl)-2-methyl-2-thiopseudoeura (2.92 g, 14.17 mmol) in MeOH (20 mL), AcOH (4.87 mL, 85 mmol) was added at room temperature. The resulting mixture was stirred for 16 h, then NaOMe (25.5 g, 142 mmol) in MeOH was added dropwise. After the addition was complete,The reaction mixture was acidified to pH 1-2 with AcOH. The resulting solid was collected by filtration, washed with CH3CN (200 mL), then dried under vacuum to give the title compound. MS m / z (M+H)+: calculated 210.1; observed 210.1. 1H-NMR (400 MHz, DMSO-d6) δ 7.83 (s, 1H), 3.67 (s, 3H). Step 2: Methyl (7-(butylamino)-1H-pyrazolo[4,3-d]pyrimidin-5-yl)carbamate Petition 870260002828, dated 12 / 01 / 2026, p. 127 / 237 118 / 211

[432] To a stirred mixture of methyl (7-hydroxy-1H-pyrazolo[4,3-d]pyrimidin-5yl)carbamate (5 g, 23.90 mmol), butan-1-amine (4.73 mL, 47.8 mmol) and DBU (3.92 mL, 26.3 mmol) in DMSO (100 mL), BOP (12.69 g, 28.7 mmol) was added at room temperature. The resulting mixture was heated to 60 °C for 3 h. The resulting mixture was cooled to room temperature, then filtered and purified directly by reversed-phase chromatography (0-50% CH3CN / water with formic acid modifier at 0,1%) to obtain the title compound. MS m / z (M+H)+: calculated 265.1; observed 265.1. 1H NMR (400 MHz, DMSO-d6) δ 12.94 (br., 1H), 9.89 (s, 1H), 8.14 - 7.99 (m, 2H), 3.67 (s, 3H), 3.56 3.51 (m, 2H), 1.66 - 1.58 (m, 2H), 1.42 - 1.33 (m, 2H), 0.92 (t, J = 7.2 Hz, 3H). Intermediate 2-1 Preparation of Compound Int. 2-1 Int. 2-1 5-azido-N-butyl-1H-pyrazolo[4,3-d]pyrimidin-7-amine μθ^^,νη Step 1: N-butyl-5-chloro-1H-pyrazolo[4,3-d]pyrimidin-7-amine

[433] To a mixture of 5,7-dichloro-1H-pyrazolo[4,3-d]pyrimidine (3 g, 15.87 mmol) in THF (30 mL) at 0 °C, DIEA (3.08 g, 23.81 mmol) and butan-1-amine (1.741 g, 23.81 mmol) were added. After the addition was complete, the mixture was heated to room temperature and stirred for 2 h. The resulting mixture was diluted with water (200 mL), then extracted with EtOAc (3 x 300 mL). The combined organic extracts were washed with brine (2 x 300 mL), then dried (Na2SO4) and filtered. The filtrate was concentrated for Petition 870260002828.from 12 / 01 / 2026, page 128 / 237 119 / 211 give the title compound, which was used directly in the next step without purification. MS m / z (M+H)+: calculated 226.1, observed 226.2. Step 2: 5-azido-N-butyl-1H-pyrazolo[4,3-d]pyrimidin-7-amine

[434] To a mixture of N-butyl-5-chloro-1H-pyrazolo[4,3-d]pyrimidin-7-amine (3.5 g, 15.51 mmol) in AcOH (6 mL) and EtOH (24 mL) at room temperature, sodium azide was added (1.512 g, 23.26 mmol), then the mixture was heated to 100 °C for 3 hours. The resulting mixture was cooled to room temperature, diluted with water (200 mL), and extracted with EtOAc (3 x 300 mL). The combined organic extracts were washed with brine (2 x 300 mL), then dried (Na2SO4), filtered, and the filtrate was concentrated. The crude product was subjected to silica gel chromatography (0-20% EtOAc / petroleum ether) to give the title compound. MS m / z (M+H)+: calculated 233.1, observed 233.1.

[435] Using the procedures described for Intermediate 2-1,The following compounds were prepared by substituting the appropriate reagents with butan-1-amine. Table 1 Comp. / Int. No. Structure Name Calc. [M+H]+ Observed [M+H]+ Comments Int. 2-2 Y IpN IH Me^^^NH ^OH (S )-2-((5-azido-1 H pyrazolo[4,3d ]pyrimidin-7yl)amino)pentan-1-ol 263.3 263.3 Intermediate 2-3 Preparation of Compound Int. 2-3 Petition 870260002828, dated 12 / 01 / 2026, p. 129 / 237 120 / 211 Me I 100 °C 5-azido-N-butyl-3-methyl-1H-pyrazolo[4,3-d]pyrimidin-7-amine Step 1: 5-azido-N-butyl-3-iodo-1H-pyrazolo[4,3-d]pyrimidin-7-amine

[436] A solution of 5-azido-N-butyl-2H-pyrazolo[4,3-d]pyrimidin-7-amine (1 g, 4.31 mmol) in DMF (30 mL), N-iodosuccinimide (1.937 g, 8.61 mmol) was then heated to 40 °C. After overnight heating, the mixture was cooled to room temperature and diluted in 10% Na2SO3 (40 mL). The resulting solid was collected by filtration,Washed with water (10 mL x 3) and then dried under vacuum to give the compound of the titer. MS m / z (M+H)+: calculated 359.0, observed 359.0. Step 2: 5-azido-N-butyl-3-methyl-1H-pyrazolo[4,3-d]pyrimidin-7-amine

[437] To a solution of 5-azido-N-butyl-3-iodo-2H-pyrazolo[4,3d]pyrimidin-7-amine (1 g, 2.79 mmol) in 1,4-dioxane (10 mL) and H2O (1 mL), Pd(dppf)Cl2 (0.204 g, 0.279 mmol), K3PO4 (1.185 g, 5.58 mmol) and 2,4,6-trimethyl-1,3,5,2,4,6-trioxatriborinane (3.51 g, 13.96 mmol) were added under N2, then the mixture was heated to 100 °C overnight. The resulting mixture was cooled to room temperature, diluted with EtOAc (30 mL), dried (Na2SO4), filtered, and then the filtrate was concentrated. The crude product was subjected to silica gel chromatography (30 to 70% EtOAc / petroleum ether) to give the title compound. MS m / z (M+H)+: calculated 247.1, observed 247.4. Intermediate 3-1 Petition 870260002828, dated 12 / 01 / 2026,page. 130 / 237 121 / 211 Preparation of Compound Int. 3-1 HN NBoc NBoc NJ NaBH4 MeO Pd2(dba)3, RuPhos NaOtBu, toluene, 100 °C Int. 3-1 4-(4-(Hydroxymethyl)-3,5-dimethoxyphenyl)piperazine-1-carboxylate tert-butyl NBoc MeO OMe Step 1: 4-(4-formyl-3,5-dimethoxyphenyl)piperazine-1-carboxylate tert-butyl

[438] To a stirred mixture of 4-bromo-2,6-dimethoxybenzaldehyde (5 g, 20.40 mmol) in toluene (20 mL), piperazine-1-carboxylate tert-butyl (5.70 g, 30.6 mmol), RuPhos (1.904 g, 4.08 mmol), Pd2(dba)3 (1.868 g, 2.040 mmol) and NaOtBu (5.88 g, 61.2 mmol) under an argon atmosphere, then the mixture was heated to 100 °C. After 6 hours, the mixture was cooled to room temperature, diluted with water (50 mL), then extracted with EtOAc (3 x 80 mL). The combined organic extracts were washed with brine (3 x 50 mL), dried (Na2SO4), filtered and then...The filtrate was concentrated. The crude product was subjected to silica gel chromatography (0 to 100% EtOAc / DCM) to obtain the title compound. MS m / z (M+H)+: calculated 351.2, observed 351.3. Step 2: tert-butyl 4-(4-(hydroxymethyl)-3,5-dimethoxyphenyl)piperazine-1-carboxylate

[439] To a stirred mixture of tert-butyl 4-(4-formyl-3,5-dimethoxyphenyl)piperazine-1-carboxylate (3 g, 8.56 mmol) in EtOH (10 mL), NaBH4 (0.389 g, 10.27 mmol) was added at room temperature. After 15 minutes, Petition 870260002828, dated 12 / 01 / 2026, p. The mixture was diluted with water (15 mL) and then extracted with Et2O (3 x 50 mL). The combined organic extracts were washed with brine (3 x 50 mL), dried (Na2SO4), and then filtered. The filtrate was then concentrated to give the title compound, which was used directly in the next step without purification. MS m / z (M+H)+: calculated 353.2, observed 353.3. Intermediate 4-1 Preparation of Compound Int. 4-1 MeO OHC OMe HO2C NBoc Me lr[dF(CF3)ppy]2(dtbbpy)PF6[Ni(dtbbpy)(H2O)4]CI2 OMe NaBH4 MeOH OMe DCM BTMG, DMSO Blue LED NCS, Me2S OMe Int. 4-1 (4-(chloromethyl)-3,5-dimethoxybenzyl)(methyl)tert-butyl carbamate Step 1: (4-formyl-3,5-dimethoxybenzyl)(methyl)tert-butyl carbamate

[440] 4-bromo-2,6-dimethoxybenzaldehyde (6 g, 24.48 mmol), N-(tert-butoxycarbonyl)-N-methylglycine (9.26 g, 49.0 mmol), Ir[dF(CF3)ppy]2(dtbbpy)PF6 (0.275 g, 0.245 mmol) and [Ni(dtbbpy)(H2O)4]Cl2 (0.575 g, 1.224 mmol) were combined in DMSO (120 mL). BTMG (10 mL, 49.0 mmol) was added. The mixture was sonicated until all solids dissolved. The resulting mixture was divided equally into 4 screw-capped flasks with stirring rods. N2 was bubbled into each mixture for 5 minutes. The flasks were stoppered, and then the mixtures were irradiated in a photoreactor. Petition 870260002828, dated 12 / 01 / 2026.Page 132 / 237 123 / 211 PennOC Photoreactor® (wavelength: 420 nm; LED intensity: 100%; fan speed: 5000 rpm; agitation: 1200 rpm) overnight. The separate mixtures were combined, diluted with H2O, then extracted with EtOAc (3x). The combined organic extracts were washed with H2O and brine, dried (MgSO4), filtered, and then the filtrate was concentrated. The crude product was subjected to silica gel chromatography (0 to 50% EtOAc:EtOH / heptane 3:1) to give the title compound. 1H NMR (400 MHz, CDCh) δ 10.47 (s, 1H), 6.44 (bs, 2H), 4.41 (s, 2H), 3.88 (s, 6H), 2.87 (bs, 3H), 1.49 (bs, 9H). Step 2: tert-butyl (4-(hydroxymethyl)-3,5-dimethoxybenzyl)(methyl)carbamate

[441] A solution of tert-butyl (4-formyl-3,5-dimethoxybenzyl)(methyl)carbamate (6.98 g, 22.56 mmol) in MeOH (100 mL) was cooled to 0 °C. NaBH4 (1.03 g, 27.2 mmol) was added to this solution in portions. After 1 hour,The evolution of the gas ceased. The cooling bath was removed and the mixture heated to room temperature. After 90 minutes, the mixture was concentrated. The residue was taken in DCM, filtered by washing a Celite® pad with DCM, then the filtrate was concentrated. The crude product was subjected to silica gel chromatography (0 to 15% EtOAc:EtOH / heptane 3:1) to give the title compound. 1H NMR (400 MHz, CDCh) δ 6.45 (bs, 2H), 4.76 (d, J = 6.6 Hz, 2H), 4.39 (s, 2H), 3.83 (s, 6H), 2.86 (bs, 3H), 1.49 (s, 9H). Step 3: tert-butyl (4-(chloromethyl)-3,5-dimethoxybenzyl)(methyl)carbamate

[442] A solution of N-chlorosuccinimide (0.472 g, 3.53 mmol) in DCM (1 mL) was cooled to 0 °C. To this solution, dimethyl sulfide (0.239 g, 3.85 mmol) was slowly added, resulting in a precipitate. The reaction mixture was cooled to -20 °C, then a solution of tert-butyl (4-(hydroxymethyl)-3,5-dimethoxybenzyl)(methyl)carbamate (1 g,Petition 870260002828, dated 12 / 01 / 2026, p. 133 / 237 124 / 211 3.21 mmol) in DCM. The mixture was stirred for 2 hours, allowing the temperature to reach 0 °C, during which time all the solid precipitate dissolved, generating a clear solution. The solution was poured over cold brine and extracted with Et2O (2x). The combined organic extracts were washed with cold brine, dried (Na2SO4), filtered, then the filtrate was concentrated to give the title compound, which was used directly in the next step, without purification. MS m / z (M+H)+: calculated 330.1, observed 329.2. Intermediate 5-1 Preparation of Compound Int. 5-1 IBX BocHN^^^^^OH* BocHN^^^^CHOCH3CN|nt.5.ή(4-oxobutyl)carbamate tert-butyl BocHN^^^^CHO

[443] A mixture of (4-hydroxybutyl)carbamate tert-butyl (1 g, 5.28 mmol) in CH3CN (30 mL) at room temperature, IBX (1.231 g, 6.34 mmol), then the mixture was heated to 80 °C. After 1 h, the mixture was cooled to room temperature,The organic extracts were diluted with water (100 mL), then extracted with EtOAc (3 x 200 mL). The combined organic extracts were washed with brine (2 x 200 mL), dried (Na2SO4), filtered, and then the filtrate was concentrated. The crude product was subjected to silica gel chromatography (0 to 70% EtOAc / petroleum ether) to give the title compound. 1H NMR (400 MHz, CDCl3): δ 3.76 - 3.73 (m, 2H), 2.53 - 2.49 (t, 2H), 2.03 - 1.97 (m, 2H), 1.53 - 1.45 (s, 9H). Intermediate 6-1 Preparation of Compound Int. 6-1 Petition 870260002828, dated 12 / 01 / 2026, p. 134 / 237 125 / 211 pyridine, DCM Int. 6-1 (4-nitrophenyl) carbonate of (6Z,9Z,28Z,31Z)-heptatriaconta-6,9,28,31-tetraen-19-yl

[444] A mixture of (6Z,9Z,28Z,31Z)-heptatriaconta-6,9,28,31-tetraen19-ol (300 mg, 0.567 mmol) and hypochlorous 4-nitrobenzoic anhydride (229 mg, 1.134 mmol) in DCM (4.5 mL) and pyridine (1.5 mL) was stirred at room temperature for 5 hours. The resulting mixture was concentrated,then purified by preparative TLC (petroleum ether:DCM = 1:1) to give the title compound.

[445] Using the procedures described for Intermediate 6-1, the following compounds were prepared by substituting the appropriate reagents with (6Z,9Z,28Z,31Z)-heptatriaconta-6,9,28,31-tetraen-19-ol. Table 2 Comp. / Int. No. R Name Calc. [M+H]+ Observed [M+H]+ Comments Int. 6-2 0 H 4-nitrophenyl(3-stearamidopropyl) carbonate 507.3 507.4 from Int. 8-2; substitute DIEA with pyridine as base Intermediate 7-1 Preparation of Compound Int. 7-1 Petition 870260002828, dated 12 / 01 / 2026, p. 135 / 237 126 / 211 THF:H2O (1:1) 4-stearamidobutanoic acid

[446] A mixture of 4-aminobutanoic acid (1 g, 9.70 mmol) and Na2CÜ3 (1.542 g, 14.55 mmol) in THF (30 mL) and water (30 mL) was cooled to 0 °C. Stearoyl chloride (2.94 g, 9.70 mmol) was added to this mixture. After the addition was complete,The mixture was stirred for 16 hours at 25 °C. The resulting mixture was cooled with saturated KHSÜ4, then extracted with CHCl3 (500 mL). The combined organic phases were washed with brine (3 x 100 mL), dried (Na2SÜ4), filtered, and then the filtrate was concentrated to give the title compound. MS m / z (MH)-: calculated 368.6, observed 368.3.

[447] Using the procedures described for Intermediate 7-1, the following compounds were prepared by substituting the appropriate reagents with 4-aminobutanoic acid. Table 3 Comp. / Int. No. R Name Calc. [MH]- Observed [MH]- Comments Int. 7-2 HO2Cx / >!í 3-stearamidopropanoic acid 354.4 354.3 Int. 7-3 H °2C X 7-stearamidoheptanoic acid 410.7 410.4 Methyl 7-aminoheptanoate hydrochloride was used as the amine; ester hydrolysis was achieved with NaOH in THF:H2O. Petition 870260002828, dated 12 / 01 / 2026, pp. 136 / 237 127 / 211 Comp. / Int. n° R Name Calc. [MH]- Observed [MH]- Comments (5:1) Int. 7-4 5-stearamidopentanoic acid 382.6 382.3 Int. 7-5 HO2C^VA 2-(3-stearamidocyclobutyl)acetic acid 396.6 396.6 MS [M+H]+ Intermediate 8-1 Preparation for Intermediate 8-1 N-(3-aminopropyl)stearamide h2n nh2pyridine,DMF

[448] A mixture of propane-1,3-diamine (1 g, 13.49 mmol) and pyridine (1.091 mL, 13.49 mmol) in DMF (15 mL) was cooled to 0 °C. Stearoyl chloride (4.09 g, 13.49 mmol) was added to this mixture. After the addition was complete, the mixture was stirred for 16 hours at 25 °C. The resulting mixture was diluted with ice-cold water, resulting in a solid. The solid was collected by filtration, washed with water (3 x 3 mL), then dried under vacuum to give the title compound. MS m / z (M+H)+: calculated 341.6, observed 341.3.

[449] Using the procedures described for Intermediate 8-1, the following compounds were prepared by replacing the appropriate reagents with propane-1,3-diamine. Table 4 Petition 870260002828, dated 12 / 01 / 2026, pp. 137 / 237 128 / 211 Comp. / Int. n° R Name Calc. [M+H]+ Observed [M+H]+ Comments Int. 8-2 HO N-(3-hydroxypropyl)stearamide 342.3 342.3 Int. 8-3 Me Me N-(5-hydroxy-4,4-dimethylpentyl)stearamide 398.4 398.7 Intermediate 9-1 Preparation of the Int. 9-1 Compound 1. amine, HATU, DIEA, DMF O Ο ---------------------- 9 / — 2. 4M HCl in 1,4-dioxaneH 2-((1s,3s)-3-(octadecylcarbamoyl)cyclobutyl)acetic acid Step 1:2-((1s,3s)-3-(octadecylcarbamoyl)cyclobutyl)tert-butyl acetate

[450] To a stirred mixture of (1s,3s)-3-(2-(tert-butoxy)-2-oxoethyl)cyclobutane-1-carboxylic acid (0.5 g, 2.334 mmol), HATU (1.78 g, 4.67 mmol) and DIEA (1.22 mL, 7.00 mmol) in DMF (10 mL), a solution of octadecan-1-amine (0.818 g, 3.03 mmol) in DMF (10 mL) at 25 °C was added. After 12 hours, the mixture was diluted with water (10 mL), then extracted with EtOAc (3 x 10 mL). The combined organic layers were washed with brine (3 x 10 mL), dried (Na2SO4), filtered, then the filtrate was concentrated to give the title compound as an 80:20 mixture with 2-((1s,3s)-3(hexadecylcarbamoyl)cyclobutyl)tert-butyl acetate. MS m / z (M+H)+: calculated 466.4, observed 466.2. Step 2: 2-((1s,3s)-3-(octadecylcarbamoyl)cyclobutyl)acetic acid

[451] To a stirred mixture of 2-(3-(octadecylcarbamoyl)cyclobutyl)tert-butyl acetate (0.932 g, 2 mmol) in 1,4-dioxane (16 mL), 4M HCl (4 mL) was added in 1,4-dioxane at 25 °C. After 6 hours, the mixture was diluted with EtOAc, then washed with brine (3 x 30 mL). Petition 870260002828, dated 12 / 01 / 2026, pp. 138 / 237 129 / 211 The organic layer was dried (Na2SO4), filtered, then the filtrate was concentrated to give the title compound as an 80:20 mixture with 2-((1s,3s)-3-(hexadecylcarbamoyl)cyclobutyl)acetic acid. MS m / z (M+H)+: calculated 410.4, observed 410.4. Intermediate 10-1 Preparation for Intermediate 10-1 Jones reagent acetone 2,2-dimethyl-5-stearamidopentanoic acid

[452] To a mixture of N-(5-hydroxy-4,4-dimethylpentyl)stearamide (Int. 83, 500 mg, 1.257 mmol) in acetone (10 mL), a solution of chromium trioxide in sulfuric acid (0.691 mL, 1.383 mmol) at 0 °C was added. After 6 hours, the mixture was diluted with water. The resulting solid was collected by filtration, washed with water, and air-dried. MS m / z (M+H)+: calculated 412.4, observed 412.1. Intermediate 11-1 Preparation for Intermediate 11-1 Me Me 1. TMSCHN2, MeOH / DCM Me Me Me Me Me H2SO4, AcOH Me Me O 2. MeMgBr, THF, 0 °C 5-methyl-5-stearamidohexanoic acid Step 1: tert-butyl methyl glutarate

[453] A solution of 5-(tert-butoxy)-5-oxopentanoic acid (5 g, 26.6 mmol) in DCM (40 mL) and MeOH (40 mL) was cooled to 0 °C. To this solution, (diazomethyl)trimethylsilane (39.8 mL, 80 mmol, 2 M in hexane) was added. After the addition was complete, the mixture was heated to the temperature Petition 870260002828, dated 12 / 01 / 2026, pp. 139 / 237 130 / 211 environment. After 3 hours, the mixture was concentrated. The crude product was subjected to silica gel chromatography (0 to 5% EtOAc / petroleum ether) to give the title compound. 1H NMR (400 MHz, CDCl3) δ 3.68 (s, 3H), 2.37 (t, J = 7.2 Hz, 2H), 2.28 (t, J = 7.6 Hz, 2H), 1.91 (quin, J = 7.2 Hz, 2H), 1.44 (s, 9H). Step 2: tert-butyl 5-hydroxy-5-methylhexanoate

[454] To a solution of tert-butyl methyl glutarate (1 g, 4.94 mmol) in THF (16 mL), MeMgBr (4.12 mL, 12.36 mmol, 3 M in THF) was added at 0 °C. After 2 hours, the mixture was cooled with saturated NH4Cl (25 mL), heated to room temperature, and then extracted with EtOAc (10 mL x 3). The combined organic phases were washed with brine (30 mL), dried (Na2SO4), filtered, then the filtrate concentrated. The crude product was subjected to silica gel chromatography (0 to 20% EtOAc / petroleum ether) to give the title compound. 1H NMR (400 MHz, CDCl3) δ 2.25 (t, J = 7.2 Hz, 2H), 1.69-1.64 (m, 2H), 1.50-1.48 (m, 2H), 1.45 (s, 9H), 1.23 (s, 6H). Step 3: 5-methyl-5-stearamidohexanoic acid

[455] To a solution of tert-butyl 5-hydroxy-5-methylhexanoate (300 mg, 1.483 mmol) in AcOH (2 mL), stearonitrile (787 mg, 2.97 mmol) was added at room temperature, then the mixture was cooled to 0 °C. H2SO4 (0.5 mL) was added. After the addition was complete, the cooling bath was removed and the mixture heated to room temperature. After stirring overnight, the mixture was cooled with saturated NaHCO3 to pH = 5. The resulting mixture was extracted with EtOAc (2 mL x 3). The combined organic layers were dried (Na2SO4), filtered, then the filtrate was concentrated. The residue was taken in MeCN (5 mL). The resulting precipitated solid was collected, then recrystallized from EtOAc to give the title compound. MS m / z (M+H)+: calculated 412.7, observed 412.3. Intermediate 12-1 Petition 870260002828, dated 12 / 01 / 2026, pp. 140 / 237 131 / 211 Preparation of Int. 12-1 ho2c NHBoc TMS-diazomethane MeO2C NHBoc 1-bromooctadecane NaH, DMF DCM:MeOH (1:1) 5-((tert-butoxycarbonyl)(octadecyl)amino)pentanoic acid Step 1: 5-((tert-butoxycarbonyl)amino)pentanoate methyl

[456] To a solution of 5-((tert-butoxycarbonyl)amino)pentanoic acid (2 g, 9.21 mmol) in MeOH (15 mL) and DCM (15 mL), 2 M (trimethylsilyl)diazomethane (23.01 mL, 46.0 mmol) in hexane at room temperature was added. After 1 hour, the mixture was concentrated to give the title compound, which was used without purification. 1H NMR (400 MHz, CDCh) δ 4.56 (s, 1H), 3.68 (s, 3H), 3.13 (q, J = 6.4 Hz, 2H), 2.34 (t, J = 7.2 Hz, 2H), 1.70 - 1.62 (m, 2H), 1.49 - 1.56 (m, 2H), 1.45 (s, 9H). Step 2: 5-((tert-butoxycarbonyl)(octadecyl)amino)methylpentanoate

[457] To a solution of methyl 5-((tert-butoxycarbonyl)amino)pentanoate (1 g, 4.32 mmol) in DMF (20 mL), NaH (0.259 g, 6.49 mmol, 60% in mineral oil) was added at 0 °C. After the addition was complete, the mixture was heated to room temperature. After 30 minutes, 1-bromooctadecane (4.32 g, 12.97 mmol) was added and the mixture was heated to 50 °C. After 2 hours, the mixture was cooled to room temperature, diluted with water (100 mL), then extracted with EtOAc (3x). The combined organic layers were washed with brine (50 mL), dried (Na2SO4), filtered, then the filtrate was concentrated. The crude product was subjected to silica gel chromatography (0 to 20% EtOAc). Petition 870260002828, dated 12 / 01 / 2026, pp. 141 / 237 132 / 211 / petroleum ether) to give the title compound. 1H NMR (400 MHz, CD3OD) δ 3.67 - 3.64 (m, 3H), 3.23-3.15 (m, 4H), 2.39-2.33 (m, 2H), 1.57 (d, J = 4.4 Hz, 6H), 1.46 (s, 9H), 1.29 (s, 30H), 0.92 - 0.88 (m, 3H). Step 3: 5-((tert-butoxycarbonyl)(octadecyl)amino)pentanoic acid

[458] To a stirred solution of methyl 5-((tert-butoxycarbonyl)(octadecyl)amino)pentanoate (240 mg, 0.496 mmol) in THF (6 mL) and H2O (2 mL), LiOH monohydrate (62.5 mg, 1.488 mmol) was added at room temperature and the mixture was heated to 40 °C. After stirring overnight, the mixture was cooled to room temperature and the pH was adjusted to 7 with 1N HCl. The resulting mixture was extracted with EtOAc (3 x 5 mL). The combined organic layers were washed with brine (3 x 5 mL), dried (Na2SO4), filtered, then the filtrate was concentrated to give the title compound, which was used in the next step without purification. 1H NMR (400 MHz, CD3OD) δ 3.23 - 3.14 (m, 4H), 2.35 - 2.28 (m, 2H), 1.65 - 1.52 (m, 6H), 1.46 (s, 9H), 1.29 (s, 30H), 0.92-0.88 ppm (m, 3H). Intermediate 13-1 Preparation for Interim 13-1 6-bromo-1-hexene NaH, DMF RuCI3. NalO4o ACN:H2O 5-(octadecyloxy)pentanoic acid Step 1:1-(hex-5-en-1-yloxy)octadecane

[459] To a solution of octadecan-1-ol (5 g, 18.48 mmol) in DMF (100 mL), NaH (3.70 g, 92 mmol) (60% in mineral oil) was added in portions at room temperature. After stirring for 30 minutes, 6-bromo-1 Petition 870260002828, dated 12 / 01 / 2026, pp. 142 / 237 133 / 211 hexene (24.70 mL, 185 mmol), and the mixture was heated to 80 °C. After overnight heating, the mixture was cooled to room temperature, diluted with water (200 mL), and extracted with EtOAc (100 mL x 3). The combined organic phases were dried (Na2SO4), filtered, and then the filtrate was concentrated. The crude product was subjected to silica gel chromatography (0 to 100% EtOAc / petroleum ether) to give the title compound. 1H NMR (400MHz, CDCh) δ 5.82 (ddt, J = 17.2, 10.4, 6.8, 6.8Hz, 1H), 5.01 (dq, J = 17.6, 1.2Hz, 1H), 4.95 (d, J = 10.0Hz, 1H), 3.45 - 3.36 (m, 4H), 2.08 (d, J = 7.2 Hz, 2H), 1.65 1.55 (m, 5H), 1.49 - 1.44 (m, 2H), 1.39 - 1.1.17 (m, 29H), 0.85 - 0.92 (m, 3H). Step 2: 5-(octadecyloxy)pentanoic acid

[460] To a solution of 1-(hex-5-en-1-yloxy)octadecane (1 g, 2.84 mmol) in MeCN (10 mL), a solution of RuCU (0.059 g, 0.284 mmol) and NaIO4 (2.426 g, 11.34 mmol) in H2O (10 mL) was added at room temperature. After 2 hours, the mixture was diluted with Na2SO3 (25 mL), then extracted with EtOAc (25 mL x 3). The combined organic layers were washed with 1N HCl (20 mL), saturated NaHCO3 (20 mL) and brine (20 mL), dried (Na2SO4), filtered, and the filtrate was concentrated to give the title compound, which was used in the next step without purification. 1H NMR (400 MHz, CDCh) δ ppm 3.39 - 3.44 (m, 4 H), 2.40 (t, J=7.27 Hz, 2 H), 1.70 - 1.75 (m, 2 H), 1.65 (br d, J=7.51 Hz, 2 H), 1.55 - 1.58 (m, 2 H), 1.26 (s, 30 H), 0.87 - 0.89 (m, 3 H). Intermediate 14-1 Preparation for Interim 14-1 Pd2(dba)3, RuPhos Cs2CO3, toluene, 110 °C 2-(4-(1,4-diazepan-1-yl)-2-metoxibenzil)-5-azido-N -butyl-2H-pirazolo[4,3d]pirimidin-7-amina Petition 870260002828, of 12 / 01 / 2026, p. 143 / 237 134 / 211 Step 1: 1-(4-((5-azido-7-(butylamino)-2H-pyrazolo[4,3-d]pyrimidin-2yl)methyl)-3-metoxifenil)piperidina-4-carboxilato de tert-butila

[461] A mixture of f 5-azido-2-(4-bromo-2-methoxybenzyl)-N-butyl-2H-pyrazolo[4,3-d]pyrimidin-7-amine (from Compound B-1 step 1, 500 mg, 1.159 mmol) and tert-butyl 1,4-diazepane-1-carboxylate (302 mg, 1.507 mmol) in toluene (10 mL), RuPhos (216 mg, 0.464 mmol), Pd2(dba)3 (212 mg, 0.232 mmol) and Cs2CO3 (1133 mg, 3.48 mmol) was added under N2, then the mixture was heated to 110 °C. After overnight heating, the mixture was cooled to room temperature and diluted with water (100 mL). The resulting mixture was then extracted with EtOAc (3 x 100 mL). The combined organic layers were washed with brine (3 x 300 mL), dried (Na2SO4), filtered, and the filtrate was concentrated. The crude product was subjected to silica gel chromatography (0 to 52% EtOAc / petroleum ether 3:1) to give the title compound. MS m / z (M+H)+: calculated 551.7, observed 551.1. Step 2: 2-(4-(1,4-diazepan-1-yl)-2-methoxybenzyl)-5-azido-N-butyl-2Hpyrazolo[4,3-d]pyrimidin-7-amine

[462] A solution of tert-butyl 4-(4-((5-azido-7-(butylamino)-2H-pyrazolo[4,3d]pyrimidin-2-yl)methyl)-3-methoxyphenyl)-1,4-diazepano-1-carboxylate (350 mg, 0.636 mmol) in DCE (2.00 mL) was cooled to 0 °C. To this solution, 4 M HCl in 1,4-dioxane (2 mL) at 0 °C was added. After 1 hour, the mixture was heated to room temperature and concentrated to give the title compound as the HCl salt, which was used without purification. MS m / z (M+H)+: calculated 451.3, Petition 870260002828, dated 12 / 01 / 2026, pp. 144 / 237 135 / 211 observed 451.3.

[463] Using the procedures described for Intermediate 14-1, the following compounds were prepared by replacing the appropriate reagents with tert-butyl 1,4-diazepane-1-carboxylate. Table 5 Comp. / Int. n° R Name Calc. [M+H]+ Observed [M+H]+ Comments Int. 14-2 O VOH acid 1-(4-((5-azido-7(butylamino)-2 H -pyrazolo[4,3d ]pyrimidin-2-yl)methyl)-3-methoxyphenyl)piperidine-4-carboxylic 480.2 480.2 Intermediate 15-1 Preparation for Interim 15-1 X-Phos Pd G3, Cs2CO: 1,4-dioxane / H2O MeOH H2, Pd / C 4N HCl 1,4-dioxane °C 5-azido-N -butyl-2-(2-methoxy-4-(piperidin-4-yl)benzyl)-2 H -pyrazolo[4,3d]pyrimidin-7-amine Petition 870260002828, dated 12 / 01 / 2026, pp. 145 / 237 136 / 211 Step 1: tert-butyl 4-(4-((5-azido-7-(butylamino)-2H-pyrazolo[4,3-d]pyrimidin-2yl)methyl)-3-methoxyphenyl)-3,6-dihydropyridine-1(2H)-carboxylate

[464] To a mixture of 5-azido-2-(4-bromo-2-methoxybenzyl)-N-butyl-2H-pyrazolo[4,3-d]pyrimidin-7-amine (from Compound B-1 step 1, 400 mg, 0.927 mmol) and tert-butyl 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-3,6-dihydropyridine1(2H)-carboxylate (430 mg, 1.391 mmol) in 1,4-dioxane (4 mL) / H2O (0.4 mL), CS2CO3 (604 mg, 1.855 mmol) were added and X-Phos Pd G3 (39.3 mg, 0.046 mmol) under N2, then the mixture was heated to 80 °C. After 2 hours, the mixture was cooled to room temperature and diluted with EtOAc (200 mL). The resulting mixture was washed with brine (3 x 100 mL), dried (Na2SOJ), filtered, and then the filtrate was concentrated. The crude product was subjected to silica gel chromatography (0 to 50% EtOAc / petroleum ether) to give the title compound. MS m / z (M+H)+: calculated 534.3, observed 534.4. Step 2: tert-butyl 4-(4-((5-azido-7-(butylamino)-2H-pyrazolo[4,3-d]pyrimidin-2yl)methyl)-3-methoxyphenyl)piperidine-1-carboxylate

[465] To a solution of 4-(4-((5-azido-7-(butylamino)-2H-pyrazolo[4,3d]pyrimidin-2-yl)methyl)-3-methoxyphenyl)-3,6-dihydropyridine-1(2H)-tert-butylcarboxylate (290 mg, 0.543 mmol) in MeOH (10 mL) Pd / C (150 mg, 1.410 mmol) was added under N2. The resulting mixture was placed under an H2 atmosphere (3 x vacuum / H2) and stirred at room temperature. After 16 hours, the mixture was degassed (3 x vacuum / N2), filtered, washed with MeOH, and the filtrate was concentrated to give the title compound. MS m / z (M+H)+: calculated 536.3, Petition 870260002828, dated 12 / 01 / 2026, pp. 146 / 237 137 / 211 observed 536.3. Step 3: 5-azido-N-butyl-2-(2-methoxy-4-(piperidin-4-yl)benzyl)-2Hpyrazolo[4,3-d]pyrimidin-7-amine

[466] To a solution of tert-butyl 4-(4-((5-azido-7-(butylamino)-2H-pyrazolo[4,3d]pyrimidin-2-yl)methyl)-3-methoxyphenyl)piperidine-1-carboxylate (250 mg, 0.467 mmol) in DCM (2 mL), 4 M HCl was added in 1,4-dioxane (2 mL) at room temperature. After 1 hour, the mixture was concentrated to give the title compound as the HCl salt, which was used without purification. MS m / z (M+H)+: calculated 436.3, observed 436.6. Intermediate 16-1 Preparation for Interim 16-1 Br 2-(4-(azetidin-3-yl)-2-methoxybenzyl)-5-azido-N-butyl-2H-pyrazolo[4,3d]pyrimidin-7-amine Step 1: tert-butyl 3-(4-((5-azido-7-(butylamino)-2H-pyrazolo[4,3-d]pyrimidin-2yl)methyl)-3-methoxyphenyl)azetidine-1-carboxylate

[467] To a solution of Nib (36.2 mg, 0.116 mmol) in DMA (1 mL), picolinimidamide hydrochloride (36.5 mg, 0.232 mmol) was added, then the mixture was heated to 50 °C. After 30 minutes, zinc powder (152 mg, 2.319 mmol) was added, followed by a solution of 5-azido-2-(4-bromo-2 Petition 870260002828, dated 12 / 01 / 2026, pp. 147 / 237 138 / 211 methoxybenzyl)-N-butyl-2H-pyrazolo[4,3-d]pyrimidin-7-amine (from Compound B-1 step 1, 500 mg, 1.159 mmol) and tert-butyl 3-bromoazetidine-1-carboxylate (411 mg, 1.739 mmol) in DMA (10 mL). After overnight stirring at room temperature, the mixture was purified directly by reversed-phase chromatography (CH3CN / water with 0.1% TFA modifier) ​​to obtain the title compound. MS m / z (M+H)+: calculated 508.3, observed 508.4. Step 2: 2-(4-(azetidin-3-yl)-2-methoxybenzyl)-5-azido-N-butyl-2Hpyrazolo[4,3-d]pyrimidin-7-amine

[468] To a solution of tert-butyl 3-(4-((5-azido-7-(butylamino)-2H-pyrazolo[4,3d]pyrimidin-2-yl)methyl)-3-methoxyphenyl)azetidine-1-carboxylate (60 mg, 0.118 mmol) in DCM (0.5 mL), 4 M HCl in 1,4-dioxane (0.5 mL) at room temperature. After 1 hour, the mixture was concentrated to give the title compound as the HCl salt, which was used without purification. MS m / z (M+H)+: calculated 408.2, observed 408.3. Intermediate 17-1 Preparation for Interim 17-1 Petition 870260002828, dated 12 / 01 / 2026, pp. 148 / 237 139 / 211 NaBH4 EtOH SOCI2 DCM ^OH TFE TBDPSCI Imidazole, DMF ^OTBDPS RuPhos Pd G4 CS2CO3 toluene, 90 °C H2, Pd / C OTBDPS (S )-5-azido-N -(1-(( tert -butyldiphenylsilyl)oxy)pentan-2-yl)-2-(2,6-dimethoxy-4(piperazin-1-yl)benzyl)-2 H -pyrazolo[4,3-d]pyrimidin-7-amine ^OTBDPS Step 1: (4-bromo-2,6-dimethoxyphenyl)methanol

[469] To a solution of 4-bromo-2,6-dimethoxybenzaldehyde (5 g, 20.40 mmol) in EtOH (60 mL), NaBH4 (0.926 g, 24.48 mmol) was added at room temperature. After 1 hour, the mixture was diluted with water (50 mL), then extracted with EtOAc (30 mL x 2). The combined organic layers were washed with brine (50 mL), dried (Na2SO4), filtered, and then the filtrate was concentrated. The crude product was subjected to silica gel chromatography (15 Petition 870260002828, dated 12 / 01 / 2026, pp. 149 / 237 140 / 211 to 50% EtOAc / petroleum ether) to give the title compound. 1H NMR (400 MHz, CDCh) δ 6.72 (s, 2H), 4.72 (d, J = 6.8 Hz, 2H), 3.84 (s, 6H), 2.32 (t, J = 6.8 Hz, 1H). Step 2:5-bromo-2-(chloromethyl)-1,3-dimethoxybenzene

[470] To a solution of (4-bromo-2,6-dimethoxyphenyl)methanol (1 g, 4.05 mmol) in DCM (10 mL), SOCl2 (0.591 mL, 8.09 mmol) was added at 0 °C. After the addition was complete, the mixture was heated to room temperature and stirred overnight. The resulting mixture was concentrated to give the title compound, which was used in the next step without purification. 1H NMR (400 MHz, CDCh) δ 6.72 (s, 2H), 4.70 (s, 2H), 3.87 (s, 6H). Step 3: (S)-2-((5-azido-2-(4-bromo-2,6-dimethoxybenzyl)-2H-pyrazolo[4,3d]pyrimidin-7-yl)amino)pentan-1-ol

[471] A solution of (S)-2-((5-azido-2H-pyrazolo[4,3-d]pyrimidin-7yl)amino)pentan-1-ol (Int. 2-2, 800 mg, 3.05 mmol) in DMF (15 mL), 5-bromo-2-(chloromethyl)-1,3-dimethoxybenzene (800 mg, 3.01 mmol) and K2CO3 (1.25 g, 9.04 mmol) was prepared at room temperature. After stirring overnight, the mixture was diluted with water (10 mL). The resulting solid was collected by filtration and then dried under vacuum to give the title compound. MS m / z (M+H)+: calculated 491.1, observed 491.2. 1H NMR (400 MHz, CD3OD) δ 8.53 (s, 1H), 6.93 (s, 2H), 5.64 (d, J = 1.6 Hz, 2H), 4.50-4.63 (m, 1H), 3.88 (s, 6H), 3,683.76 (m, 2H), 1.61-1.86 (m, 2H), 1.38-1.54 (m, 2H), 0.97 (t, J = 7.2 Hz, 3H). Step 4: (S)-5-azido-2-(4-bromo-2,6-dimethoxybenzyl)-N-(1-((tertbutyldiphenylsilyl)oxy)pentan-2-yl)-2H-pyrazolo[4,3-d]pyrimidin-7-amine

[472] To a solution of (S)-2-((5-azido-2-(4-bromo-2,6-dimethoxybenzyl)2H-pyrazolo[4,3-d]pyrimidin-7-yl)amino)pentan-1-ol (900 mg, 1.832 mmol) in DMF (15 mL), imidazole (374 mg, 5.50 mmol) and TBDPSCl (0.565 mL, 2.198 mmol) were added at room temperature. After stirring overnight, the mixture Petition 870260002828, dated 12 / 01 / 2026, pp. 150 / 237 141 / 211 was diluted with water (15 mL), then extracted with EtOAc (15 mL x 2). The combined organic layers were washed with brine (20 mL), dried (Na2SO4), filtered, and then the filtrate was concentrated. The crude product was subjected to silica gel chromatography (0 to 10% MeOH / DCM) to give the title compound. MS m / z (M+H)+: calculated 731.2, observed 731.2. Step 5: (S)-4-(4-((5-azido-7-((1-((tert-butyldiphenylsilyl)oxy)pentan-2yl)amino)-2H-pyrazolo[4,3-d]pyrimidin-2-yl)methyl)-3,5-dimethoxyphenyl)piperazine-1benzylcarboxylate

[473] To a solution of (S)-5-azido-2-(4-bromo-2,6-dimethoxybenzyl)-N-(1((tert-butyldiphenylsilyl)oxy)pentan-2-yl)-2H-pyrazolo[4,3-d]pyrimidin-7-amine (500 mg, 0.685 mmol) in toluene (10 mL), benzyl piperazine-1-carboxylate (226 mg, 1.028 mmol), RuPhos Pd G4 (58.3 mg, 0.069 mmol) and Cs2CO3 (670 mg, 2.055 mmol) were added. The mixture was purged with N2, then heated to 90 °C. After overnight heating, the mixture was cooled to room temperature, diluted with water (10 mL), then extracted with DCM (15 mL x 2). The combined organic layers were dried (Na2SO4), filtered, and then the filtrate was concentrated. The crude product was subjected to silica gel chromatography (0 to 5% MeOH / DCM) to give the title compound. MS m / z (M+H)+: calculated 869.4, observed 869.4. Step 6: (S)-5-azido-N-(1-((tert-butyldiphenylsilyl)oxy)pentan-2-yl)-2-(2,6dimethoxy-4-(piperazin-1-yl)benzyl)-2H-pyrazolo[4,3-d]pyrimidin-7-amine

[474] To a solution of (S)-4-(4-((5-amino-7-((1-(( tert-butyldiphenylsilyl)oxy)pentan-2-yl)amino)-2H-pyrazolo[4,3-d]pyrimidin-2-yl)methyl)3,5-dimethoxyphenyl)piperazine-1-carboxylate benzyl (370 mg, 0.439 mmol) in TFE (8 mL), Pd / C (47 mg) was added. The mixture was degassed (3 x vacuum / N2), then placed under an H2 atmosphere (flask). After 2 hours, the mixture was filtered, and the filtrate was concentrated to give the title compound. Petition 870260002828, dated 12 / 01 / 2026, pp. 151 / 237 142 / 211 which was used in the next step without purification. MS m / z (M+H)+: calculated 735.4, observed 735.4. EXAMPLE 3 Preparation of Compound A-1 CMBP benzene 5N NaOH 1,4-dioxane DCM HATU, DIEA, DCM HO,C. 2NHBoc TMSCI, phenol Me Stearic acid HATU, DIEA, DCM H2N NH N -(5-(4-(4-((5-amino-7-(butylamino))-2 H -pyrazole[4,3-d ]pyrimidine-2Petition 870260002828, dated 12 / 01 / 2026, pp. 152 / 237 143 / 211 yl)methyl)-3,5-dimethoxyphenyl)piperazin-1-yl)-5-oxopentyl)stearamide (Compound A-1) Step 1: 4-(4-((7-(butylamino)-5-((methoxycarbonyl)amino)-2H-pyrazole[4,3d]pyrimidin-2-yl)methyl)-3,5-dimethoxyphenyl)piperazine-1-tert-butyl carboxylate

[475] To a stirred mixture of tert-butyl 4-(4-(hydroxymethyl)-3,5-dimethoxyphenyl)piperazine-1-carboxylate (Int. 3-1, 13.87 g, 39.4 mmol) in benzene (80 mL), methyl (7-(butylamino)-1H-pyrazolo[4,3d]pyrimidin-5-yl)carbamate (Int. 1-1, 8 g, 30.3 mmol) and cyanomethylenetributylphosphorane (10.96 g, 45.4 mmol) were added under an argon atmosphere, then the mixture was heated to 80 °C. After 3 hours, the mixture was cooled to room temperature, then diluted with water (10 mL) and extracted with EtOAc (3 x 20 mL). The combined organic extracts were washed with brine (3 x 10 mL), dried (Na2SO4), filtered, and then the filtrate was concentrated. The crude product was subjected to silica gel chromatography (0 to 100% EtOAc / DCM) to obtain the title compound. MS m / z (M+H)+: calculated 599.3, observed 599.3. Step 2: tert-butyl 4-(4-((5-amino-7-(butylamino)-2H-pyrazolo[4,3-d]pyrimidin-2yl)methyl)-3,5-dimethoxyphenyl)piperazine-1-carboxylate

[476] A stirred mixture of 4-(4-((7-(butylamino)-5-((methoxycarbonyl)amino)-2H-pyrazolo[4,3-d]pyrimidin-2-yl)methyl)-3,5-dimethoxyphenyl)piperazine-1-carboxylate tert-butyl (2.6 g, 4.34 mmol) in 1,4-dioxane (5 mL), NaOH (10 M, 20 mL, 200 mmol), was heated to 60 °C. After 12 hours, the mixture was cooled to room temperature, diluted with water (20 mL), and extracted with EtOAc (3 x 80 mL). The combined organic extracts were washed with brine (50 mL), dried (Na2SO4), filtered, and then the filtrate was concentrated. The crude product was subjected to silica gel chromatography (0 to 10% MeOH / DCM) to determine the title compound. MS m / z Petition 870260002828, dated 12 / 01 / 2026, pp. 153 / 237 144 / 211 (M+H)+: calculated 541.3, observed 541.4. Step 3: N7-butyl-2-(2,6-dimethoxy-4-(piperazin-1-yl)benzyl)-2H-pyrazolo[4,3d]pyrimidine-5,7-diamine

[477] To a stirred mixture of tert-butyl 4-(4-((5-amino-7-(butylamino)-2Hpyrazolo[4,3-d]pyrimidin-2-yl)methyl)-3,5-dimethoxyphenyl)piperazine-1-carboxylate (1.8 g, 3.33 mmol) in DCM (25 mL), a phenol solution (9.40 g, 100 mmol) in DCM (5 mL) at room temperature was added. The mixture was cooled to 5 °C and then a chlorotrimethylsilane solution (0.24 mL, 1.878 mmol) in DCM (3 mL) was added dropwise. After the addition was complete, the mixture was warmed to room temperature. After 25 minutes, the mixture was poured into chilled 2 N NaOH (30 mL) and extracted with ethyl EtOAc (5 x 150 mL). The combined organic extracts were dried (Na2SO4), filtered, and then the filtrate was concentrated. The crude product was subjected to reverse-phase chromatography (0 to 60% MeCN / water with 0.5% NH4OH modifier) ​​to give the title compound. MS m / z (M+H)+: calculated 441.3, observed 441.2. Step 4: tert-butyl (5-(4-(4-((5-amino-7-(butylamino)-2H-pyrazolo[4,3-d]pyrimidin-2yl)methyl)-3,5-dimethoxyphenyl)piperazin-1-yl)-5-oxopentyl)carbamate

[478] To a stirred mixture of 5-((tert-butoxycarbonyl)amino)pentanoic acid (225 mg, 1.035 mmol) in DMF (2 mL), a solution of HATU (738 mg, 1.941 mmol) in DMF at room temperature was added. After 30 minutes, N7-butyl-2-(2,6-dimethoxy-4(piperazin-1-yl)benzyl)-2H-pyrazolo[4,3-d]pyrimidine-5,7-diamine (570 mg, 1.294 mmol) and DIEA (0.452 mL, 2.59 mmol) were added. After 5 hours, the mixture was cooled to room temperature, diluted with water (30 mL) and extracted with EtOAc (3 x 50 mL). The combined organic extracts were washed with brine (3 x 25 mL), dried (Na2SO4), filtered, and then the filtrate was concentrated. The product Petition 870260002828, dated 12 / 01 / 2026, pp. 154 / 237 Crude 145 / 211 was subjected to silica gel chromatography (1 to 10% MeOH / DCM) to give the title compound. MS m / z (M+H)+: calculated 640.4, observed 640.5. Step 5: 5-amino-1-(4-(4-((5-amino-7-(butylamino)-2H-pyrazolo[4,3d]pyrimidin-2-yl)methyl)-3,5-dimethoxyphenyl)piperazin-1-yl)pentan-1-one

[479] A solution of tert-butyl (5-(4-(((5-amino-7-(butylamino)-2H-pyrazolo[4,3d]pyrimidin-2-yl)methyl)-3,5-dimethoxyphenyl)piperazin-1-yl)-5-oxopentyl)carbamate (550 mg, 0.860 mmol) in 10% TFA / DCM (2 mL) was stirred at room temperature. After 30 minutes, the mixture was diluted with toluene (30 mL), then concentrated. The crude product was subjected to reverse-phase chromatography (0 to 100% MeCN / water with 1% NH4OH modifier) ​​to give the title compound. MS m / z (M+H)+: calculated 540.3, observed 540.5. Step 6: N-(5-(4-(4-((5-amino-7-(butylamino)-2H-pyrazolo[4,3-d]pyrimidin-2yl)methyl)-3,5-dimethoxyphenyl)piperazin-1-yl)-5-oxopentyl)stearamide

[480] A stirred mixture of stearic acid (274 mg, 0.964 mmol) in DMF (7 mL) was added to a solution of HATU (423 mg, 1.112 mmol) in DMF at room temperature. After 30 minutes, 5-amino-1-(4-(4((5-amino-7-(butylamino)-2H-pyrazolo[4,3-d]pyrimidin-2-yl)methyl)-3,5-dimethoxyphenyl)piperazin-1-yl)pentan-1-one (400 mg, 0.741 mmol) and DIEA (0.259 mL, 1.482 mmol) were added. After 2 hours, the mixture was cooled to room temperature, diluted with water (20 mL), and extracted with EtOAc (3 x 50 mL). The combined organic extracts were washed with brine (3 x 20 mL), dried (Na2SO4), filtered, and then the filtrate was concentrated. The crude product was subjected to silica gel chromatography (1 to 10% MeOH / DCM) to give the title compound. Compound A-1: ​​MS m / z (M+H)+: calculated 806.6, observed 806.6.RMN 1H (400 MHz, CDCl3) δ 12.41 (s, 1H), 7.41 (s, 1H), 6.71 - 6.68 (m, 1H), 6.11 (s, 2H), 5.78 - 5.76 (m, 1H), 5.38 (s, 2H), 3.85 - 3.82 (m, 9H), 3.65 - 3.60 (m, 5H), 3.28 3.25 (m, 7H), 2.41 (t, J = 7.2 Hz, 2H), 2.16 (t, J = 7.2Hz, 2H), 1.70 - 1.56 (m, 18H),. Petition: 870260002828, on January 12, 2026, page. 155 / 237 146 / 211 Petition: 870260002828, on January 12, 2026, page. 156 / 237 147 / 211(S)-N -(5-(4-(4-((5-amino-7-((1-hidroxipentan-2-il)amino)-2 H-pirazolo[4,3d ]pirimidin-2-il)metil)-3,5-dimetoxifenil)piperazin-1-il)-5oxopentil)estearamida (Composto A-2) Etapa 1: (S)-N-(5-(4-(4-((5-azido-7-((1-((terc-butildifenilsilil)oxi)pentan-2il)amino)-2H-pirazolo[4,3-d]pirimidin-2-il)metil)-3,5-dimetoxifenil)piperazin-1il)-5-oxopentil)estearamida

[481] A solution of 5-stearamidopentanoic acid (Int. 7-4, 129 mg, 0.337 mmol) in DMF (10 mL), DIEA (109 mg, 0.842 mmol) and PyBOP (175 mg, 0.337 mmol) was added at room temperature. After 10 minutes, (S)-5-azido-N-(1-((tert-butyldiphenylsilyl)oxy)pentan-2-yl)-2-(2,6-dimethoxy-4-(piperazin-1-yl)benzyl)-2H-pyrazolo[4,3-d]pyrimidin-7-amine (Int. 171, 300 mg, 0.281 mmol) was added at room temperature. After 30 minutes, the mixture was diluted with water (10 mL), then extracted with EtOAc (15 mL x 2). The combined organic layers were dried (Na2SO4), filtered, and then the filtrate was concentrated. The crude product was purified by TLC prep. (DCM / MeOH = 10:1) to give the title compound and (S)-1-(4-(4-((5-azido-7-((1((tert-butyldiphenylsilyl)oxy)pentan-2-yl)amino)-2H-pyrazolo[4,3-d]pyrimidin-2yl)methyl)-3,5-dimethoxyphenyl)piperazin-1-yl)octadecan-1-one (Int. 18-1). Title Compound: MS m / z (M+H)+: calculated 1100.7, observed 1100.7. Int.18-1: MS m / z (M+H)+: calculated 1001.6, observed 1001.7. Step 2: (S)-N-(5-(4-(4-((5-azido-7-((1-hydroxypentan-2-yl)amino)-2Hpyrazolo[4,3-d]pyrimidin-2-yl)methyl)-3,5-dimethoxyphenyl)piperazin-1-yl)-5oxopentyl)stearamide

[482] To a solution of (S)-N- (5-(4-(4-((5-azido-7-((1-(( tert -butyldiphenylsilyl)oxy)pentan-2-yl)amino)-2H-pyrazolo[4,3-d]pyrimidin-2-yl)methyl)3,5-dimethoxyphenyl)piperazin-1-yl)-5-oxopentyl)stearamide (150 mg, 0.075 mmol) in THF (2 mL), TBAF (0.112 mL, 0.112 mmol, 1M in THF) was added to the Petition 870260002828, dated 12 / 01 / 2026, pp. 157 / 237 148 / 211 room temperature. After 1 hour, the mixture was diluted with water (10 mL), then extracted with EtOAc (15 mL x 2). The combined organic layers were dried (Na2SO4), filtered, then the filtrate was concentrated to give the title compound, which was used in the next step without purification. MS m / z (M+H)+: calculated 862.6, observed 862.5. Stage 3: (S)-N-(5-(4-(4-((5-amino-7-((1-hydroxypentan-2-yl)amino)-2Hpyrazolo[4,3-d]pyrimidin-2-yl)methyl)-3,5-dimethoxyphenyl)piperazin-1-yl)-5oxopentyl)estearamida

[483] To a solution of (S)-N-(5-(4-(4-((5-azido-7-((1-hydroxypentan-2yl)amino)-2H-pyrazolo[4,3-d]pyrimidin-2-yl)methyl)-3,5-dimethoxyphenyl)piperazin-1yl)-5-oxopentyl)stearamide (55 mg, 0.064 mmol) in THF (1.5 mL) and H2O (0.3 mL), BuaP (0.079 mL, 0.319 mmol) was added and the mixture was heated to 50 °C. After 1 hour, the mixture was cooled to room temperature and then concentrated. The crude product was purified by reverse-phase chromatography (CH3CN / water with 0.2% FA modifier) ​​to give the title compound. Compound A-2: MS m / z (M+H)+: calculated 836.6, observed 836.5. 1H NMR (400 MHz, CD3OD) δ 7.57 (s, 1H), 6.27 (s, 2H), 5.42 (s, 2H), 4.49 - 4.40 (m, 1H), 3.84 (s, 6H), 3.72 (dd, J = 5.2, 10.0 Hz, 4H), 3.68 - 3.61 (m, 2H), 3.27 - 3.18 (m, 4H), 2.48 (t, J = 7.2 Hz, 2H), 2.17 (t, J = 7.2 Hz, 2H), 1.73 - 1.53 (m, 10H), 1.50 - 1.36 (m, 4H), 1.30 - 1.24 (m, 27H), 0.97 (t, J = 7.2 Hz, 4H), 0.89 (t, J = 6.8 Hz, 3H).

[484] Using the procedures described for Compound A-2, the following compounds were prepared by replacing the appropriate reagents with 5-aminopentanoic acid in step 1. Petition 870260002828, dated 12 / 01 / 2026, pp. 158 / 237 149 / 211 H Table 6 Comp. / Ex. no. R Name Calc. [M+H]+ Observed [M+H]+ A-3 (5 )-1-(4-(4-((5-amino-7((1-hydroxypentan-2yl)amino)-2 H pyrazolo[4,3d ]pyrimidin-2-yl)methyl)3,5dimethoxyphenyl)piperazin1-yl)octadecan-1-one 737.5 737.5 EXAMPLE 4 Preparation of Compound B-1 MeO Ύ ΥΛ Br -- 1 H Me^ / χ^ΝΗ K2CO3, DMF Me^ ^1 N— 15%TFA / DCM \=< TI OM Ny^N Me^ ^NBoc Br / —\ ( ) ^^7 HN NBoc N—7 XX RPh“PdG2 VrJí. T Cs2CO3, 1,4-dioxane 100 °C | ^NHBoc \m 7, / / ​​ / / ^Nh°2c^ / ^^ <n^ e HATU, DIEA, DCM \ / Y l^' N—' OMe Me. ,NH Petition 870260002828, dated 12 / 01 / 2026, pp. 159 / 237 150 / 211 Me. .NH PMe3 THF:H2O (10:1) Compound B-1 N -(5-(4-(4-((5-amino-7-(butylamino)-2H-pyrazolo[4,3-d]pyrimidin-2yl)methyl)-3-methoxyphenyl)piperazin-1-yl)-5-oxopentyl)stearamide (Compound B-1) Step 1: 5-Azido-2-(4-bromo-2-methoxybenzyl)-N-butyl-2H-pyrazolo[4,3d]pyrimidin-7-amine

[485] 5-Azido-N-butyl-1H-pyrazolo[4,3-d]pyrimidin-7-amine (Int. 2-1, 938 mg, 4.04 mmol), 4-bromo-1-(bromomethyl)-2-methoxybenzene (1.36 g, 4.86 mmol) and K2CO3 (1.2 g, 8.68 mmol) were combined in DMF (20 mL) at room temperature. After overnight stirring, the mixture was diluted with H2O, then extracted with EtOAc (3x). The combined organic extracts were washed with brine, dried (Na2SO4), filtered, then the filtrate was concentrated. The crude product was subjected to silica gel chromatography (0 to 50% EtOAc:EtOH / heptane 3:1) to give the title compound. MS m / z (M+H)+: calculated 431.3, observed 431.0. Petition 870260002828, dated 12 / 01 / 2026, pp. 160 / 237 151 / 211 Step 2: tert-butyl 4-(4-((5-azido-7-(butylamino)-2H-pyrazolo[4,3-d]pyrimidin-2yl)methyl)-3-methoxyphenyl)piperazine-1-carboxylate

[486] 5-Azido-2-(4-bromo-2-methoxybenzyl)-N-butyl-2H-pyrazolo[4,3-d]pyrimidin-7-amine (1.38 g, 3.20 mmol), tert-butyl piperazine-1-carboxylate (0.775 g, 4.16 mmol) and CS2CO3 (3.13 g, 9.60 mmol) were combined in 1,4-dioxane (20 mL). The mixture was degassed (3 x pump / N2). RuPhos Pd G2 (0.25 g, 0.322 mmol) was added, and the mixture was heated to 100 °C. After overnight agitation at 100 °C, the mixture was cooled to room temperature, diluted with EtOAc and filtered through a Celite® pad, washed with EtOAc, then the filtrate was concentrated. The crude product was subjected to silica gel chromatography (0 to 50% EtOAc:EtOH / heptane 3:1) to give the title compound. MS m / z (M+H)+: calculated 537.3, observed 537.1. Step 3: 5-azido-N-butyl-2-(2-methoxy-4-(piperazin-4-yl)benzyl)-2Hpyrazolo[4,3-d]pyrimidin-7-amine

[487] A solution of tert-butyl 4-(4-((5-azido-7-(butylamino)-2H-pyrazolo[4,3d]pyrimidin-2-yl)methyl)-3-methoxyphenyl)piperazine-1-carboxylate (799 mg, 1.489 mmol) in DCM (8 mL), TFA dioxane (1.5 mL, 19.47 mmol) at room temperature. After 2 hours, the mixture was concentrated. The residue was taken in DCM:heptane 1:1, concentrated (2x), then dried under vacuum to give the TFA salt of the title compound, which was used directly in the next step. MS m / z (M+H)+: calculated 437.2, observed 437.1. Step 4: tert-butyl (5-(4-(4-((5-azido-7-(butylamino)-2H-pyrazolo[4,3-d]pyrimidin-2yl)methyl)-3-methoxyphenyl)piperazin-1-yl)-5-oxopentyl)carbamate

[488] 5-((tert-butoxycarbonyl)amino)pentanoic acid (421 mg, 1.936 mmol) and HATU (736 mg, 1.936 mmol) were combined in DCM (5 mL), in Petition 870260002828, dated 12 / 01 / 2026, pp. 161 / 237 152 / 211 followed by DIEA (1,300 mL, 7.45 mmol) was added at room temperature. After 1 hour, a solution of crude 5-azido-N-butyl-2-(2-methoxy-4(piperazin-1-yl)benzyl)-2H-pyrazolo[4,3-d]pyrimidin-7-amine (TFA salt, 650 mg, 1.489 mmol) in DCM (10 mL) was added. After stirring overnight at room temperature, the mixture was concentrated. The crude product was subjected to silica gel chromatography (0 to 100% DCM:MeOH / DCM 9:1) to give an impure product which was subsequently purified by silica gel chromatography (0 to 100% EtOAc:EtOH / heptane 3:1) to give the title compound. MS m / z (M+H)+: calculated 636.4, observed 636.2. Step 5: 5-amino-1-(4-(4-((5-azido-7-(butylamino)-2H-pyrazolo[4,3d]pyrimidin-2-yl)methyl)-3-methoxyphenyl)piperazin-1-yl)pentan-1-one

[489] tert-butyl(5-(4-(4-((5-azido-7-(butylamino)-2H-pyrazolo[4,3-d]pyrimidin-2-yl)methyl)-3-methoxyphenyl)piperazin-1-yl)-5-oxopentyl)carbamate (848 mg, 1.334 mmol) was taken in DCM (10 mL) and then TFA (1.1 mL, 14.28 mmol) was added at room temperature. After 90 minutes, the mixture was concentrated to give the TFA salt of the title compound, which was used directly in the next step. MS m / z (M+H)+: calculated 536.3, observed 536.3. Step 6: N-(5-(4-(4-((5-azido-7-(butylamino)-2H-pyrazolo[4,3-d]pyrimidin-2yl)methyl)-3-methoxyphenyl)piperazin-1-yl)-5-oxopentyl)stearamide

[490] Stearic acid (493 mg, 1.734 mmol) and HATU (659 mg, 1.734 mmol) were combined in DCM (5 mL), then DIEA (1.2 mL, 6.87 mmol) was added at room temperature. After 30 minutes, the mixture was transferred to a flask containing crude 5-amino-1-(4-(4-((5-azido-7-(butylamino)-2H-pyrazolo[4,3-d]pyrimidin-2-yl)methyl)-3-methoxyphenyl)piperazin-1-yl)pentan-1-one (TFA salt, 715 mg, 1.334 mmol) and DCM (10 mL). After stirring overnight at room temperature, the mixture was concentrated. The crude product was Petition 870260002828, dated 12 / 01 / 2026, pp. 162 / 237 153 / 211 submitted to silica gel chromatography (0 to 100% DCM:MeOH / DCM at 9:1) to give an impure product which was subsequently purified by silica gel chromatography (0 to 100% EtOAc:EtOH / heptane at 3:1) to give the title compound. MS m / z (M+H)+: calculated 802.6, observed 802.9. Step 7: N-(5-(4-(4-((5-amino-7-(butylamino)-2H-pyrazolo[4,3-d]pyrimidin-2yl)methyl)-3-methoxyphenyl)piperazin-1-yl)-5-oxopentyl)stearamide

[491] N-(5-(4-(4-((5-azido-7-(butylamino)-2H-pyrazolo[4,3-d]pyrimidin-2-yl)methyl)-3-methoxyphenyl)piperazin-1-yl)-5-oxopentyl)stearamide (641 mg, 0.799 mmol) was taken in THF (8 mL):H2O (0.800 mL), resulting in a thick suspension. The mixture was heated to 50 °C and, as the mixture heated, the suspension became a solution. To this solution, 1 M trimethylphosphine (2.4 mL, 2.400 mmol) was added in THF and heating continued at 50 °C. After 3 hours, the mixture was cooled to room temperature, cooled with MeOH, and then concentrated. The crude product was subjected to silica gel chromatography (0 to 15% MeOH:DCM) to give the title compound. Compound B1: MS m / z (M+H)+: calculated 776.6, observed 776.5. 1H NMR (400 MHz, DMSOd6) δ 11.5 (br., 1H), 8.11 (s, 1H), 7.72 - 7.65 (m, 2H), 7.06 - 6.80 (m, 1H), 6.60 (s, 1H), 6.49 - 6.47 (m, 1H), 6.32 (s, 1H), 5.32 (s, 2H), 3.81 (s, 3H), 3.57 - 3.42 (m, 6H), 3.32 - 3.02 (m, 4H), 2.36 - 2.32 (m, 2H), 2.07 - 1.99 (m, 4H), 1.47 - 1.34 (m, 8H), 1.29 - 1.18 (m, 30H), 0.91 - 0.83 (m, 6H).

[492] Using the procedures described for Compound B-1, the following compounds were prepared by replacing the appropriate reagents with stearic acid. Petition 870260002828, dated 12 / 01 / 2026, pp. 163 / 237 154 / 211 Table 7 Comp. R Name Calc. [M+H]+ Observed [M+H]+ B-2 Me N-(5-(4-(4-((5-amino-7(butylamino)-2 H pyrazolo[4,3-d ]pyrimidin-2yl)methyl)-3methoxyphenyl)piperazin-1-yl)5oxopentyl)tetradecanamida 720.5 720.5 B-3 N-(5-(4-(4-((5-amino-7(butylamino)-2 H pyrazolo[4,3-d ]pyrimidin-2yl)methyl)-3methoxyphenyl)piperazin-1-yl)5-oxopentyl)oleamide 774.6 774.6 B-4 ^Me (9 Z,12Z)-N-(5-(4-(4-((5amino-7-(butylamino)-2 H pyrazolo[4,3-d ]pyrimidin-2yl)methyl)-3methoxyphenyl)piperazin-1-yl)5-oxopentyl)octadeca-9,12dienamida 772.6 772.5 Preparation of Compound B-5 PMeTHF:H2O (10:1) Petition 870260002828, de 12 / 01 / 2026, pág. 164 / 237 155 / 211 N -(5-(4-(4-((5-amino-7-(butylamino)-2 H -pyrazolo[4,3-d ]pyrimidin-2yl)methyl)-3-methoxyphenyl)-1,4-diazepan-1-yl)-5-oxopentyl)stearamide Step 1: N-(5-(4-(4-((5-azido-7-(butylamino)-2H-pyrazolo[4,3-d]pyrimidin-2yl)methyl)-3-methoxyphenyl)-1,4-diazepan-1-yl)-5-oxopentyl)stearamide

[493] To a mixture of 2-(4-(1,4-diazepan-1-yl)-2-methoxybenzyl)-5-azido-N-butyl-2H-pyrazolo[4,3-d]pyrimidin-7-amine hydrochloride (Int. 14-1, 300 mg, 0.666 mmol) and 5-stearamidopentanoic acid (Int. 7-4, 383 mg, 0.999 mmol) in DMF (5 mL), HATU (506 mg, 1.332 mmol) and DIEA (0.349 mL, 1.998 mmol) were added at room temperature. After 2 hours, the mixture was diluted with water (100 mL), then extracted with EtOAc (3 x 100 mL). The combined organic layers were washed with brine (3 x 100 mL), dried (Na2SO4), filtered, and then the filtrate was concentrated. The crude product was subjected to silica gel chromatography (0 to 6% MeOH / DCM) to give the title compound. MS m / z (M+H)+: calculated 816.6, observed 816.7. Step 2: N-(5-(4-(4-((5-amino-7-(butylamino)-2H-pyrazolo[4,3-d]pyrimidin-2yl)methyl)-3-methoxyphenyl)-1,4-diazepan-1-yl)-5-oxopentyl)stearamide

[494] To a solution of N-(5-(4-(4-((5-azido-7-(butylamino)-2H-pyrazolo[4,3-d]pyrimidin-2-yl)methyl)-3-methoxyphenyl)-1,4-diazepan-1-yl)-5oxopentil)stearamide (290 mg, 0.355 mmol) in THF (3 mL):H2O (0.60 mL), PMe3 (1.066 mL, 1.066 mmol) was added, then the mixture was heated to 50 °C. After heating overnight, the mixture was cooled to room temperature and then cooled with MeOH (5 mL), then the resulting mixture was Petition 870260002828, dated 12 / 01 / 2026, pp. 165 / 237 156 / 211 concentrated. The crude product was subjected to silica gel chromatography (0 to 6% MeOH / DCM) to give the title compound. Compound B-5: MS m / z (M+H)+: calculated 790.6, observed 790.6. 1H NMR (400 MHz, DMSO-d6) δ 8.16 (s, 1H), 7.72 (d, J = 7.2 Hz, 1H), 7.60 - 7.56 (m, 1H), 6.93 (d, J = 8.0 Hz, 1H), 6.31 - 6.27 (m, 2H), 6.19 (s, 2H), 5.26 (s, 2H), 3.79 (s, 3H), 3.66 - 3.39 (m, 8H), 3.29 3.27 (m, 2H), 2.99 - 2.95 (m, 2H), 2.26 (t, J=7.2Hz, 1H), 2.16 (t, J 7.2Hz, 1H), 2.03 - 1.98 (m, 2H), 1.87 - 1.76 (m, 2H), 1.59 - 1.55 (m, 2H), 1.47 - 1.22 (m, 36H), 0.90 (t, J = 7.2 Hz, 3H), 0.85 (t, J = 7.2 Hz, 3H).

[495] Using the procedures described for Compound B-5, the following compounds were prepared by substituting the appropriate reagents with 2-(4-(1,4-diazepan-1-yl)-2-methoxybenzyl)-5-azido-N-butyl-2Hpyrazolo[4,3-d]pyrimidin-7-amine hydrochloride and 5-stearamidopentanoic acid in step 1. Table 8 Comp . / Ex. n° R Name Calc. [M+H]+ Observed [M+H]+ B-6 Ar O ,— / N H2N \= / \ / / N —' OMe μθ^ / χ^νη N-(5-(4-(4-((5-amino-7(butylamino))-2 H pyrazole[4,3-d ]pyrimidine2-yl)methyl)-3methoxyphenyl)piperidine-1yl)-5oxopentyl)stearamide 775.6 775.6 B-7 Ar o / —' ? H2N \= / Γ PN—' OMe N-(5-(3-(4-((5-amino-7(butylamino)-2) H pyrazolo[4,3-d ]pyrimidin2-yl)methyl)-3methoxyphenyl)azetidin-1yl)-5oxopentyl)stearamide 747.6 747.6 Petition 870260002828, of 12 / 01 / 2026, p. 166 / 237 157 / 211 Comp . / Ex. n° R Name Calc. [M+H]+ Observed [M+H]+ B-8 O / —7 O H2N \= / Γ \ OMe Me^^^NH 1-(4-((5-amino-7(butylamino)-2 H pyrazolo[4,3-d ]pyrimidin2-yl)methyl)-3methoxyphenyl)-N-pyrimidine2-yl)methyl)-3methoxyphenyl)-N-pyrimidine(3)-dip 776.6 776.6 Preparation of Compounds B-9 and B-10 (1 s ,3 s )-3-(2-(4-(4-((5-amino-7-(butylamino)-2 H -pyrazole[4,3-d ]pyrimidin-2 yl)methyl)-3-methoxyphenyl)piperazin-1-yl)-2-oxoethyl)-N-octadecylcyclobutano-B-carboxamide (B-carboxamide) Petition 870260002828, dated 12 / 01 / 2026, pág. 167 / 237 158 / 211 and (1 s ,3 s )-3-(2-(4-(4-((5-amino-7-(butylamino)-2 H -pyrazolo[4,3-d ]pyrimidin-2 yl)methyl)-3-methoxyphenyl)piperazin-1-yl)-2-oxoethyl)-N -hexadecylcyclobutane-1 carboxamida (B-10) Etapa 1: (1s,3s)-3-(2-(4-(4-((5-amino-7-(butylamino)-2H-pyrazole[4,3 Petition 870260002828, dated 12 / 01 / 2026, pág. 168 / 237 159 / 211 d]pyrimidin-2-yl)methyl)-3-methoxyphenyl)piperazin-1-yl)-2-oxoethyl)-Noctadecylcyclobutane-1-carboxamida and (1s,3s)-3-(2-(4-(4-((5-amino-7(butylamino)-2H-pyrazolo[4,3-d]pyrimidin-2-yl)methyl)-3-methoxyphenyl)piperazin-1yl)-2-oxoethyl)-N-hexadecylcyclobutane-1-carboxamida

[496] To a stirred mixture of 2-(3-(octadecylcarbamoyl)cyclobutyl)acetic acid (Int. 9-1 as an 80:20 mixture) with 2-((1s,3s)-3-(hexadecylcarbamoyl)cyclobutyl)acetic acid, 0.3 g, 0.732 mmol), DMAP (8.95 mg, 0.073 mmol), DIEA (0.192 mL, 1.098 mmol), EDC (0.211 g, 1.098 mmol) and HOBt (0.148 g, 1.098 mmol) in DMF (10 mL), a solution of N7-butyl-2-(2-methoxy-4-(piperazin-1-yl)benzyl)-2H-pyrazolo[4,3d]pyrimidine-5,7-diamine (0.391 g, 0.952 mmol) in DMF (10 mL) at 25 °C. After 6 hours, the mixture was diluted with H2O, then extracted with EtOAc (3 x 10 mL). The combined organic layers were washed with brine (3 x 10 mL), dried (Na2SO4), filtered, and then the filtrate was concentrated. The crude product was subjected to silica gel chromatography (0 to 20% MeOH / DCM) to give a purified mixture of the title compounds.The mixture was subsequently purified by chiral chromatography (CHIRALPAK OD, 30% EtOH in hexanes containing 0.1% TFA modifier) ​​to give P1 and P2.

[497] P1: (1s,3s)-3-(2-(4-(4-((5-amino-7-(butylamino)-2H-pyrazolo[4,3-d]pyrimidin-2-yl)methyl)-3-methoxyphenyl)piperazin-1-yl)-2-oxoethyl)-N hexadecylcyclobutane-1-carboxamide Compound B-10 MS m / z (M+H)+: calculated 774.6, observed 774.6. 1H NMR (400 MHz, DMSO-d6) δ 8.37 (br., 1H), 7.67 (s, 1H), 7.58 (t, J = 5.6 Hz, 1H), 6.96 (d, J = 8.4 Hz, 1H), 6.60 (d, J = 2.4 Hz, 1H), 6.50 6.43 (m, 1H), 5.32 (s, 2H), 3.80 (s, 3H), 3.55 - 3.43 (m, 5H), 3.16 - 3.11 (m, 2H), 2.99 - 2.95 (m, 2H), 2.85 - 2.73 (m, 1H), 2.46 - 2.43 (m, 4H), 2.14 - 2.13 (m, 2H), 1.76 - 1.75 (m, 2H), 1.58 -1.55 (m, 2H), 1.23 (s, 32H), 0.95 - 0.85 (m, 6H).

[498] P2: (1s,3s)-3-(2-(4-(4-((5-amino-7-(butylamino)-2H-pyrazolo[4,3 Petition 870260002828, dated 12 / 01 / 2026, pp. 169 / 237 160 / 211 d ]pyrimidin-2-yl)methyl)-3-methoxyphenyl)piperazin-1-yl)-2-oxoethyl)-N octadecylcyclobutane-1-carboxamide Compound B-9: MS m / z (M+H)+: calculated 802.6, observed 802.6. 1H NMR (400 MHz, DMSO-d6) δ 8.11 (br., 1H), 7.67 (s, 1H), 7.58 (t, J = 5.6 Hz, 1H), 6.96 (d, J = 8.4 Hz, 1H), 6.60 (d, J = 2.4 Hz, 1H), 6.50 6.43 (m, 1H), 6.18 (br., 1H), 5.32 (s, 2H), 3.80 (s, 3H), 3.55 (t, J = 5.2 Hz, 4H), 3.43 (d, J = 6.8 Hz, 1H), 3.16 - 3.11 (m, 4H), 2.99 - 2.95 (m, 2H), 2.85 - 2.73 (m, 1H), 2.46 - 2.43 (m, 4H), 2.14 - 2.13 (m, 2H), 1.76 - 1.75 (m, 2H), 1.58 -1.55 (m, 2H), 1.23 (s, 34H), 0.93 - 0.80 (m, 6H).

[499] Using the procedures described for Compounds B-9 and B-10, the following compounds were prepared by replacing the appropriate reagents with 2-(3-(octadecylcarbamoyl)cyclobutyl)acetic acid. Table 9 Comp. / Ex. no. R Name Calc. [M+H]+ Observed [M+H]+ Comments B-11 OHN -(3-(4-(4-((5amino-7(butylamino)-2 H pyrazolo[4,3d ]pyrimidin-2yl)methyl)-3methoxyphenyl)pipera zin-1-yl)-3oxopropyl)steara mide 748.6 748.6 B-12 OHN -(7-(4-(4-((5amino-7(butylamino)-2 H pyrazolo[4,3d]pyrimidin-2yl)methyl)-3methoxyphenyl)pipera 804.6 804.7 Petition 870260002828, dated 12 / 01 / 2026, pp. 170 / 237 161 / 211 Comp. / Ex. n° R Name Calc. [M+H]+ Observed [M+H]+ Comments zin-1-yl)-7-oxoheptyl)stearamide B-13 0 HN -(3-(2-(4-(4-((5^^a-minoe7(butylamino)-2 H pyrazolo[4,3d ]pyrimidine-2yl)methylxyphenyl))) zin-1-yl)-2oxoethyl)cyclobutyl)e stearamide 788.6 788.8 B-14 O Me Me HN -(5-(4-(4-((5^''Aminoi-e7(butylamino)-2 H pyrazolo[4,3d ]pyrimidine-2yl)methyl)-3piperathoxyphenyl) zinc-1-yl)-4,4dimethyl-5oxopentyl)ester mida 804.6 804.7 B-15 Me Me QHN -(6-(4-(4-((5amino-7(butylamino)-2 H pyrazolo[4,3d ]pyrimidine-2yl)methyl)-3methoxyphenyl)piper zin-1-yl)-2-methyl-6oxo-hexan-2yl)stearamide 804.6 804.8 B-16 1-(4-(4-((5-amino7-(butylamino)-2 H pyrazolo[4,3d ]pyrimidine-2yl)methyl)-3methoxyphenyl)pipera-1-octacyl)-5 an-1-one 763.6 763.6 B-17 H 1-(4-(4-((5-3 mino7-(butylamino)-2 H pyrazolo[4,3d ]pyrimidin-2yl)methyl)-3methoxyphenyl)pipera zinc-1-yl)-5(octadecylamino)p entan-1-one 76.6 from They. 12-1, then desprotected with HCl in 1,4-dioxane.

[500] Using the procedures described for Compound B-1, the Petition 870260002828, dated 12 / 01 / 2026, pp. 171 / 237 162 / 211 compounds below were prepared by replacing the appropriate reagents with 5-azido-N-butyl-1H-pyrazolo[4,3-d]pyrimidin-7-amine in step 1. OMe Table 10 Comp. / Ex. no. R Name Calc. [M+H]+ Observed [M+H]+ Comments B-18 Me H2N. .N. 7 y γη ΝγΥΝ' Me^^-^NH N -(5-(4-(4-((5-amino-7(butylamino)-3-methyl2 H -pyrazolo[4,3d ]pyrimidin-2-yl)methyl)3methoxyphenyl)piperazin1-yl)-5oxopentyl)stearamide 790.6 790.6 from Int. 2-3 EXAMPLE 5 Preparation of Compound C-1 Petition 870260002828, dated 12 / 01 / 2026, pp. 172 / 237 163 / 211 (9 Z,12 Z)-N -(4-((4-((5-amino-7-(butylamino)-2 H -pyrazolo[4,3-d ]pyrimidin-2yl)methyl)-3,5-dimethoxybenzyl)(methyl)amino)butyl)octadeca-9,12-dienamide (Compound C-1) Step 1: tert-butyl (4-((5-azido-7-(butylamino)-2H-pyrazolo[4,3-d]pyrimidin-2-yl)methyl)3,5-dimethoxybenzyl)(methyl)carbamate

[501] To a mixture of tert-butyl (4-(chloromethyl)-3,5-dimethoxybenzyl)(methyl)carbamate (Int. 2-1, 1 g, 3.03 mmol) in DMF (20 mL), 5-azido-N-butyl-1H-pyrazolo[4,3-d]pyrimidin-7amine (Int. 4-1, 0.634 g, 2.73 mmol) and K2CO3 (0.503 g, 3.64 mmol) were added at room temperature. After 2 h, the mixture was diluted with H2O (20 mL), then extracted Petition 870260002828, dated 12 / 01 / 2026, pp. 173 / 237 164 / 211 with EtOAc (3 x 30 mL). The combined organic extracts were washed with brine (2 x 30 mL), dried (Na2SO4), filtered, and then the filtrate was concentrated. The crude product was subjected to silica gel chromatography (0 to 70% EtOAc / petroleum ether) to give the title compound. MS m / z (M+H)+: calculated 526.3, observed 526.3. Step 2: 5-azido-N-butyl-2-(2,6-dimethoxy-4-((methylamino)methyl)benzyl)-2Hpyrazolo[4,3-d]pyrimidin-7-amine

[502] To a solution of tert-butyl (4-((5-azido-7-(butylamino)-2H-pyrazolo[4,3d]pyrimidin-2-yl)methyl)-3,5-dimethoxybenzyl)(methyl)carbamate (1.2 g, 2.283 mmol) in DCM (10 mL), TFA (2 mL) was added at room temperature. After 3 hours, the mixture was concentrated to give the TFA salt of the title compound, which was used directly in the next step. MS m / z (M+H)+: calculated 426.2, observed 426.3. Step 3: tert-butyl (4-((4-((5-azido-7-(butylamino)-2H-pyrazolo[4,3-d]pyrimidin-2yl)methyl)-3,5-dimethoxybenzyl)(methyl)amino)butyl)carbamate

[503] To a mixture of crude 5-azido-N-butyl-2-(2,6-dimethoxy-4-((methylamino)methyl)benzyl)-2H-pyrazolo[4,3-d]pyrimidin-7-amine (TFA salt, 1.1 g, 2.163 mmol) and tert-butyl (4-oxobutyl)carbamate (Int. 5-1, 0.608 g, 3.24 mmol) in DCM (8 mL), NaBH(OAc)3 (0.917 g, 4.33 mmol) was added at room temperature. After 3 hours, the mixture was concentrated. The crude product was subjected to silica gel chromatography (0 to 20% MeOH / DCM) to give the title compound. MS m / z (M+H)+: calculated 597.4, observed 597.5. Step 4: N1-(4-((5-azido-7-(butylamino)-2H-pyrazolo[4,3-d]pyrimidin-2yl)methyl)-3,5-dimethoxybenzyl)-N1-methylbutane-1,4-diamine

[504] To a solution of tert-butyl (4-((4-((5-azido-7-(butylamino)-2H-pyrazolo[4,3d]pyrimidin-2-yl)methyl)-3,5-dimethoxybenzyl)(methyl)amino)butyl)carbamate (790 mg, 1.324 mmol) in DCM (10 mL), TFA (2 mL) was added to Petition 870260002828, dated 12 / 01 / 2026, pp. 174 / 237 165 / 211 room temperature. After 3 hours, the mixture was concentrated to give the TFA salt of the title compound, which was used directly in the next step. MS m / z (M+H)+: calculated 497.3, observed 497.4. Step 5: (9Z,12Z)-N-(4-((4-((5-azido-7-(butylamino)-2H-pyrazolo[4,3d]pyrimidin-2-yl)methyl)-3,5-dimethoxybenzyl)(methyl)amino)butyl)octadeca-9,12dienamide

[505] To a mixture of crude N-(4-((5-azido-7-(butylamino)-2H-pyrazolo[4,3d]pyrimidin-2-yl)methyl)-3,5-dimethoxybenzyl)-N1-methylbutane-1,4-diamine (TFA salt, 447 mg, 0.9 mmol) in DCM (6 mL), DIEA (0.314 mL, 1.800 mmol) and (9Z,12Z)-octadeca-9,12-dienoyl chloride (296 mg, 0.990 mmol) were added at 0 °C. After the additions were completed, the mixture was heated to room temperature. After 2 hours, EtOAc (30 mL) was added and the mixture was washed with saturated NaHCO3 (2 x 30 mL). The organic layer was dried (Na2SO4), filtered, and then the filtrate was concentrated. The crude product was subjected to silica gel chromatography (0 to 15% MeOH / DCM) to give the title compound. MS m / z (M+H)+: calculated 759.5, observed 759.6. Step 6: (9Z,12Z)-N-(4-((4-((5-amino-7-(butylamino)-2H-pyrazolo[4,3d]pyrimidin-2-yl)methyl)-3,5-dimethoxybenzyl)(methyl)amino)butyl)octadeca-9,12dienamide

[506] To a mixture of (9Z,12Z)-N-(4-((4-((5-azido-7-(butylamino)-2Hpyrazolo[4,3-d]pyrimidin-2-yl)methyl)-3,5-dimethoxybenzyl)(methyl)amino)butyl)octadeca-9,12-dienamide (430 mg, 0.566 mmol) in THF (5 mL) and water (0.5 mL), trimethylphosphane (1 M in THF, 1.699 mL, 1.699 mmol) was added, and the mixture was then heated to 50 °C. After 16 hours, the mixture was cooled to room temperature and diluted with EtOAc (30 mL). The resulting mixture was washed with water (30 mL), dried (Na2SO4), filtered, and the filtrate was concentrated. The crude product was purified by preparative TLC. Petition 870260002828, dated 12 / 01 / 2026, pp. 175 / 237 166 / 211 using MeOH / DCM / ammonia (1 / 10 / 0.05) to give the title compound. Compound C-1: MS m / z (M+H)+: calculated 733.5, observed 733.5. 1H NMR (400 MHz, CD3OD): δ 7.49 (s, 1H), 6.70 (s, 2H), 5.46 (s, 2H), 5.33 - 5.28 (m, 4H), 3.85 (s, 6H), 3.52 - 3.48 (m, 4H), 3.16 (t, J = 6.4 Hz, 2H), 2.74 (t, J = 6.2 Hz, 2H), 2.41 (t, J = 7.1 Hz, 2H), 2.22 (s, 3H), 2.14 (t, J = 7.5 Hz, 2H), 2.04 - 2.01 (m 4H), 1.66 - 1.41 (m, 10H), 1.36- 1.29 (m, 14H), 0.97 (t, J = 7.4 Hz, 3H), 0.88 (t, J = 6.8 Hz, 3H).

[507] Using the procedures described for Compound C-1, the following compounds were prepared by replacing the appropriate reagents with (9 Z,12 Z )-octadeca-9,12-dienoyl chloride. Table 11 With p· R Calc Name· [M+H]+ Observed [M+H]+ C-2 Μ and N-(4-((4-((5-amino-7(butylamino)-2 H pyrazolo[4,3d ]pyrimidin-2yl)methyl)-3,5dimethoxybenzyl)(methyl)amino)butyl)tetradec anamide 681.5 681.7 C-3 N-(4-((4-((5-amino-7(butylamino)-2H pyrazolo[4,3d]pyrimidin-2yl)methyl)-3,5dimethoxybenzyl)(methyl)amino)butyl)oleamid a 735.6 735.6 Petition 870260002828, dated 12 / 01 / 2026, pp. 176 / 237 167 / 211 With p· R Name Calc. [M+H]+ Observed [M+H]+ C-4 N-(4-((4-((5-amino-7(butylamino)-2 H pyrazolo[4,3d ]pyrimidin-2yl)methyl)-3,5dimethoxybenzyl)(methyl )amino)butyl)stearamide 737.6 737.8 Preparation of Compound C-5 N -(4-((4-((5-amino-7-(butylamino)-2 H -pyrazolo[4,3-d ]pyrimidin-2-yl)methyl)3,5-dimethoxybenzyl)(methyl)amino)-4-oxobutyl)stearamide Petition 870260002828, dated 12 / 01 / 2026, pp. 177 / 237 168 / 211 Step 1: N-(4-((4-((5-azido-7-(butylamino)-2H-pyrazolo[4,3-d]pyrimidin-2yl)methyl)-3,5-dimethoxybenzyl)(methyl)amino)-4-oxobutyl)stearamide

[508] A mixture of 4-stearamidobutanoic acid (Int. 7-1, 132 mg, 0.357 mmol), 5-azido-N-butyl-2-(2,6-dimethoxy-4-((methylamino)methyl)benzyl)-2H-pyrazolo[4,3-d]pyrimidin-7-amine hydrochloride (Compound C-1 step 2, 110 mg, 0.238 mmol), HATU (181 mg, 0.476 mmol) and DIEA (0.208 mL, 1.191 mmol) in DMF (3 mL) was stirred at room temperature. After overnight stirring, the mixture was purified directly by reversed-phase chromatography (CHECN / water with 0.05% FA modifier) ​​to obtain the title compound. MS m / z (M+H)+: calculated 777.5, observed 777.6. Step 2: N-(4-((4-((5-amino-7-(butylamino)-2H-pyrazolo[4,3-d]pyrimidin-2yl)methyl)-3,5-dimethoxybenzyl)(methyl)amino)-4-oxobutyl)stearamide

[509] To a solution of N-(4-((4-((5-azido-7-(butylamino)-2H-pyrazolo[4,3d]pyrimidin-2-yl)methyl)-3,5-dimethoxybenzyl)(methyl)amino)-4-oxobutyl)stearamide (160 mg, 0.206 mmol) in THF (3 mL):H2O (0.60 mL), PMe3 (1 M in THF, 0.618 mL, 0.618 mmol) was added and the mixture was heated to 50 °C. After 5 hours, the mixture was cooled to room temperature and then cooled with MeOH (5 mL) in Petition 870260002828, dated 12 / 01 / 2026, pp. 178 / 237 169 / 211 followed the resulting mixture was concentrated. The crude product was purified by reversed-phase chromatography (1:3 CH3CN:MeOH / water) to give the title compound. Compound C-5: MS m / z (M+H)+: calculated 751.6, observed 751.6. 1H NMR (400 MHz, DMSO-d6) δ 7.99 - 7.54 (m, 2H), 7.37 (d, J = 3.6 Hz, 1H), 6.54 (d, J = 19.6 Hz, 2H), 5.92 (s, 2H), 5.36 (s, 2H), 4.54 (d, J = 16.8Hz, 2H), 3.79 (d, J = 8.4Hz, 6H), 3.44 - 3.39 (m, 2H), 3.10 - 3.00 (m, 2H), 2.93 (s, 2H), 2.84 (s, 1H), 2.38 2.33 (m, 2H), 2.03 - 1.98 (m, 2H), 1.70 - 1.65 (m, 2H), 1.60 - 1.55 (m, 2H), 1.34 1.30 (m, 2H), 1.22 (d, J = 3.2 Hz, 30H), 0.90 - 0.82 (m, 6H). EXAMPLE 6 Preparation of Compound D-1 nh2 (4-((4-((5-amino-7-(butylamino)-2H-pyrazolo[4,3-d]pyrimidin-2-yl)methyl)3,5-dimethoxybenzyl)(methyl)amino)butyl)heptatriaconta-6,9,28,31-tetraen-19-yl (Compound D-1) Step 1: (4-((4-((5-azido-7-(butyl-amino)-2H-pyrazolo[4,3-d]pyrimidin-2yl)methyl)-3,5-dimethoxybenzyl)(methyl)-amino)butyl)carbamate (6Z,9Z,28Z,31Z) Petition 870260002828, dated 12 / 01 / 2026, p. 179 / 237 170 / 211 heptatriaconta-6,9,28,31-tetraen-19-ila

[510] To a mixture of (4-nitrophenyl) carbonate of (6Z,9Z,28Z,31Z)heptatriaconta-6,9,28,31-tetraen-19-yl (Int. 6-1, 355 mg, 0.511 mmol) and N 1-(4((5-azido-7-(butylamino)-2H-pyrazolo[4,3-d]pyrimidin-2-yl)methyl)-3,5-dimethoxybenzyl)-N1-methylbutane-1,4-diamine crude (TFA salt, 274 mg, 0.460 mmol) in THF (5 mL), K2CO3 (0.058 mL, 1.023 mmol) was added and the mixture was heated to 65 °C. After 15 hours, the mixture was cooled to room temperature, then concentrated. The crude product was subjected to silica gel chromatography (0 to 10% MeOH / DCM) to give the title compound. MS m / z (M+H)+: calculated 1051.8, observed 1052.0. Step 2: (4-((4-((5-amino-7-(butylamino)-2H-pyrazolo[4,3-d]pyrimidin-2yl)methyl)-3,5-dimethoxybenzyl)(methyl)-amino)butyl)carbamate of (6Z,9Z,28Z,31Z)heptatriaconta-6,9,28,31-tetraen-19-yl

[511] To a mixture of (4-((4-((5-azido-7-(butylamino)-2H-pyrazolo[4,3d]pyrimidin-2-yl)methyl)-3,5-dimethoxybenzyl)(methyl)-amino)butyl)carbamate of (6Z,9Z,28Z,31Z)-heptatriaconta-6,9,28,31-tetraen-19-yl (500 mg, 0.475 mmol) in THF (10 mL) and H2O (1.0 mL), trimethylphosphane (1 M in THF, 1.426 mL, 1.426 mmol) was added at room temperature. After 15 hours, the mixture was cooled with MeOH (1.42 mL), then concentrated. The crude product was purified by preparative TLC (DCM:MeOH = 10:1) to give the title compound. Compound D-1: MS m / z (M+H)+: calculated 1025.8, observed 1025.7. 1H NMR (300 MHz, CD3OD): δ 7.65 (s, 1H), 6.71 (s, 2H), 5.49 (s, 2H), 5.35 - 5.32 (m, 8H), 4.86 - 4.85 (m, 1H), 3.86 (s, 6H), 3.56 - 3.55 (m, 4H), 3.12 - 3.10 (m, 2H), 2.77 - 2.75 (m, 4H), 2.45 - 2.43 (m, 2H), 2.25 (s, 3H), 2.05 - 2.03 (m, 8H), 1.68 1.66 (m, 6H), 1.46 - 1.44 (m, 6H), 1.32 - 1.27 (m, 36H), 0.97 - 0.94 (m, 9H). Preparation of Compound D-2 Petition 870260002828, dated 12 / 01 / 2026, pp. 180 / 237 171 / 211 4-(4-((5-amino-7-(butylamino)-2H-pyrazolo[4,3-d]pyrimidin-2-yl)methyl)-3methoxyphenyl)-N -(3-stearamidopropyl)piperazine-1-carboxamide Step 1: 4-(4-((5-amino-7-(butylamino)-2H-pyrazolo[4,3-d]pyrimidin-2yl)methyl)-3-methoxyphenyl)-N-(3-stearamidopropyl)piperazine-1-carboxamide

[512] A mixture of N-(3-aminopropyl)stearamide (Int. 8-1, 457 mg, 1.342 mmol), CDI (136 mg, 0.839 mmol), DMAP (13.67 mg, 0.112 mmol) and DIEA (0.586 mL, 3.36 mmol) in DCM (10 mL) was stirred at 0 °C. After 30 minutes, N7-butyl-2-(2-methoxy-4-(piperazin-1-yl)benzyl)-2H-pyrazolo[4,3d]pyrimidine-5,7-diamine hydrochloride (500 mg, 1.119 mmol) was added. The mixture was Petition 870260002828, dated 12 / 01 / 2026, pp. 181 / 237 172 / 211 heated to room temperature and then heated to 50 °C. After 3 hours, the mixture was cooled to room temperature and then concentrated. The crude product was purified by reverse-phase chromatography (CH3CN / water with 0.1% TFA modifier) ​​to give the title compound. Compound D-2: MS m / z (M+H)+: calculated 777.6, observed 777.6. RMN1H (300 MHz, DMSO-d6) δ 8.89 (s, 1H), 7.83 - 7.55 (m, 2H), 7.16 - 6.98 (m, 2H), 6.60 - 6.48 (m, 2H), 5.34 (s, 2H), 3.80 (s, 3H), 3.47 (s, 6H), 3.12 (s, 4H), 3.04 - 3.01 (m, 4H), 2.03 (t, J = 7.2 Hz, 2H), 1.60 - 1.48 (m, 6H), 1.22 (s, 28H), 0.96 - 0.77 (m, 6H). Preparation of Compound D-3 3-stearamidopropyl 4-(4-((5-amino-7-(butylamino)-2H-pyrazolo[4,3-d]pyrimidin-2-yl)methyl)-3methoxyphenyl)piperazine-1-carboxylate Petition 870260002828, dated 12 / 01 / 2026, pp. 182 / 237 173 / 211 Step 1: 3-stearamidopropyl 4-(4-((5-azido-7-(butylamino)-2H-pyrazolo[4,3-d]pyrimidin-2yl)methyl)-3-methoxyphenyl)piperazine-1-carboxylate

[513] A mixture of (3-stearamidopropyl) 4-nitrophenyl carbonate (Int. 6-2, 130 mg, 0.257 mmol), 5-azido-N-butyl-2-(2-methoxy-4-(piperazin-1yl)benzyl)-2H-pyrazolo[4,3-d]pyrimidin-7-amine (Compound B-1 step 3, 56 mg, 0.128 mmol) and DIEA (0.045 mL, 0.257 mmol) in DCM (0.5 mL) was stirred at room temperature. After 1 hour, the mixture was purified directly by preparative TLC (DCM / MeOH = 15:1) to give the title compound. MS m / z (M+H)+: calculated 804.6, observed 804.7. Step 2: 3-stearamidopropyl 4-(4-((5-amido-7-(butylamino)-2H-pyrazolo[4,3-d]pyrimidin-2yl)methyl)-3-methoxyphenyl)piperazine-1-carboxylate

[514] To a solution of 4-(4-((5-azido-7-(butylamino)-2H-pyrazolo[4,3d]pyrimidin-2-yl)methyl)-3-methoxyphenyl)piperazine-1-carboxylate (80 mg, 0.099 mmol) in THF (3 mL):H2O (0.5 mL), PMe3 (1 M in THF, 0.298 mL, 0.298 mmol) was added and the mixture was heated to 50 °C. After 5 hours, the mixture was cooled to room temperature and then cooled with MeOH (5 mL) Petition 870260002828, dated 12 / 01 / 2026, pp. 183 / 237 174 / 211 resulting mixture was concentrated. The crude product was purified by preparative TLC (DCM:MeOH = 10:1) to give the title compound. Compound D-3: MS m / z (M+H)+: calculated 778.6, observed 778.6. 1H NMR (400MHz, DMSOd6) δ 7.80 (t, J = 5.6Hz, 1H), 7.64 (s, 1H), 7.55 (s, 1H), 6.91 (d, J = 8.0Hz, 1H), 6.60 (d, J = 2.0Hz, 1H), 6.49 - 6.45 (m, 1H), 5.56 (s, 2H), 5.29 (s,2H), 4.01 (t, J = 6.4 Hz, 2H), 3.80 (s, 3H), 3.49 - 3.38 (m, 6H), 3.14 - 3.11 (m, 6H), 2.03 (t, J = 7.2 Hz, 2H), 1.71 - 1.68 (m, 2H), 1.58 - 1.53 (m, 2H), 1.47 - 1.26 (m, 4H), 1.28 - 1.15 (m, 28H), 0.91 - 0.83 (m, 6H). Preparation of Compound D-4 tmscf3, tbaf THF OH Tf2O OTf diea, 1,4-dioxane pyridine, DCM N -(5-(4-(4-((5-amino-7-(butylamino)-2H-pyrazolo[4,3-d]pyrimidin-2yl)methyl)-3-methoxyphenyl)piperazin-1-yl)-6,6,6-trifluorohexyl)stearamide Petition 870260002828, dated 12 / 01 / 2026, pp. 184 / 237 175 / 211 Step 1: 6-chloro-1,1,1-trifluorohexan-2-ol

[515] To a solution of 5-chloropentanal (4.5 g, 37.3 mmol) and trimethyl(trifluoromethyl)silane (6.37 g, 44.8 mmol) in THF (80 mL), tetrabutylammonium fluoride (0.485 mL, 0.485 mmol, 1 M in THF) at 0 °C was added. After 1 hour, the cooling bath was removed and the mixture heated to room temperature. After 2 hours, the mixture was cooled with 1N HCl (60 mL). After stirring for 2 hours, the mixture was diluted with water (60 mL) and extracted with EtOAc (35 mL x 2). The combined organic layers were dried (Na2SO4), filtered, and then the filtrate was concentrated. The crude product was subjected to silica gel chromatography (0 to 5% EtOAc / petroleum ether) to give the title compound. 1H NMR (400 MHz, CDCL) δ 3.99 - 3.83 (m, 1H), 3.56 (t, J = 6.4 Hz, 2H), 2.85 - 2.66 (m, 1H), 1.90 - 1.79 (m, 2H), 1.78 - 1.68 (m, 2H), 1.67 1.54 (m, 2H). Step 2: 6-chloro-1,1,1-trifluorohexan-2-yl trifluoromethanesulfonate

[516] To a solution of 6-chloro-1,1,1-trifluorohexan-2-ol (1.6 g, 8.39 mmol) and pyridine (1.013 mL, 12.59 mmol) in DCM (25 mL), anhydride was added Petition 870260002828, dated 12 / 01 / 2026, pp. 185 / 237 176 / 211 trifluoromethanesulfonic acid (1.702 mL, 10.07 mmol) was added dropwise at 0 °C. After 1 hour, the cooling bath was removed and the mixture heated to room temperature. After 2 hours, the mixture was diluted with water (10 mL) and extracted with EtOAc (15 mL x 2). The combined organic layers were washed with 1 N HCl (20 mL) and saturated NaHCO3, dried (Na2SO4), filtered, and then the filtrate was concentrated to give the title compound, which was used in the next step without purification. 1H NMR (400 MHz, CDCb) δ 5.11 - 4.96 (m, 1H), 3.58 (t, J = 6.4 Hz, 2H), 2.06 - 1.96 (m, 2H), 1.94 - 1.82 (m, 2H), 1.79 - 1.62 (m, 2H). Step 3: N7-butyl-2-(4-(4-(6-chloro-1,1,1-trifluorohexan-2-yl)piperazin-1-yl)2-methoxybenzyl)-2H-pyrazolo[4,3-d]pyrimidine-5,7-diamine

[517] A solution of N-butyl-2-(2-methoxy-4-(piperazin-1-yl)benzyl)-2H-pyrazolo[4,3-d]pyrimidine-5,7-diamine (1.4 g, 3.41 mmol) in 1,4-dioxane (16 mL), DIEA (1.787 mL, 10.23 mmol) and 6-chloro-1,1,1-trifluorohexan-2-yl trifluoromethanesulfonate (1.650 g, 5.12 mmol) was heated to 80 °C. After overnight heating, the mixture was cooled to room temperature and concentrated. The crude product was purified by reversed-phase chromatography (CH3CN / water with NH4HCO3 modifier at 10 mM) to give the desired compound. MS m / z (M+H)+: calculated 583.3, observed 583.4. 1H NMR (400 MHz, CD3OD) δ 7.52 (s, 1H), 7.08 (d, J = 8.4 Hz, 1H), 6.57 (d, J = 2.0 Hz, 1H), 6.50 (dd, J = 2.0, 8.4 Hz, 1H), 5.32 (s, 2H), 3.81 (s, 3H) 1.47 - 1.38 (m, 2H), 0.96 (t, J = 7.2 Hz, 3H). Step 4: 2-(4-(4-(6-azido-1,1,1-trifluorohexan-2-yl)piperazin-1-yl)-2methoxybenzyl)-N7-butyl-2H-pyrazolo[4,3-d]pyrimidine-5,7-diamine

[518] A solution of N-butyl-2-(4-(4-(6-chloro-1,1,1-trifluoro-hexan-2-yl)piperazin-1-yl)-2-methoxybenzyl)-2H-pyrazolo[4,3-d]pyrimidine-5,7-diamine (160 Petition 870260002828, dated 12 / 01 / 2026, pp. 186 / 237 (177 / 211 mg, 0.274 mmol) in DMF (2 mL), sodium azide (80 mg, 1.231 mmol) was added and the mixture was heated to 100 °C. After 2 hours, the mixture was cooled to room temperature and diluted with water (5 mL). The pH was adjusted to > 9 with saturated NaHCO3 (15 mL) and then the mixture was extracted with EtOAc (15 mL x 2). The combined organic layers were dried (Na2SO4), filtered, and then the filtrate was concentrated. The crude product was purified by preparative TLC (DCM / MeOH=10:1) to give the title compound. MS m / z (M+H)+: calculated 590.3, observed 590.3. Step 5: 2-(4-(4-(6-amino-1,1,1-trifluorohexan-2-yl)piperazin-1-yl)-2methoxybenzyl)-N7-butyl-2H-pyrazolo[4,3-d]pyrimidine-5,7-diamine

[519] To a solution of 2-(4-(4-(6-azido-1,1,1-trifluorohexan-2-yl)piperazin-1-yl)-2-methoxybenzyl)-N-butyl-2H-pyrazolo[4,3-d]pyrimidine-5,7diamine (100 mg, 0.170 mmol) in MeOH (2 mL), Pd / C (18.05 mg) was added. The mixture was purged with H2 (15 psi). After 2 hours, the mixture was concentrated. The crude product was purified by preparative TLC (DCM / MeOH=10:1) to give the title compound. MS m / z (M+H)+: calculated 564.3, observed 564.3. Step 6: N-(5-(4-(4-((5-amino-7-(butylamino)-2H-pyrazolo[4,3-d]pyrimidin-2yl)methyl)-3-methoxyphenyl)piperazin-1-yl)-6,6,6-trifluorohexyl)stearamide

[520] A solution of 2-(4-(4-(6-amino-1,1,1-trifluoro-hexan-2-yl)piperazin-1-yl)-2-methoxybenzyl)-N-butyl-2H-pyrazolo[4,3-d]pyrimidine-5,7diamine (60 mg, 0.106 mmol) in DCM (2 mL), DIEA (0.056 mL, 0.319 mmol) and stearoyl chloride (32.2 mg, 0.106 mmol) was prepared at room temperature. After 2 hours, the mixture was concentrated. The crude product was purified by reverse-phase chromatography (CH3CN / water with 0.2% FA modifier) ​​to give the title compound. Compound D-4: MS m / z (M+H)+: calculated 830.6, observed 830.5. RMN1H (400 MHz, CD3OD) δ 7.63 (s, 1H), 7.14 (d, J = 8.4 Hz, 1H), 6.58 (d, J = 2.0 Hz, 1H), 6.52 (dd, J = 2.0, 8.4 Hz, 1H), 5.37 (s, Petition 870260002828, dated 12 / 01 / 2026, pp. 187 / 237 178 / 211 2H), 3.83 (s, 3H), 3.58 (t, J = 7.2 Hz, 2H), 3.25 - 3.12 (m, 7H), 3.10 - 3.03 (m, 2H), 2.84 - 2.75 (m, 2H), 2.19 - 2.11 (m, 2H), 1.78 - 1.51 (m, 9H), 1.40 (s, 3H), 1.32 1.20 (m, 28H), 0.98 (t, J = 7.2 Hz, 3H), 0.89 (t, J = 6.8 Hz, 3H). Preparation of Compound D-5 N -(4-((4-((7-(butylamino)-5-hydroxy-2H-pyrazolo[4,3-d ]pyrimidin-2yl)methyl)-3,5-dimethoxybenzyl)(methyl)amino)butyl)stearamide Petition 870260002828, dated 12 / 01 / 2026, pp. 188 / 237 179 / 211 Step 1: tert-butyl (4-((7-(butylamino)-5-chloro-2H-pyrazolo[4,3-d]pyrimidin-2-yl)methyl)3,5-dimethoxybenzyl)(methyl)carbamate

[521] To a solution of N-butyl-5-chloro-2H-pyrazolo[4,3-d]pyrimidin-7amine (Int. 2-1 step 1, 800 mg, 3.54 mmol) in DMF (15 mL), tert-butyl (4(chloromethyl)-3,5-dimethoxybenzyl)(methyl)carbamate (Int. 4-1, 1169 mg, 3.54 mmol) and K2CO3 (1470 mg, 10.63 mmol) was added at room temperature. After stirring overnight, the mixture was diluted with water (80 mL), then extracted with EtOAc (15 mL x 3). The combined organic layers were washed with brine (20 mL x 2), dried (Na2SO4), filtered, and then the filtrate was concentrated. The crude product was subjected to silica gel chromatography (0 to 40% EtOAc / petroleum ether) to give the title compound. MS m / z (M+H)+: calculated 519.2, observed 519.3. 1H NMR (400 MHz, CD3OD) δ 7.88 (s, 1H), 6.59 (s, 2H), 5.57 (s, 2H), 4.44 (s, 2H), 3.85 (s, 6H), 3.55 (t, J = 7.2 Hz, 2H), 2.86 (s, 3H), 1.66 (quin, J = 7.2 Hz, 2H), 1.48 (br s, 9H), 1.45 - 1.39 (m, 2H), 0.98 (t, J = 7.6 Hz, 3H). Petition 870260002828, dated 12 / 01 / 2026, pp. 189 / 237 180 / 211 Step 2: N-butyl-5-chloro-2-(2,6-dimethoxy-4-((methylamino)methyl)benzyl)-2Hpyrazolo[4,3-d]pyrimidin-7-amine

[522] To a solution of tert-butyl (4-((7-(butylamino)-5-chloro-2H-pyrazolo[4,3d]pyrimidin-2-yl)methyl)-3,5-dimethoxybenzyl)(methyl)carbamate (1 g, 1.927 mmol) in DCM (15 mL), TFA (3 mL) was added at room temperature. After 3 hours, the mixture was concentrated to give the TFA salt of the title compound, which was used without purification. MS m / z (M+H)+: calculated 419.2, observed 419.3. 1H NMR (400 MHz, CD3OD) δ 7.99 (s, 1H), 6.85 (s, 2H), 5.65 (s, 2H), 4.19 (s, 2H), 3.91 (s, 6H), 3.63 (t, J = 7.2 Hz, 2H), 2.74 (s, 3H), 1.68 (quin, J = 7.2 Hz, 2H), 1.44 (qd, J = 7.6, 15.2 Hz, 2H), 0.98 (t, J = 7.6 Hz, 3H). Step 3: tert-butyl (4-((4-((7-(butylamino)-5-chloro-2H-pyrazolo[4,3-d]pyrimidin-2yl)methyl)-3,5-dimethoxybenzyl)(methyl)amino)butyl)carbamate

[523] To a solution of N-butyl-5-chloro-2-(2,6-dimethoxy-4-((methylamino)methyl)benzyl)-2H-pyrazolo[4,3-d]pyrimidin-7-amine (300 mg, 0.716 mmol) in DMF (10 mL), DIEA (0.375 mL, 2.148 mmol) and tert-butyl (4-bromobutyl)carbamate (217 mg, 0.859 mmol) were added, and the mixture was heated to 40 °C. After overnight heating, the mixture was cooled to room temperature with water (50 mL) and extracted with EtOAc (10 mL x 3). The combined organic layers were washed with brine (30 mL), dried (Na2SO4), filtered, and then the filtrate was concentrated. The crude product was subjected to silica gel chromatography (0 to 5% MeOH / DCM) to give the title compound. MS m / z (M+H)+: calculated 590.3, observed 590.3. Step 4: N1-(4-((7-(butylamino)-5-chloro-2H-pyrazolo[4,3-d]pyrimidin-2yl)methyl)-3,5-dimethoxybenzyl)-N1-methylbutane-1,4-diamine

[524] To a solution of tert-butyl (4-((4-((7-(butylamino)-5-chloro-2H-pyrazolo[4,3d]pyrimidin-2-yl)methyl)-3,5-dimethoxybenzyl)(methyl)amino)butyl)carbamate (250 mg, 0.424 mmol) in DCM (5 mL), TFA (1 mL) was added to Petition 870260002828, dated 12 / 01 / 2026, pp. 190 / 237 181 / 211 room temperature. After overnight stirring, the mixture was concentrated to give the TFA salt of the title compound, which was used without purification. MS m / z (M+H)+: calculated 490.3, observed 490.3. Step 5: N-(4-((4-((7-(butylamino)-5-chloro-2H-pyrazolo[4,3-d]pyrimidin-2yl)methyl)-3,5-dimethoxybenzyl)(methyl)amino)butyl)stearamide

[525] To a solution of N1-(4-((7-(butylamino)-5-chloro-2H-pyrazolo[4,3d]pyrimidin-2-yl)methyl)-3,5-dimethoxybenzyl)-N1-methylbutane-1,4-diamine (200 mg, 0.408 mmol) in DCM (5 mL), DIEA (0.214 mL, 1.224 mmol) and stearoyl chloride (124 mg, 0.408 mmol) were added at 0 °C. After the addition was complete, the mixture was heated to room temperature. After 2 hours, the mixture was diluted with water (15 mL), then extracted with DCM (3 mL x 3). The combined organic layers were washed with brine (15 mL), dried (Na2SO4), filtered, then the filtrate was concentrated. The crude product was subjected to silica gel chromatography (0 to 5% MeOH / DCM) to give the title compound. MS m / z (M+H)+: calculated 756.5, observed 756.4. Step 6: N-(4-((4-((7-(butylamino)-5-hydroxy-2H-pyrazolo[4,3-d]pyrimidin-2yl)methyl)-3,5-dimethoxybenzyl)(methyl)amino)butyl)stearamide

[526] To a solution of N-(4-((4-((7-(butylamino)-5-chloro-2H-pyrazolo[4,3d]pyrimidin-2-yl)methyl)-3,5-dimethoxybenzyl)(methyl)amino)butyl)stearamide (90 mg, 0.119 mmol) in DMSO (7.5 mL), K2CO3 (49.3 mg, 0.357 mmol) and acetohydroxamic acid (17.86 mg, 0.238 mmol) were added, and the mixture was then heated to 140 °C by microwave irradiation for 2 hours. Acetohydroxamic acid (17.86 mg, 0.238 mmol) was added and the mixture was heated to 140 °C by microwave irradiation for 2 hours. The mixture was diluted with water (20 mL) and extracted with DCM (3 mL x 3). The combined organic layers were washed with brine (15 mL), dried (Na2SO4), filtered, and then the filtrate was concentrated. The crude product was purified by Petition 870260002828, dated 12 / 01 / 2026, pp. 191 / 237 182 / 211 reversed-phase chromatography (CH3CN / water with 0.2% FA modifier) ​​to give the title compound. Compound D-5: MS m / z (M+H)+: calculated 738.6, observed 738.4. 1H NMR (400 MHz, CD3OD) δ 7.41 (s, 1H), 6.76 (s, 2H), 5.46 (s, 2H), 3.88 (s, 6H), 3.77 (br s, 2H), 3.53 (t, J = 7.2 Hz, 2H), 3.18 (t, J = 6.8 Hz, 2H), 2.71 - 2.61 (m, 2H), 2.41 (s, 3H), 2.16 (t, J = 7.2 Hz, 2H), 1.68 - 1.61 (m, 4H), 1.60 - 1.50 (m, 4H), 1.43 (dd, J = 7.2, 15.2 Hz, 2H), 1.27 (br s, 28H), 0.97 (t, J = 7.2 Hz, 3H), 0.92 - 0.86 (m, 3H). Preparation of Compound D-6 HCl 1,4-dioxane (6Z,9Z,28Z,31Z)heptatriaconta-6,9,28,31-tetraen-19-yl Petition 870260002828, dated 12 / 01 / 2026, pp. 192 / 237 183 / 211 Step 1: (5-(4-(4-((5-amino-7-(butylamino)-2H-pyrazole[4,3-d]pyrimidine-2yl)methyl)-3-methoxyphenyl)piperazin-1-yl)-5-oxopentyl)tert-butyl carbamate

[527] To a solution of 5-(( tert -butoxycarbonyl)amino)pentanoic acid (0.699 g, 3.22 mmol) in DMF (20 ml), TEA (0.678 g, 6.70 mmol) and HATU (1.528 g, 4.02 mmol) were added at room temperature. After 20 minutes, N7-butyl-2-(2-methoxy-4-(piperazin-1-yl)benzyl)-2H-pyrazolo[4,3- d]pyrimidine-5,7-diamine (1.1 g, 2.68 mmol). After overnight stirring, the mixture was filtered and purified directly by reverse-phase chromatography (CH3CN / water with 10 mM NH4HCO3 modifier) ​​to obtain the title compound. MS m / z (M+H)+: calculated 610.4, observed 610.5. 1H NMR (400 MHz, CD3OD) δ 7.53 (s, 1H), 7.11 (d, J = 8.4 Hz, 1H), 6.60 (d, J = 2.0 Hz, 1H), 6.53 (dd, J = 2.0, 8.4 Hz, 1H), 5.34 (s, 2H), 3.83 (s, 3H), 3.75 - 3.65 (m, 4H), 3.50 (t, J=7.2Hz, 2H), 3.25 - 3.21 (m, 2H), 3.20 - 3.16 (m, 2H), 3.06 (t, J=6.8Hz, 2H), 2.45 (t, J=7.6 Hz, 2H), 1.68 - 1.59 (m, 4H), 1.57 - 1.49 (m, 2H), 1.48 - 1.43 (m, 2H), 1.41 (s, 9H), 0.97 (t, J = 7.2 Hz, 3H). Step 2: 5-amino-1-(4-(4-((5-amino-7-(butylamino)-2H-pyrazolo[4,3d]pyrimidin-2-yl)methyl)-3-methoxyphenyl)piperazin-1-yl)pentan-1-one

[528] To a solution of tert-butyl (5-(4-(4-((5-amino-7-(butylamino))-2H-pyrazolo[4,3-d ]pyrimidin-2-yl)methyl)-3-methoxyphenyl)piperazin-1-yl)-5oxopentyl)carbamate (800 mg, 1.312 mmol) in DCM (10 ml), Petition 870260002828, dated 12 / 01 / 2026, pp. 193 / 237 184 / 211 TFA (2 ml) was added at room temperature. After 1 hour, the mixture was concentrated to give the TFA salt of the title compound, which was used without purification. MS m / z (M+H)+: calculated 510.3, observed 510.3. Step 3: (6Z,9Z,28Z,31Z)heptatriaconta-6,9,28,31-tetraen-19-yl

[529] To a solution of 5-amino-1-(4-(4-((5-amino-7-(butylamino)-2Hpyrazolo[4,3-d]pyrimidin-2-yl)methyl)-3-methoxyphenyl)piperazin-1-yl)pentan-1-one (660 mg, 1.295 mmol) in DMF (8 mL) and THF (8 mL), DIEA (4.52 mL, 25.9 mmol) and (4-nitrophenyl)carbonate of (6Z,9Z,28Z,31Z)-heptatriaconta6,9,28,31-tetraen-19-yl (Int. 6-1, 1168 mg, 1.683 mmol) were added at room temperature. After 30 minutes, the mixture was diluted with water (20 mL), then extracted with EtOAc (20 mL x 2). The combined organic layers were dried (Na2SO4), filtered, and then the filtrate was concentrated. The crude product was subjected to silica gel chromatography (0 to 10% MeOH / DCM) to give the title compound with impurities. The compound was subsequently purified by reverse-phase chromatography (CH3CN / water with 0.1% TFA modifier) ​​to give the title compound as the TFA salt. The salt was taken in saturated NaHCO3 (20 mL) and then extracted with EtOAc (20 mL x 2).The combined organic layers were dried (Na2SO4), filtered, and then the filtrate was concentrated to give the title compound. Compound D-6: MS m / z (M+H)+: calculated 1064.8, observed 1064.8. 1H NMR (400 MHz, CD3OD) δ 7.61 (s, 1H), 7.14 (d, J = 8.4 Hz, 1H), 6.60 (d, J = 1.6 Hz, 1H), 6.53 (dd, J = 2.0, 8.4 Hz, 1H), 5.39 - 5.26 (m, 10H), 4.67 (td, J = 6.0, 12.0 Hz, 1H), 3.84 (s, 3H), 3.74 - 3.66 (m, 4H), 3.55 (t, J = 7.2 Hz, 2H), 3.25 - 3.21 (m, 2H), 3.20 - 3.16 (m, 2H), 3.13 (br t, J = 6.4 Hz, 2H), 2.76 (t, J = 6.0 Hz, 4H), 2.46 (br t, J = 7.2 Hz, 2H), 2.09 - 2.00 (m, 8H), 1.70 - 1.61 (m, 4H), 1.56 - 1.47 (m, 5H), 1.45 - 1.39 (m, 2H), 1.35 - 1.25 (m, 36H), 0.97. Petition 870260002828, dated 12 / 01 / 2026, pp. 194 / 237 185 / 211 (t, J = 7.2 Hz, 3H), 0.90 (t, J = 6.8 Hz, 6H). EXAMPLE 7 Preparation of Pneumococcal Polysaccharide-Carrier Protein Conjugates

[530] One or more polysaccharides (as highlighted below and in the Tables and Examples) were dissolved, sized to a target molecular weight, chemically activated, and subjected to ultrafiltration buffer exchange. The activated polysaccharide and purified CRM197 (a carrier protein) were individually lyophilized and redissolved in DMSO. The redissolved polysaccharide and CRM197 solutions were then combined and conjugated as described below. The resulting conjugate was purified by ultrafiltration before a final filtration through a 0.2 µm filter. Several process parameters at each step, such as pH, temperature, concentration, and time, were controlled to produce conjugates with the desired attributes. Polysaccharide Size Reduction

[531] Purified pneumococcal capsular polysaccharide powder (also referred to as Ps) was dissolved in water. Except for ST-19A (the serotype is also referred to as ST), which was not reduced in size, the dissolved polysaccharide was filtered through a 0.45 µm filter and homogenized or subjected to acid hydrolysis to reduce the molecular weight of Ps. The target size of Ps was achieved for homogenization by controlling the pressure and the number of passes. The target size of Ps was obtained for acid hydrolysis by controlling the temperature and time. The polysaccharide was then filtered through a 0.2 µm filter, concentrated, and diafiltered against water using a 5 or 10 kDa NMWCO tangential flow ultrafiltration membrane. O-Deacetylation (ST-15B only)

[532] The reduced-size Ps ST-15B solution was heated to 60 °C Petition 870260002828, dated 12 / 01 / 2026, pp. 195 / 237 186 / 211 and sodium bicarbonate buffer pH 9.4 was added until a final concentration of 50 mM was reached. The mixture was incubated at 60 °C to release O-acetyl groups. Potassium phosphate buffer pH 6 was added to neutralize the pH, and the solution was cooled to room temperature. The solution was then concentrated and diafiltered against water using a 5 or 10 kDa NMWCO tangential flow ultrafiltration membrane. Deketalization (ST-4 only)

[533] The reduced-size Ps ST-4 solution was adjusted to 50 °C and pH 4.1 with a sodium acetate buffer to partially decetalize the polysaccharide. The polysaccharide solution was then cooled to 22 °C before activation. Polysaccharide Oxidation

[534] The polysaccharide solution was adjusted to 22 °C for all serotypes except for ST-5, 7F, and 19F, which were adjusted to 4 °C. The solution was also adjusted to pH 4-5 with a sodium acetate buffer to minimize polysaccharide size reduction due to activation. Polysaccharide activation was initiated by adding a sodium metaperiodate solution. The amount of sodium metaperiodate added was controlled to achieve a target level of polysaccharide activation (moles of aldehyde per mole of repeating unit of the polysaccharide).

[535] The activated product for all serotypes, except ST-5, was diafiltered against 10 mM potassium phosphate, pH 6.4, followed by diafiltration against water using a 5 or 10 kDa NMWCO tangential flow ultrafiltration membrane. For ST-5, the activated product was diafiltered against 10 mM sodium acetate, pH 4.1, followed by diafiltration against water using a 5 kDa NMWCO tangential flow ultrafiltration membrane. Ultrafiltration was conducted at 2-8 °C for all serotypes. Petition 870260002828, dated 12 / 01 / 2026, pp. 196 / 237 187 / 211 Conjugation of polysaccharides to CRM197

[536] Purified CRM197, obtained by expression in Pseudomonas fluorescens as previously described (WO 2012 / 173876 A1), was diafiltered against 2 mM phosphate buffer, pH 7.2, using a 5 kDa NMWCO tangential flow ultrafiltration membrane and filtered through a 0.2 μm filter. The activated polysaccharides were formulated for lyophilization with water and sucrose. CRM197 was formulated for lyophilization at 6 mg Pr / mL (CRM197 protein is also referred to as “Pr”) with a sucrose concentration of 1% w / v. The formulated solutions of Ps and CRM197 were lyophilized individually. The lyophilized materials of Ps and CRM197 were redissolved individually in equal volumes of DMSO. Additives such as salt were added to Ps-DMSO for some serotypes. Polysaccharide and CRM197 solutions were combined to achieve a target polysaccharide concentration and a polysaccharide to CRM197 mass ratio.The mass ratio was selected to control the polysaccharide ratio for CRM197 in the resulting conjugate. A reducing agent, such as sodium cyanoborohydride, was added for most serotypes, and conjugation proceeded at 22 °C. Final Reduction

[537] A reducing agent, such as sodium borohydride, was added after the conjugation reaction and incubated at 22 °C for all serotypes. The batch was diluted in 150 mM sodium chloride, with approximately 0.025% (w / v) polysorbate 20, at approximately 4 °C. Potassium phosphate buffer was then added to neutralize the pH. Some batches were concentrated and diafiltered at approximately 4 °C against 150 mM sodium chloride, 25 mM potassium phosphate, pH 7, using a 30 kDa NMWCO tangential flow ultrafiltration membrane. Final Filtration and Product Storage Petition 870260002828, dated 12 / 01 / 2026, pp. 197 / 237 188 / 211

[538] Individual batches were then concentrated and diafiltered against 10 mM histidine in 150 mM sodium chloride, pH 7.0, with 0.015% (w / v) PS-20, at 4 °C, using a 300 kDa NMWCO tangential flow ultrafiltration membrane. Specifically, for ST-5, halfway through the diafiltration step, the ST-5 conjugate was collected and incubated with 50 mM sodium bicarbonate, pH 9.3, for 3 hours. The ST-5 solution was neutralized with 1.5 M potassium phosphate, pH 6.0, before completing the diafiltration.

[539] Individual batches of retentate were filtered through a 0.2 µm filter (with a 0.5 µm pre-filter) and then diluted with an additional 10 mM histidine in 150 mM sodium chloride, pH 7.0, with 0.015% (w / v) PS-20, dispensed into aliquots and frozen at < -60 °C. Details on the specific conjugates for each serotype can be found in previous descriptions (WO2011 / 100151, WO2019 / 139692 and WO2020 / 131763). EXAMPLE 8 Formulation of Pneumococcal Conjugate Compositions

[540] Individual pneumococcal polysaccharide-carrier protein conjugates, prepared using different chemistries, as described in Example 7, were used to formulate a 1- or 24-valent pneumococcal conjugate composition, designated PCV1 or PCV24, respectively.

[541] The PCV1 formulation, to be added to Compound A-1-SNE, Compound B-1-SNE, or Compound D-1-SNE, contained serotype 6B conjugated using reductive amination, as described in the Examples above, and formulated in 20 mM L-histidine pH 5.8, 150 mM NaCl, and 0.1% (w / v) PS-20 for a final concentration of 0.4 pg / mL (w / v) of pneumococcal polysaccharide (PnPs) in the vaccine. The PCV1 vaccine formulation, prepared with APA and serotype 6B conjugated by reductive amination in an aprotic solvent (DMSO), as described in Example 7, was formulated in 20 mM L-histidine pH 5.8, Petition 870260002828, dated 12 / 01 / 2026, pp. 198 / 237 189 / 211 150 mM NaCl and 0.2% (w / v) PS-20 and 250 μg (Al) / mL in the form of APA for a final concentration of 0.4 μg / mL (w / v) of pneumococcal polysaccharide (PnPs) in the vaccine.

[542] The PCV24 formulation, to be added to compound A-1-SNE for the IRM study, contained serotypes 1, 3, 4, 5, 6A, 6B, 7F, 8, 9V, 10A, 11A, 12F, 14, 15A, de-O-Ac15B, 18C, 19A, 19F, 22F, 23B, 23F, 24F, 33F and 35B, all conjugated to CRM197 using reductive amination and formulated in 20 mM L-histidine, pH 5.8, 150 mM NaCl and 0.1% PS-20. Each carrier protein-polysaccharide conjugate was formulated at 0.8 μg / mL (w / v) of pneumococcal polysaccharide (PnPs) for a final concentration of 19.2 μg / mL of PnPs in the vaccine.

[543] The PCV24 formulation, with or without APA for the IRM study, contained serotypes 1, 3, 4, 5, 6A, 6B, 7F, 8, 9V, 10A, 11A, 12F, 14, 15A, de-O-Ac15B, 18C, 19A, 19F, 22F, 23B, 23F, 24F, 33F and 35B, all conjugated to CRM197 as described in the Examples above, using reductive amination and formulated in 20 mM L-Histidine, pH 5.8, 150 mM NaCl and 0.2% PS-20 and 250 pg (Al) / mL in the form of APA (if required). Each polysaccharide-carrier protein conjugate was formulated at 4.0 μg / mL (w / v) of pneumococcal polysaccharide (PnPs) for a final concentration of 96 μg / mL of PnPs in the vaccine.

[544] PCV20, which contains the following serotypes (1, 3, 4, 5, 6A, 6B, 7F, 8, 9V, 10A, 11A, 12F, 14, 15B, 18C, 19A, 19F, 22F, 23F, 33F), all conjugated to CRM197, was acquired from Myonex.

[545] The PCV26 formulation, to be added to compound B-1-SNE for the mouse study, contained serotypes 1, 3, 4, 5, 6A, 6B, 7F, 8, 9V, 10A, 11A, 12F, 14, 15A, de-O-Ac15B, Ac15B, 18C, 19A, 19F, 22F, 23B, 23F, 24F, 33F, and 35B, all conjugated to CRM197 using reductive amination and formulated in 20 mM L-histidine, pH 5.8, 150 mM NaCl, and 0.1% PS-20. Each conjugate Petition 870260002828, dated 12 / 01 / 2026, pp. 199 / 237 The 190 / 211 polysaccharide-carrier protein was formulated at 0.8 pg / mL (w / v) of pneumococcal polysaccharide (PnPs) for a final concentration of 19.2 pg / mL of PnPs in the vaccine.

[546] To prepare the PCV formulations, the required volumes of monovalent conjugates by volume to obtain the indicated final concentration of pneumococcal polysaccharide (w / v) (also known as PnPs) were calculated based on the batch volume or mass and the polysaccharide concentration by volume.

[547] The formulation process consisted of preparing a volume combination of conjugates at a final concentration of 2X of PnP combinations in 20 mM Histidine, 0.05 to 0.15% (w / v) PS-20 and 150 mM sodium chloride, pH 5.8.

[548] Solutions of Histidine pH 5.8, PS-20, and sodium chloride were prepared and added to the formulation vessel. Individual pneumococcal polysaccharide-carrier protein conjugates, stored frozen, were thawed at 2-8 °C and then added to the formulation vessel. During the addition of the polysaccharide-carrier protein conjugate to the formulation buffer (conjugate combination), the vessel was mixed to ensure homogeneity using a magnetic stir bar or a magnetic impeller. After all additions were made and the solution was stirred, the conjugate combination was passed through sterilizing filters and collected in a container with or without APA. In some cases, the sterilizing filters were washed with 150 mM sodium chloride to adjust the batch to the desired concentration.

[549] The formulations were packaged in plastic syringes, glass syringes or vials. EXAMPLE 9 Petition 870260002828, dated 12 / 01 / 2026, pp. 200 / 237 191 / 211 Preparation of a Stable Nanoemulsion Adjuvant System (SNE) With and Without Compounds

[550] SNE adjuvant formulations are prepared as described in the examples above, using the following compounds: (N -(5-(4-(4-((5-amino-7-(butylamino)-2H-pyrazolo[4,3-d]pyrimidin-2yl)methyl)-3,5-dimethoxyphenyl)piperazin-1-yl)-5-oxopentyl)stearamide (Compound A1); (5)-N -(5-(4-(4-((5-amino-7-((1-hydroxypentan-2-yl)amino)-2H-pyrazolo[4,3d]pyrimidin-2-yl)methyl)-3,5-dimethoxyphenyl)piperazin-1-yl)-5-oxopentyl)stearamide (Compound A-2); (5 )-1-(4-(4-((5-amino-7-((1-hydroxypentan-2-yl)amino)-2H-pyrazolo[4,3d ]pyrimidin-2-yl)methyl)-3,5-dimethoxyphenyl)piperazin-1-yl)octadecan-1-one (Compound A-3); N -(5-(4-(4-((5-amino-7-(butylamino)-2H-pyrazolo[4,3-d]pyrimidin-2-yl)methyl)3-methoxyphenyl)piperazin-1-yl)-5-oxopentyl)stearamide (Compound B-1); N -(5-(4-(4-((5-amino-7-(butylamino)-2 H-pyrazolo[4,3-d ]pyrimidin-2-yl)methyl)3-methoxyphenyl)piperazin-1-yl)-5-oxopentyl)tetradecanoamide (Compound B-2); N -(5-(4-(4-((5-amino-7-(butylamino)-2 H-pyrazolo[4,3-d ]pyrimidin-2-yl)methyl)3-methoxyphenyl)piperazin-1-yl)-5-oxopentyl)oleamide (Compound B-3); (9 Z,12 Z)-N -(5-(4-(4-((5-amino-7-(butylamino)-2 H-pyrazolo[4,3-d ]pyrimidin2-yl)metil)-3-methoxyphenyl)piperazin-1-yl)-5-oxopentyl)octadeca-9,12-dienamide (Composto B-4); N -(5-(4-(4-((5-amino-7-(butylamino)-2 H-pyrazolo[4,3-d ]pyrimidin-2-yl)methyl)3-methoxyphenyl)-1,4-diazepan-1-yl)-5-oxopentyl)stearamide (Compound B-5); N -(5-(4-(4-((5-amino-7-(butylamino)-2 H-pyrazolo[4,3-d ]pyrimidin-2-yl)methyl)3-methoxyphenyl)piperidin-1-yl)-5-oxopentyl)stearamide (Compound B-6); N -(5-(3-(4-((5-amino-7-(butylamino)-2 H-pyrazolo[4,3-d ]pyrimidin-2-yl)methyl) Petition 870260002828, de 12 / 01 / 2026, pág. 201 / 237 192 / 211 3-methoxyphenyl)azetidin-1-yl)-5-oxopentyl)stearamide (Compound B-7); 1-(4-((5-amino-7-(butylamino)-2 H -pyrazolo[4,3-d ]pyrimidin-2-yl)methyl)-3methoxyphenyl)-N-(3-stearamidopropyl)piperidine-4-carboxamide (Compound B-8); (1 s ,3 s )-3-(2-(4-(4-((5-amino-7-(butylamino)-2 H-pyrazolo[4,3-d ]pyrimidin-2 yl)methyl)-3-methoxyphenyl)piperazin-1-yl)-2-oxoethyl)-N -octadecylcyclobutano-1carboxamide (Compound B-9 (1 s ,3 s )-3-(2-(4-(4-((5-amino-7-(butylamino)-2 H-pyrazolo[4,3-d ]pyrimidin-2 yl)methyl)-3-methoxyphenyl)piperazin-1-yl)-2-oxoethyl)-N -hexadecylcyclobutano-1carboxamide (Compound B-10); N -(3-(4-(4-((5-amino-7-(butylamino)-2 H-pyrazolo[4,3-d ]pyrimidin-2-yl)methyl)3-methoxyphenyl)piperazin-1-yl)-3-oxopropyl)stearamide (Compound B-11); N -(7-(4-(4-((5-amino-7-(butylamino)-2 H-pyrazolo[4,3-d ]pyrimidin-2-yl)methyl)3-methoxyphenyl)piperazin-1-yl)-7-oxo-heptyl)stearamide (Compound B-12); N -(3-(2-(4-(4-((5-amino-7-(butylamino)-2 H -pyrazolo[4,3-d ]pyrimidin-2yl)methyl)-3-methoxyphenyl)piperazin-1-yl)-2-oxoethyl)cyclobutyl)esteramide (Compound B-13); N -(5-(4-(4-((5-amino-7-(butylamino)-2 H-pyrazolo[4,3-d ]pyrimidin-2-yl)methyl)3-methoxyphenyl)piperazin-1-yl)-4,4-dimethyl-5-oxopentyl)estearamida (Compound B14); N -(6-(4-(4-((5-amino-7-(butylamino)-2 H-pyrazolo[4,3-d ]pyrimidin-2-yl)methyl)3-methoxyphenyl)piperazin-1-yl)-2-methyl-6-oxo-hexan-2-yl)estearamida (Compound B-15); 1-(4-(4-((5-amino-7-(butylamino)-2H-pyrazolo[4,3-d]pyrimidin-2-yl)methyl)-3methoxyphenyl)piperazin-1-yl)-5-(octadecyloxy)pentan-1-one (Compound B-16); 1-(4-(4-((5-amino-7-(butylamino)-2H-pyrazolo[4,3-d]pyrimidin-2-yl)methyl)-3methoxyphenyl)piperazin-1-yl)-5-(octadecylamino)pentan-1-one (Compound B-17); N-(5-(4-(4-((5-amino-7-(butylamino)-3-methyl-2H-pyrazolo[4,3-d]pyrimidin-2 Petition 870260002828, dated 12 / 01 / 2026, pág. 202 / 237 193 / 211 yl)methyl)-3-methoxyphenyl)piperazin-1-yl)-5-oxopentyl)stearamide (Compound B-18); (9 Z,12 Z)-N -(4-((4-((5-amino-7-(butilamino)-2 H -pyrazolo[4,3-d ]pyrimidin-2yl)metil)-3,5-dimethoxybenzil)(metil)amino)butil)octadeca-9,12-dienamida (Composto C-1); N -(4-((4-((5-amino-7-(butylamino)-2 H -pyrazolo[4,3-d ]pyrimidin-2-yl)methyl)3,5-dimethoxybenzyl)(methyl)amino)butyl)tetradecanoamide (Compound C-2); N -(4-((4-((5-amino-7-(butylamino)-2 H -pyrazolo[4,3-d ]pyrimidin-2-yl)methyl)3,5-dimethoxybenzyl)(methyl)amino)butyl)oleamide (Compound C-3); N -(4-((4-((5-amino-7-(butylamino)-2 H -pyrazolo[4,3-d ]pyrimidin-2-yl)metil)3,5-dimethoxybenzil)(metil)amino)butyl)estearamide (Composto C-4); N-(4-((4-((5-amino-7-(butylamino)-2H-pyrazolo[4,3-d]pyrimidin-2-yl)metil)3,5-dimethoxybenzil)(metil)amino)-4-oxobutyl)estearamide (Composto C-5); (4-((4-((5-amino-7-(butylamino)-2 H -pyrazolo[4,3-d ]pyrimidin-2-yl)methyl)-3,5dimethoxybenzyl)(methyl)amino)butyl)carbamate de (6 Z,9 Z,28 Z,31Z)heptatriaconta-6,9,28,31-tetraen-19-yl (Compound D-1); 4-(4-((5-amino-7-(butylamino)-2H-pyrazolo[4,3-d]pyrimidin-2-yl)methyl)-3methoxyphenyl)-N-(3-estearamidopropyl)piperazine-1-carboxamide (Compound D2); 4-(4-((5-amino-7-(butylamino)-2H-pyrazolo[4,3-d]pyrimidin-2-yl)methyl)-3methoxyphenyl)piperazine-1-carboxylate de 3-estearamidopropyl (Compound) D-3); N-(5-(4-(4-((5-amino-7-(butylamino)-2H-pyrazolo[4,3-d]pyrimidin-2-yl)methyl)3-methoxyphenyl)piperazin-1-yl)-6,6,6-trifluoro-hexyl)estearamida (Compound D-4); N-(4-((4-((7-(butylamino)-5-hydroxy-2H-pyrazolo[4,3-d]pyrimidin-2-yl)methyl)3,5-dimethoxybenzyl)(methyl)amino)butyl)stearamide (Compound D-5), and (6Z,9Z,28Z,31Z)heptatriaconta-6,9,28,31-tetraen-19-yl (5-(4-(4-((5-amino-7-(butylamino)-2H-pyrazolo[4,3-d]pyrimidin-2-yl)methyl)-3methoxyphenyl)piperazin-1-yl)-5-oxopentyl)carbamate (Compound D-6). Petition 870260002828, dated 12 / 01 / 2026, pp. 203 / 237 194 / 211

[551] SNE is a multi-component emulsion formulation consisting of 3 stabilizing ingredients: SPAN-85, PS-20 and squalene with a compound, for example, Compound A-1 (referred to as Compound A-1-SNE, as per Table 12) and without a compound (referred to as SNE, as per Table 13). This formulation is prepared by combining and mixing the compound, SPAN-85, PS-20 and squalene components after dissolving them in 100% EtOH (Table 12).

[552] The production process of the compound-stable nanoemulsion (Compound-SNE) consists of 5 steps: 1) preparation of a solution of a mixture of components including the 3 stabilizing ingredients: SPAN-85, PS-20 and squalene, with a compound; 2) formation of the SNE by means of mixing in a T-pan; 3) ultrafiltration; 4) filtration with bioburden reduction, and 5) sterile filtration and filling into vials. Preparation of the Stabilizing Mixture Solution / Compound

[553] The stabilizing / compound components were weighed and combined before being dissolved in ethanol and before being sterilely filtered to form the component mixture. A histidine buffer (20 mM histidine, pH 5.8) was prepared. Formation of SNE through T-mixing

[554] The mixture of components and the Histidine buffer were then mixed at the adjacent ends of a T-tube mixer. The outflow from the T-mixer was immediately diluted 1:1 with 20 mM histidine, 0.05% PS-20 and 75 mM NaCl and then collected as the formed SNE. Ultrafiltration

[555] The SNE intermediate was then subjected to dialysis or ultrafiltration with a 500 kDa NMWCO to concentrate the material approximately 10 Petition 870260002828, dated 12 / 01 / 2026, pp. 204 / 237 195 / 211 times, as well as to perform buffer exchange of the material against 20 mM Histidine, 0.05% (w / v) PS-20 and 75 mM NaCl, pH 5.8, or 20 mM Histidine, pH 5.8, or 20 mM histidine, 0.05% PS-20, pH 5.8. After dialysis or diafiltration, a final concentration step was performed to achieve the final target concentration. Filtration with Bioload Reduction

[556] The adjuvant volume was then pre-filtered with a 0.45 pm cellulose acetate (CA) filter, followed by a 0.2 pm CA bioburden reduction filter, and stored as a liquid at 4 °C. Sterile Filtration and Filling into Bottles

[557] The adjuvant volume was filtered through a 0.45 pm polyvinylidene fluoride (PVDF) bioburden reduction filter and a 0.22 pm PVDF sterilizing gradient filter and received. The filtered adjuvant volume was then diluted with 20 mM Histidine, 0.05% (w / v) PS-20 and 75 mM NaCl, pH 5.8, until the target SNE adjuvant concentration was reached. This final diluted adjuvant volume was then packaged in glass vials and stored at 4 °C. Table 12: Composition of Compound Adjuvant A-1-SNE Component Description Content of Each Component (% by mol) Molecular Weight (g / mol) Content of Each Component (% by Mass) Compound A-1 N-(5-(4-(4-((5-amino-7(butylamino)-2H-pyrazolo[4,3d]pyrimidin-2-yl)methyl)-3,5-dimethoxyphenyl)piperazin-1-yl)5-oxopentyl)stearamide 2.42-2.71 599.3 2.44-3.03 Squalene Squalene 70.62-79.16 410.72 48.780-60.61 SPAN-85 sorbitan trioleate 10.19-15.15 957.5 18.18-24.39 PS-20 polysorbate-20 7.94-11.81 1228 18.18-24.39 20 mM Histidine Matrix, 0.05% N / A Petition 870260002828, dated 12 / 01 / 2026, pp. 205 / 237 196 / 211 Component Description Content of Each Component (% by mol) Molecular Weight (g / mol) Content of Each Component (% by Mass) PS-20 buffer, 75 mM NaCl, pH 5.8 Table 13: Composition of Compound Adjuvant B-1-SNE Component Description Content of Each Component (% by mol) Molecular Weight (g / mol) Content of Each Component (% by Mass) Compound B-1 N-(5-(4-(4-((5-amino-7(butylamino)-2H-pyrazolo[4,3-d]pyrimidin-2yl)methyl)-3-methoxyphenyl)piperazin-1-yl)-5-oxopentyl)stearamide 1.67-3.73 431.3 1.22-3.03 Squalene Squalene 78.33-141.1 410.72 60.61-97.6 SPAN-85 sorbitan trioleate 2.02-15.1 957.5 4.44-24.4 PS-20 polysorbate-20 1.57-11.7 1228 4.44-24.4 Buffer Matrix 20 mM Histidine, 0 to 0.05% PS-20, 0 to 75 mM NaCl, pH 5.8 to 7.0 N / A Table 14: Composition of C-4-SNE Compound Adjuvant Component Description Content of Each Component (% by mol) Molecular Weight (g / mol) Content of Each Component (% by Mass) Compound C4 N-(4-((4-((5-amino-7-(butylamino)2H-pyrazolo[4,3-d]pyrimidin-2yl)methyl)-3,5-dimethoxybenzyl)(methyl)amino)butyl)e stearamide 2.22 737.6 3.03 Squalene Squalene 79.56 410.72 60.61 SPAN-85 sorbitan trioleate 10.24 957.5 18.18 PS-20 polysorbate-20 7.98 1228 18.18 Buffer Matrix 20 mM Histidine, 0.05% PS-20, 75 mM NaCl, pH 5.8 N / A Table 15: SME Adjuvant Composition Petition 870260002828, dated 12 / 01 / 2026, pp. 206 / 237 197 / 211 Component Description Content of Each Component (% by mol) Molecular Weight (g / mol) Content of Each Component (% by Mass) Squalene Squalene 83.33 410.72 92.91 SPAN-85 sorbitan trioleate 8.33 957.5 3.99 PS-20 polysorbate-20 8.33 1228 3.11 Buffer Matrix 20 mM Histidine, 0.05% PS-20, 75 mM NaCl, pH 5.8 N / A EXAMPLE 9A Alternative Preparation of a Stable Nanoemulsion Adjuvant System (Compound B-1-SNE)

[558] Compound B-1-SNE is a multi-component emulsion formulation consisting of 3 stabilizing ingredients: SPAN-85, PS-20 and squalene, in addition to Compound B-1 (as per Table 16). This formulation is prepared by combining and mixing the components Compound B-1, SPAN-85, PS-20 and squalene after dissolving them in 100% EtOH.

[559] The production process of the stable nanoemulsion compound (Compound B-1-SNE) consists of 5 steps: 1) preparation of a solution of a mixture of components that includes the 3 stabilizing ingredients: SPAN-85, PS-20, squalene and compound B-1; 2) formation of SNE by means of T-mixing or controlled precipitation process using mixing systems to trigger the self-assembly of the nanoemulsion; 3) ultrafiltration; 4) filtration with bioburden reduction, and 5) sterile filtration and filling into vials. Preparation of the Stabilizing Mixture Solution / Compound

[560] The stabilizing / compound components were weighed and combined before being dissolved in ethanol, then heated to 40 °C for 30 minutes and sterile filtered to form the component mixture. Formation of SNE through T-mixing or precipitation process. Petition 870260002828, dated 12 / 01 / 2026, pp. 207 / 237 198 / 211 controlled using mixing systems to trigger the self-assembly of the nanoemulsion.

[561] The mixture of components and the Histidine buffer were then mixed at the adjacent ends of a T-tube mixer or microfluidic set. The output stream from the apparatus was immediately diluted 1:1 with 20 mM Histidine at pH 5.8 and then collected as the formed SNE. Ultrafiltration

[562] The SNE intermediate was then subjected to dialysis or ultrafiltration with a 500 kDa NMWCO to concentrate the material approximately 10 times, as well as to perform buffer exchange of the material against 20 mM Histidine, 0.05% (w / v) PS-20 and 75 mM NaCl, pH 5.8, or 20 mM Histidine, pH 5.8, or 20 mM histidine, 0.05% PS-20, pH 5.8. After dialysis or diafiltration, a final concentration step was performed to achieve the final target concentration.

[563] Solutions of Histidine pH 5.8, PS-20, sodium chloride, L-met, and EDTA were prepared and added to a formulation container. The volume of SNE adjuvant was added to the formulation container. During the addition of SNE to the formulation buffer, the container was stirred to ensure homogeneity using a magnetic stir bar or a magnetic impeller. After all additions were made and the solution was stirred, the formulations were filled into plastic syringes, glass syringes, or vials. Table 16: Composition of Compound Adjuvant B-1-SNE Petition 870260002828, dated 12 / 01 / 2026, pp. 208 / 237 199 / 211 Component Description Content of Each Component (% by mol) Molecular Weight (g / mol) Content of Each Component (% by Mass) Compound B-1 N-(5-(4-(4-((5-amino-7(butylamino)-2H-pyrazolo[4,3-d]pyrimidin-2yl)methyl)-3-methoxyphenyl)piperazin-1-yl)-5-oxopentyl)stearamide 0.01 to 0.1 431.3 0.30-3.03 Squalene Squalene 80.0-98.0 410.72 61.5-97.0 SPAN-85 sorbitan trioleate 1.5-15.0 957.5 3.1-25.0 PS-20 polysorbate-20 1.0-10.0 1228 1.2-24.0 Buffer Matrix 5 to 25 mM Histidine, pH 5.8, 0.05% PS-20, 0 to 75 mM NaCl, 5 to 12 mM L-met, 5 to 10 mM EDTA N / A EXAMPLE 10 Cell-based TLR 7 / 8 assay to assess activity of Compound-SNE

[564] As shown in Figure 1, a cell-based activation system was used to evaluate the activity of Compound-formulated nanoemulsion systems (Compound B-1-SNE), prepared as described in the examples above. HEK-Blue™ TLR7 and TLR8 cells (InvivoGen) were engineered to evaluate TLR7 and TLR8 stimulation by monitoring NF-κB and AP-1 activation. Compound B-1-SNE samples were diluted 1:2 in an 8-point titration in histidine / PS-20 diluent buffer in a sterile V-bottom plate. 20 pL of the samples were transferred to the corresponding wells of two flat-bottom assay plates. The medium was aspirated from human HEK-Blue™ TLR 7 and TLR 8 cells (T-75 vials) and carefully washed with pre-warmed DPBS (37 °C) to a total volume of 5 mL / vial. The DPBS was carefully removed from the cells, which were gently detached manually and resuspended in 2 mL of DPBS.Suspensions for the cell assay were then prepared with approximately 2.2 x 105. Petition 870260002828, dated 12 / 01 / 2026, pp. 209 / 237 200 / 211 cells per mL of HEK-Blue™ detection medium (InvivoGen). 180 pL of cell suspension in detection medium were added to each well of two flat-bottomed assay plates containing the diluted samples of Compound B1-SNE, for a final sample dilution of 1:10 (180 pL of cell suspension in detection medium and 20 pL of sample). The cells were then incubated at 37 °C in 5% CO2 for 20 hours. The reporter gene, NF-κB, induces the production of secreted embryonic alkaline phosphatase (SEAP) when stimulated and can be monitored using the SEAP detection kit provided by the manufacturer. SEAP colorimetric changes were read at an absorbance of 640 nm using a SpectroMax Stakmax plate reader. As shown in Figure 1, the compound B-1-SNE activates TLR7 and TLR8 receptors with an EC50 of 65.4 pg / mL for TLR7 and 82.3 pg / mL for TLR8.EC50 values ​​were calculated based on the total concentration of Compound B-1-SNE using GraphPad Prism software and analyzed using least squares slope matching of the agonist versus response variable (four parameters). EXAMPLE 10A Additional Information on the Cell-Based TLR 7 / 8 Assay for Evaluating Compound-SNE Activity.

[565] In addition to the description in Example 10, a cell-based activation system was used to evaluate the activity of Compound-formulated nanoemulsion systems, prepared as described in the examples above. HEK-Blue™ TLR7 and TLR8 (InvivoGen) cells were engineered to evaluate TLR7 and TLR8 stimulation by monitoring NF-κB and AP-1 activation. Compound-SNE samples were diluted 1:2 in an 8-point titration in histidine / PS-20 diluent buffer in a sterile V-bottom plate. 20 pL of the samples were transferred to the corresponding wells of two assay plates. Petition 870260002828, dated 12 / 01 / 2026, pp. 210 / 237 201 / 211 flat bottom. The medium was aspirated from human HEK-Blue™ TLR 7 and TLR 8 cells (T-75 vials) and carefully washed with pre-warmed DPBS (37 °C) to a total volume of 5 mL / vial. The DPBS was carefully removed from the cells, which were gently detached manually and resuspended in 2 mL of DPBS. Suspensions for the cell assay were then prepared with approximately 2.2 x 10⁵ cells per mL of HEK-Blue™ detection medium (InvivoGen). 180 pL of cell suspension in detection medium were added to each well of the two flat-bottom assay plates containing the diluted Compound-SNE samples, for a final sample dilution of 1:10 (180 pL of cell suspension in detection medium and 20 pL of sample). The cells were then incubated at 37 °C in 5% CO2 for 20 hours.The reporter gene, NF-κB, induces the production of secreted embryonic alkaline phosphatase (SEAP) when stimulated and can be monitored using the manufacturer's supplied SEAP detection kit. Colorimetric changes in SEAP were read at an absorbance of 640 nm using a SpectroMax Stakmax plate reader. EC50 values ​​were calculated based on Compound concentrations only, not the total Compound-SNE concentration (Table 17) using GraphPad Prism software and analyzed using least squares slope fitting of the agonist versus response variable (four parameters). As shown in Table 17, the Compounds formulated as an SNE activate both TLR7 and TLR8 receptors. Table 17: EC50 values, based on compound concentration, for compounds formulated as SNEs. Petition 870260002828, dated 12 / 01 / 2026, pp. 211 / 237 202 / 211 Compound Number huTLR7 EC50 (pg / mL) huTLR8 EC50 (Pg / mL) B-1 0.65 0.43 B-2 0.15 0.22 B-3 0.12 0.1 B-4 0.3 0.3 A-1 12.01 4.33 C-4 3.65 0.86 C-2 0.23 0.12 C-3 0.37 0.12 C-1 0.19 0.07 D-1 17.63 159.2 B-12 18.8 20.53 D-3 18.46 10.77 Compound Number huTLR7 EC50 (Pg / mL) huTLR8 EC50 (pg / mL) B-13 67.68 2.38 C-5 0.48 0.07 B-11 2.3 0.3 B-6 3.25 2.01 B-10 90.94 56.99 D-2 13.76 4.52 B-8 50.18 41.9 B-5 10.59 3.33 B-7 6.3 2.53 B-14 108.3 9.53 A-2 6.3 0.38 B-18 0.25 0.17 EXAMPLE 11 PCV1 Immunogenicity in Mice: Evaluation of Adjuvant Systems

[566] Young fem...

Claims

1. Compound, characterized in that it has the structure presented in Formula I: wherein: Ra is selected from H, -OH, (C1-C6)alkyl, (C1-C6)alkenyl, (C1-C6)alkynyl, -O(C1-C6)alkyl, -O(C1-C6)alkenyl, -O(C1-C6)alkynyl, chlorine, fluorine and NR'R, wherein said (C1-C6)alkyl, (C1-C6)alkenyl, (C1-C6)alkynyl, -O(C1-C6)alkyl, -O(C1-C6)alkenyl and -O(C1-C6)alkynyl are optionally substituted with one to four substituents, selected independently from the group consisting of -OH, -O(C1-C4)alkyl, -O(C1-C4)alkenyl, -O(C1C4)alkynyl, chlorine and fluorine;Ra' is selected from H, -OH, (C1-C6)alkyl, (C1-C6)alkenyl, (C1-C6)alkynyl, -O(C1-C6)alkyl, -O(C1-C6)alkenyl, -O(C1-C6)alkynyl, chlorine, fluorine and -NR'R'', wherein said (C1-C6)alkyl, (C1-C6)alkenyl, (C1-C6)alkynyl, -O(C1-C6)alkyl, -O(C1-C6)alkenyl and -O(C1-C6)alkynyl are optionally substituted with one to four substituents, selected independently from the group consisting of -OH, -O(C1-C4)alkyl, -O(C1-C4)alkenyl, -O(C1C4)alkynyl, chlorine and fluorine;Ra” is selected from H, -OH, (C1-C6)alkyl, (C1-C6)alkenyl, (C1-C6)alkynyl, -O(C1-C6)alkyl, -O(C1-C6)alkenyl, -O(C1-C6)alkynyl, chlorine, fluorine and NR'R, wherein said (C1-C6)alkyl, (C1-C6)alkenyl, (C1-C6)alkynyl, -O(C1-C6)alkyl, -O(C1-C6)alkenyl and -O(C1-C6)alkynyl are optionally substituted with one to four substituents, selected independently from the group consisting of -OH, -O(Ci-C4)alkyl, -O(Ci-C4)alkenyl, -O(C1C4)alkynyl, chlorine and fluorine;R' and R'' are independently selected from H, (C1-C6)alkyl, (C1-C6)alkenyl and (C1-C6)alkynyl, wherein said (C1-C6)alkyl, (C1-C6)alkenyl and (C1-C6)alkynyl are optionally substituted with one to four substituents, independently selected from the group consisting of -OH, -O(C1-C4)alkyl, -O(C1-C4)alkenyl, -O(C1-C4)alkynyl, chlorine and fluorine, or R' and R'', together with the nitrogen to which they are attached, combine to form a (C3-C6)heterocycloalkyl, wherein said (C3-C6)heterocycloalkyl is optionally substituted with one to four substituents, independently selected from the group consisting of -OH, -O(C1-C4)alkyl, O(C1-C4)alkenyl, -O(C1-C4)alkynyl, chlorine and fluorine;each occurrence of Rb is independently selected from H, -OH, (C1-C6)alkyl, (C1-C6)alkenyl, (C1-C6)alkynyl, -O(C1-C6)alkyl, -O(C1-C6)alkenyl, -O(C1-C6)alkynyl, chlorine, fluorine or NR'R, wherein said (C1-C6)alkyl, (C1-C6)alkenyl, (C1-C6)alkynyl, -O(C1-C6)alkyl, -O(C1-C6)alkenyl and -O(C1-C6)alkynyl are optionally substituted with one to four substituents, independently selected from the group consisting of -OH, -O(C1-C4)alkyl, -O(C1-C4)alkenyl, -O(C1-C4)alkynyl, chlorine and fluorine;A is a carbon- or nitrogen-bonded spacer selected from (C1-C6)alkyl, heterocycloalkyl, heterocycloalkyl-C(O)-Rz-, (C1-C4)alkyl-N(Rz)-Rz-, aryl and heteroaryl, wherein said (C1-C6)alkyl, heterocycloalkyl, aryl and heteroaryl are optionally substituted with one to six substituents, independently selected from the group consisting of -OH, (C1-C6)alkyl, (C1-C6)alkenyl, (C1-C6)alkynyl, -O(C1-C6)alkyl, -O(C1-C6)alkenyl, -O(C1-C6)alkynyl, chlorine, fluorine and NR'R'', wherein said (C1-C6)alkyl, (C1-C6)alkenyl, (C1-C6)alkynyl, -O(C1-C6)alkyl, -O(C1C6)alkenyl and -O(C1-C6)alkynyl are optionally substituted with one to six substituents, selected independently from the group consisting of -OH, -O(C1-C4)alkyl, -O(C1-C4)alkenyl, -O(C1-C4)alkynyl, chlorine and fluorine; each occurrence of Rz is independently H or (C1-C6)alkyl;B is a functional group selected from; SH . Z? ς HS ς Η HS )n ' TN-cA , An-C-n4 oo Jnc-oA ,|-CO^- , Ac-Nl· e II S II < ς II δ e OOOD is a lipid selected from (C6-C20)alkyl, (C6-C20)alkenyl and (C6C20)alkynyl, wherein said (C6-C20)alkyl, (C6-C20)alkenyl and (C6C20)alkynyl are optionally substituted with one to six substituents, independently selected from the group consisting of -OH, -O(C1Hz C4)alkyl, -O(C1-C4)alkenyl, -O(C1-C4)alkynyl, chlorine and fluorine; or D is Z; each occurrence of Z is independently selected from (C6C20)alkyl, (C6-C20)alkenyl and (C6-C20)alkynyl, wherein said (C6C20)alkyl, (C6-C20)alkenyl and (C6-C20)alkynyl are optionally substituted with one to six substituents, independently selected from the group consisting of -OH, -O(C1-C4)alkyl, -O(C1-C4)alkenyl, -O(C1-C4)alkynyl, chlorine and fluorine; m is 0, 1, 2, 3, 4 or 5; en is 0, 1, 2, 3, 4 or 5;or a pharmaceutically acceptable salt thereof.

2. Compound, according to claim 1, characterized in that it has the structure shown in Formula Ia: Petition 870260002828, dated 12 / 01 / 2026, p. 224 / 237 4 / 16 where: R' and R'' are selected independently from H, (C1-C6)alkyl, (C1-C6)alkenyl and (C1-C6)alkynyl, wherein said (C1-C6)alkyl, (C1-C6)alkenyl and (C1-C6)alkynyl are optionally substituted with one to four substituents, selected independently from the group consisting of -OH, -O(C1-C4)alkyl, -O(C1-C4)alkenyl, -O(C1-C4)alkynyl, chlorine and fluorine, or R' and R'', together with the nitrogen to which they are attached, combine to form a (C3-C6)heterocycloalkyl, wherein said (C3-C6)heterocycloalkyl is optionally substituted with one to four substituents, selected independently from the group consisting of -OH, -O(C1-C4)alkyl, O(C1-C4)alkenyl, -O(C1-C4)alkynyl, chlorine and fluorine;each occurrence of Rb is -O(C1-C4)alkyl, wherein said -O(C1-C4)alkyl is optionally substituted with one or two substituents, selected independently from the group consisting of -OH, -O(C1-C4)alkyl, O(C1-C4)alkenyl, -O(C1-C4)alkynyl, chlorine and fluorine; A is selected from each occurrence of Rz is independently H or (C1-C6)alkyl; each occurrence of Rd is selected independently from -OH, (C1-C4)alkyl, -O(C1-C4)alkyl, chlorine and fluorine;Petition 870260002828, dated 12 / 01 / 2026, page 225 / 237 5 / 16 in a lipid chain selected from: carbon in the lipid chain is any optionally substituted with -OH, -O(C1-C4)alkyl, -O(C1-C4)alkenyl, -O(C1-C4)alkynyl, chlorine and fluorine, where is the cis or trans stereochemistry, X1 is -O-, -C(R)2-, or -NR-, and each occurrence of R is selected independently from H, (C1C4)alkyl, (C1-C4)alkenyl, (C1-C4)alkynyl, -OH, -O(C1-C4)alkyl, -O(C1C4)alkenyl, -O(C1-C4)alkynyl, chlorine and fluorine; m is 0, 1 or 2; n is 0, 1, 2 or 3; p is 0, 1 or 2; q is 0, 1, 2, 3, 4, 5, 6, 7, 8 or 9; s is 1, 2, 3, 4, 5, 6, 7 or 8; et is 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17 or 18; or a pharmaceutically acceptable salt thereof.

3. Compound according to claim 1, characterized in that it has the structure shown in Formula II: Petition 870260002828, dated 12 / 01 / 2026, p. 226 / 237 6 / 16 where: R1 is (C1-C6)alkyl, wherein said (C1-C6)alkyl is optionally substituted with one to four substituents selected independently of -OH and -O(CH3); R2 is H, methyl or -O(CH3); each occurrence of R3 is independently H, (C1-C4)alkyl, (C1-C4)alkenyl, (C1-C4)alkynyl or -O(C1-C4)alkyl wherein said (C1-C4)alkyl, (C1-C4)alkenyl, (C1-C4)alkynyl or -O(C1-C4)alkyl are optionally substituted with one or two substituents selected independently of -OH and -O(CH3);each occurrence of R4 is independently H, (C1-C4)alkyl, (C1-C4)alkenyl, (C1-C4)alkynyl or -O(C1-C4)alkyl wherein said (C1-C4)alkyl, (C1-C4)alkenyl, (C1-C4)alkynyl or -O(C1-C4)alkyl are optionally substituted with one or two substituents selected independently from -OH and -O(CH3); R5 and R6 are selected from (C6-C20)alkyl, (C6-C20)alkenyl and (C6C20)alkynyl, wherein said (C6-C20)alkyl, (C6-C20)alkenyl and (C6C20)alkynyl are optionally substituted with one to six substituents selected independently from -OH, -O(C1-C4)alkyl, -O(C1C4)alkenyl, -O(C1-C4)alkynyl, chlorine and fluorine; and each occurrence of n is 4; or a pharmaceutically acceptable salt thereof.

4. Compound according to claim 3, characterized in that it has the structure shown in Formula IIa: wherein: R1 is butyl, wherein said butyl is optionally substituted with one or two -OH; each occurrence of R3 is independently H or -O(CH3); and R5 and R6 are selected from (C10-C20)alkyl, (C10-C20)alkenyl and (C10C20)alkynyl; or a pharmaceutically acceptable salt thereof.

5. Compound, according to claim 1, characterized in that it has the structure shown in Formula III: Petition 870260002828, dated 12 / 01 / 2026, p.228 / 237 8 / 16 where: R1 is (C1-C6)alkyl, wherein said (C1-C6)alkyl is optionally substituted with one to four substituents selected independently of -OH and -O(CH3); R2 is H, methyl or -O(CH3); each occurrence of R3 is independently H, (C1-C4)alkyl, (C1-C4)alkenyl, (C1-C4)alkynyl or -O(C1-C4)alkyl wherein said (C1-C4)alkyl, (C1-C4)alkenyl, (C1-C4)alkynyl or -O(C1-C4)alkyl are optionally substituted with one or two substituents selected independently of -OH and -O(CH3); R4 is selected from (C6-C20)alkyl, (C6-C20)alkenyl and (C6C20)alkynyl, wherein said (C6-C20)alkyl, (C6-C20)alkenyl and (C6C20)alkynyl are optionally substituted with one to six substituents selected from -OH, -O(C1-C4)alkyl, -O(C1-C4)alkenyl, -O(C1C4)alkynyl, chlorine and fluorine; en equals 4; or a pharmaceutically acceptable salt thereof.

6. Compound according to claim 5, characterized in that it has the structure shown in Formula IIIa: Petition 870260002828, dated 12 / 01 / 2026, p. 229 / 237 9 / 16 wherein: R1 is butyl, wherein said butyl is optionally substituted with one or two -OH; each occurrence of R3 is independently H or -O(CH3); and R4 is selected from (C10-C20)alkyl, (C10-C20)alkenyl and (C10C20)alkynyl; or a pharmaceutically acceptable salt thereof.

7. Compound according to claim 1, characterized in that it has the structure shown in Formula IV: wherein: R1 is (C1-C6)alkyl, wherein said (C1-C6)alkyl is optionally substituted with one to four substituents selected independently of -OH and -O(CH3); R2 is H, methyl or -O(CH3); Petition 870260002828, dated 12 / 01 / 2026, p.230 / 237 10 / 16 each occurrence of R3 is independently H, (C1-C4)alkyl, (C1-C4)alkenyl, (C1-C4)alkynyl or -O(C1-C4)alkyl wherein said (C1-C4)alkyl, (C1-C4)alkenyl, (C1-C4)alkynyl and -O(C1-C4)alkyl are optionally substituted with one or two substituents selected independently from -OH and -O(CH3); each occurrence of R4 is independently selected from (C6C20)alkyl, (C6-C20)alkenyl and (C6-C20)alkynyl, wherein said (C6C20)alkyl, (C6-C20)alkenyl and (C6-C20)alkynyl are optionally substituted with one to six substituents independently selected from -OH, O(C1-C4)alkyl, -O(C1-C4)alkenyl, -O(C1-C4)alkynyl, chlorine or fluorine; en equals 4; or a pharmaceutically acceptable salt thereof.

8. Compound according to claim 7, characterized in that it has the structure shown in Formula IVa: wherein: R1 is butyl, wherein said butyl is optionally substituted with one or two -OH; each occurrence of R3 is independently H or -O(CH3); and each occurrence of R4 is independently selected from (C10C20)alkyl, (C10-C20)alkenyl and (C10-C20)alkynyl; Petition 870260002828, dated 12 / 01 / 2026, pp. 231 / 237 11 / 16 or a pharmaceutically acceptable salt thereof.

9. Composto, de accordo com a reivindicação 1, characterized by the fact that it is selected from: (N -(5-(4-(4-((5-amino-7-(butilamino)-2 H -pyrazolo[4,3- d ]pyrimidin-2yl)metil)-3,5-dimethoxyphenyl)piperazin-1-yl)-5-oxopentyl)esteramide (5)-N -(5-(4-(4-((5-amino-7-((1-hydroxypentan-2-yl)amino)-2 H-pyrazolo[4,3d ]pyrimidin-2-yl)metil)-3,5-dimethoxyphenyl)piperazin-1-yl)-5oxopentyl)esteramida; N -(5-(4-(4-((5-amino-7-(butylamino)-2 H-pyrazolo[4,3-d ]pyrimidin-2-yl)methyl)3-methoxyphenyl)piperazin-1-yl)-5-oxopentyl)stearamide; N -(5-(4-(4-((5-amino-7-(butylamino)-2 H-pyrazolo[4,3-d ]pyrimidin-2-yl)methyl)3-methoxyphenyl)piperazin-1-yl)-5-oxopentyl)tetradecanamida; N -(5-(4-(4-((5-amino-7-(butylamino)-2 H-pyrazolo[4,3-d ]pyrimidin-2-yl)methyl)3-methoxyphenyl)piperazin-1-yl)-5-oxopentyl)oleamide; (9 Z,12 Z)-N -(5-(4-(4-((5-amino-7-(butylamino)-2 H -pyrazolo[4,3-d [pyrimidin2-yl)methyl)-3-methoxyphenyl)piperazin-1-yl)-5-oxopentyl)octadeca-9,12-dienamide;N -(5-(4-(4-((5-amino-7-(butylamino)-2 H-pyrazolo[4,3-d ]pyrimidin-2-yl)methyl)3-methoxyphenyl)-1,4-diazepan-1-yl)-5-oxopentyl)stearamide; N -(5-(4-(4-((5-amino-7-(butylamino)-2 H-pyrazolo[4,3-d ]pyrimidin-2-yl)methyl)3-methoxyphenyl)piperidin-1-yl)-5-oxopentyl)stearamide; N -(5-(3-(4-((5-amino-7-(butylamino)-2 H-pyrazolo[4,3-d ]pyrimidin-2-yl)methyl)3-methoxyphenyl)azetidin-1-yl)-5-oxopentyl)stearamide; 1-(4-((5-amino-7-(butylamino)-2H-pyrazolo[4,3-d]pyrimidin-2-yl)methyl)-3methoxyphenyl)-N-(3-estearamidopropyl)piperidina-4-carboxamide; (1 s ,3 s )-3-(2-(4-(4-((5-amino-7-(butilamino)-2 H-pyrazolo[4,3-d ]pyrimidin-2yl)metil)-3-methoxyphenyl)piperazin-1-yl)-2-oxoethyl)-N -hexadecylciclobutano-1carboxamide; Petition 870260002828, de 12 / 01 / 2026, pág. 232 / 237 12 / 16 N -(3-(4-(4-((5-amino-7-(butylamino)-2 H-pyrazolo[4,3-d ]pyrimidin-2-yl)methyl)3-methoxyphenyl)piperazin-1-yl)-3-oxopropyl)stearamide;N -(7-(4-(4-((5-amino-7-(butylamino)-2 H-pyrazolo[4,3-d ]pyrimidin-2-yl)methyl)3-methoxyphenyl)piperazin-1-yl)-7-oxoheptyl)stearamide; N -(3-(2-(4-(4-((5-amino-7-(butylamino)-2 H -pyrazolo[4,3-d ]pyrimidin-2-yl)methyl)-3-methoxyphenyl)piperazin-1-yl)-2-oxoethyl)cyclobutyl)stearamide; N -(5-(4-(4-((5-amino-7-(butylamino)-2 H-pyrazolo[4,3-d ]pyrimidin-2-yl)methyl)3-methoxyphenyl)piperazin-1-yl)-4,4-dimethyl-5-oxopentyl)stearamide; N -(5-(4-(4-((5-amino-7-(butylamino)-3-methyl-2 H-pyrazolo[4,3-d ]pyrimidin-2-yl)methyl)-3-methoxyphenyl)piperazin-1-yl)-5-oxopentyl)stearamide; (9 Z,12 Z)-N -(4-((4-((5-amino-7-(butylamino)-2 H -pyrazolo[4,3-d ]pyrimidin-2-yl)methyl)-3,5-dimethoxybenzyl)(methyl)amino)butyl)octadeca-9,12-dienamide; N -(4-((4-((5-amino-7-(butylamino)-2 H -pyrazolo[4,3-d ]pyrimidin-2-yl)methyl)3,5-dimethoxybenzyl)(methyl)amino)butyl)tetradecananamide; N -(4-((4-((5-amino-7-(butylamino)-2 H -pyrazolo[4,3-d ]pyrimidin-2-yl)methyl)3,5-dimethoxybenzyl)(methyl)amino)butyl)oleamide;N -(4-((4-((5-amino-7-(butylamino)-2 H -pyrazolo[4,3-d ]pyrimidin-2-yl)methyl)3,5-dimethoxybenzyl)(methyl)amino)butyl)estearamida; N -(4-((4-((5-amino-7-(butylamino)-2 H -pyrazolo[4,3-d ]pyrimidin-2-yl)methyl)3,5-dimethoxybenzyl)(methyl)amino)-4-oxobutyl)estearamida; (6 Z,9 Z,28 Z,31Z )-heptatriaconta-6,9,28,31-tetraen-19-yl(4-((4-((5-amino-7(butylamino)-2 H-pyrazolo[4,3-d ]pyrimidin-2-yl)methyl)-3,5dimethoxybenzyl)(methyl)amino)butyl)carbamate; 4-(4-((5-amino-7-(butylamino)-2 H -pyrazolo[4,3-d ]pyrimidin-2-yl)methyl)-3methoxyphenyl)-N-(3-estearamidopropyl)piperazine-1-carboxamida; and 3-estearamidopropyl4-(4-((5-amino-7-(butylamino)-2H-pyrazolo[4,3d ]pyrimidin-2-yl)methyl)-3-methoxyphenyl)piperazine-1-carboxylate; Petition 870260002828, dated 12 / 01 / 2026, pág. 233 / 237 13 / 16 ou um sal pharmaceutically aceitável do mesmo.; 10. Compound, characterized in that it is: N-(5-(4-(4-((5-amino-7-(butylamino)-2H-pyrazolo[4,3-d]pyrimidin-2-yl)methyl)3-methoxyphenyl)piperazin-1-yl)-5-oxopentyl)stearamide; or a pharmaceutically acceptable salt thereof.

11. Formulation, characterized in that it comprises: (i) a compound defined in any one of claims 1 to 10 or a pharmaceutically acceptable salt thereof; (ii) one or more emulsifiers; and (iii) a terpene.

12. Formulation, characterized in that it comprises: (i) a compound defined in any one of claims 1 to 10 or a pharmaceutically acceptable salt thereof; (ii) sorbitan trioleate (SPAN-85); (iii) polysorbate-20 (PS-20) or polysorbate-80 (PS-80); and (iv) squalene.

13. Formulation according to claim 12, characterized in that the compound is N-(5-(4-(4-((5-amino-7-(butylamino)-2H-pyrazolo[4,3d]pyrimidin-2-yl)methyl)-3-methoxyphenyl)piperazin-1-yl)-5-oxopentyl)stearamide, or a pharmaceutically acceptable salt thereof.

14. Pharmaceutical composition, characterized in that it comprises: (i) at least one antigen; (ii) a compound defined in any one of claims 1 to 10 or a pharmaceutically acceptable salt thereof; (iii) one or more emulsifiers; (iv) a terpene; and (v) a pharmaceutically acceptable carrier.

15. Pharmaceutical composition, characterized in that it comprises: (i) at least one antigen; (ii) a compound defined in any one of claims 1 to 10 or a pharmaceutically acceptable salt thereof; (iii) sorbitan trioleate (SPAN-85); (iv) polysorbate-20 (PS-20) or polysorbate-80 (PS-80); (v) squalene; and (vi) a pharmaceutically acceptable carrier. Petition 870260002828, dated 12 / 01 / 2026, pp. 234 / 237 14 / 16 16. Pharmaceutical composition, according to claim 15, characterized in that the compound is N-(5-(4-(4-((5-amino-7(butylamino)-2H-pyrazolo[4,3-d]pyrimidin-2-yl)methyl)-3-methoxyphenyl)piperazin-1yl)-5-oxopentyl)stearamide, or a pharmaceutically acceptable salt thereof.

17. Immunogenic composition, characterized in that it comprises: (i) at least one antigen; (ii) a compound defined in any one of claims 1 to 10 or a pharmaceutically acceptable salt thereof; (iii) one or more emulsifiers; (iv) a terpene; and (v) a pharmaceutically acceptable carrier.

18. Immunogenic composition, characterized in that it comprises: (i) at least one antigen; (ii) a compound defined in any one of claims 1 to 10 or a pharmaceutically acceptable salt thereof; (iii) sorbitan trioleate (SPAN-85); (iv) polysorbate-20 (PS-20) or polysorbate-80 (PS-80); (v) squalene; and (vi) a pharmaceutically acceptable carrier.

19. Immunogenic composition, according to claim 18, characterized in that the compound is N-(5-(4-(4-((5-amino-7(butylamino)-2H-pyrazolo[4,3-d]pyrimidin-2-yl)methyl)-3-methoxyphenyl)piperazin-1yl)-5-oxopentyl)stearamide, or a pharmaceutically acceptable salt thereof.

20. Single-dose vaccine composition, characterized in that it comprises: (i) at least one antigen; (ii) a compound defined in any one of claims 1 to 10 or a pharmaceutically acceptable salt thereof; (iii) one or more emulsifiers; (iv) a terpene; and (v) a pharmaceutically acceptable carrier, wherein a single dose of the vaccine composition is sufficient to elicit a desired immune response against at least one antigen. Petition 870260002828, dated 12 / 01 / 2026, pp. 235 / 237 15 / 16 21. Single-dose vaccine composition, characterized in that it comprises: (i) at least one antigen; (ii) a compound defined in any one of claims 1 to 10 or a pharmaceutically acceptable salt thereof; (iii) sorbitan trioleate (SPAN-85); (iv) polysorbate-20 (PS-20) or polysorbate-80 (PS-80); (v) squalene; and (vi) a pharmaceutically acceptable carrier, wherein a single dose of the vaccine composition is sufficient to elicit a desired immune response against at least one antigen.

22. Single-dose vaccine composition according to claim 21, characterized in that the compound is N-(5-(4-(4-((5-amino-7(butylamino)-2H-pyrazolo[4,3-d]pyrimidin-2-yl)methyl)-3-methoxyphenyl)piperazin-1-yl)-5-oxopentyl)stearamide, or a pharmaceutically acceptable salt thereof.

23. Use of (i) at least one antigen; (ii) a compound defined in any one of claims 1 to 10 or a pharmaceutically acceptable salt thereof; (iii) one or more emulsifiers; (iv) a terpene; and (v) a pharmaceutically acceptable carrier, characterized in that it is for the manufacture of a pharmaceutical composition for treating or preventing a disease in a patient in need thereof.

24. Use of (i) at least one antigen; (ii) a compound defined in any one of claims 1 to 10 or a pharmaceutically acceptable salt thereof; (iii) sorbitan trioleate (SPAN-85); (iv) polysorbate-20 (PS-20) or polysorbate-80 (PS-80); (v) squalene; and (vi) a pharmaceutically acceptable carrier, characterized in that it is for the manufacture of a pharmaceutical composition for treating or preventing a disease in a patient who needs it.

25. Use according to claim 24, characterized in that the compound is N-(5-(4-(4-((5-amino-7-(butylamino)-2H-pyrazolo[4,3-d]pyrimidin2-yl)methyl)-3-methoxyphenyl)piperazin-1-yl)-5-oxopentyl)stearamide, or a pharmaceutically acceptable salt thereof. Petition 870260002828, dated 12 / 01 / 2026, pp. 236 / 237 16 / 16 26. Use, according to any one of claims 23 to 25, characterized in that the patient is a human.

27. Use, according to any one of claims 23 to 25, characterized in that the patient is a non-human animal.

28. Product, process, system, kit, means or use, characterized in that it comprises one or more elements described in the descriptive report, claims, drawings, sequence listing, or summary of this application, when applicable.